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The overall objective of this thesis was to fill critical knowledge gaps for the 
development of the tissue engineered heart valve (TEHV). Heart valve tissue engineering is a 
promising solution for the currently unmet need of an ideal prosthetic heart valve. However, the 
TEHV still faces a number of challenges ranging from scaffold creation to the lack of consistent 
recellularization. Therefore, the progression of this thesis was designed around the pathway 
leading to the THEV and focuses on addressing some of the key challenges. There are the three 
principal steps in TEHV development: scaffold formation through decellularization, seeding a 
patient specific cell population, and conditioning through culture in a bioreactor. The current 
body of work followed these steps with three aims focused on valve decellularization, cell 
seeding, and bioreactor conditioning, respectively. The first aim provided a detailed investigation 
into the species-specific effects of decellulzation on human and ovine aortic heart valves. The 
tested multi-detergent decellularization process lead to cell free scaffolds for both human and 
ovine heart valves; however, decellularization was found to more greatly affect ovine tissue than 
human tissue. The next aim of this thesis investigated the ability for recellularization, and the 
potential mechanism by which recellularization occurred for four cell populations: MNCs, low 
dose MSCs, high dose MSCs, and VICs. The higher dose of MSCs showed the greatest cellular 
infiltration compared to MNCs or VICs and maintained a phenotype similar to native cells. The 
final aim of the thesis was to develop bioreactor-conditioning protocols to increase the 
recellularization of cell seeded valves. Detailed investigations into bioreactor conditioning were 
performed individually for valves seeded with MNCs and MSCs. Bioreactor conditioning for 
MNC seeded valves focused on the duration of bioreactor culture and found three weeks of 
culture resulted in proliferation of the MSC sub-population and partial recellularization. The 
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investigation into bioreactor conditioning for MSC seeded valves focused on non-physiologic 
parameters of chamber pressure and hypoxic conditioning to increase recellularization into the 
distal leaflet. Hypoxic conditions greatly increased the infiltration of seeded cells while cyclic 
negative pressure conditioning better maintained stem cell gene markers. The goal driving this 
thesis was the clinical application of a TEHV and the described methodologies were developed 
to be translatable to the clinic. The current body of work offers real, obtainable advances for the 
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CHAPTER 1: INTRODUCTION TO THESIS 
The overall objective of this thesis was to fill critical knowledge gaps for the advance of a 
biologically and physiologically practical tissue engineered heart valve (TEHV). The ultimate 
clinical goal driving this work was the development of a heart valve prosthetic capable of 
optimal hemodynamics and growth after implantation. There is a significant unmet need for an 
ideal prosthetic heart valve and the TEHV has the potential to create a new paradigm in the field 
valve replacement. However, a number of challenges remain before the TEHV may be realized. 
Therefore, the progression of experiments in this body of work was designed around a clinically 
realistic pathway leading to the THEV and focused on addressing some of the key challenges. 
There are the three principal steps in TEHV development: scaffold formation through 
decellularization, seeding a patient specific cell population, and conditioning through culture in a 
bioreactor (Figure 1.1). This project addresses a major challenge in each step through the 
following three specific aims: (1) characterize the effects of a multi-detergent decellularization 
protocol, (2) compare candidate seeding cell populations for recellularization potential, (3) 
develop a bioreactor conditioning protocol to enhance valve recellularization.  
The first aim of this thesis focused on challenges concerning the safety of decellularized 
valve scaffolds by elucidating and comparing the effects of decellularization on both human and 
ovine aortic valves. The second aim addressed the primary challenge of valve recellularization 
by investigating the mechanisms of scaffold repopulation associated with various cell 
populations. The third aim further investigated the challenge of recellularization by identifying 
bioreactor conditioning parameters that may be utilized to increase the recellularization of valve 
scaffolds. The third aim was broken down into two parts, with one part focused on tuning 
bioreactor conditions for MNC seeded heart valves and the other part focused on the bioreactor 
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conditions for MSC seeded heart valves. The chapters that follow reflect the progression of these 
aims.  
Chapter 2 provides background on the current state of heart valve tissue engineering 
through a literature review of the existing methods for the decellularization and subsequent 
recellularization techniques that have been employed for heart valve tissue engineering. This 
review focuses on the broad approaches for TEHV processing and lays the groundwork for 
describing the two mechanisms of recellularization: in situ recellularization through host cell 
recruitment and in vitro recellularization through seeded cell proliferation. Chapter 2 addresses 
the entire thesis as it provides valuable insight into the previously explored methods for heart 
valve tissue engineering.  
Chapter 3 covers the first aim of the project and the first step on the pathway to the 
TEHV, scaffold creation through heart valve decellularization. This chapter provides a detailed 
investigation comparing the species-specific effects of heart valve decellularization. Human and 
ovine aortic valves were subjected to an identical decellularization protocol and the results were 
described and compared through mechanical and biochemical means. Therefore, the results of 
this chapter are relevant to the remainder of the current thesis as the second and third aim utilized 
decellularized valves as scaffolds for TEHVs. 
Chapter 4 begins to address the primary challenge of the TEHV: recellularization of the 
leaflet interstitium. This chapter focused on the cell seeding step in the pathway to the TEHV 
and offers a comparison of various cell populations for valve seeding. Decellularized valve 
scaffolds were seeded with mononuclear cells (MNCs), low dose of mesenchymal stem cells 
(MSCs), high dose of MSCs, or valve interstitial cells (VICs). The tissue engineered valves were 
then analyzed for cellular repopulation, mechanical properties, matrix remodeling, and cytokine 
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production. The results of this chapter provided insight for Chapter 5 and Chapter 6, where 
bioreactor conditioning parameters were developed for individual cell populations. 
Chapter 5 covers the first part of the third aim, which tackled the third step in the 
pathway to a TEHV: enhancing valve recellularization through bioreactor conditioning. The 
design of this study was built off of the findings of Chapter 4 and further investigated MNC 
seeded heart valves. Decellularized valve scaffolds were seeded with MNCs and underwent 
various durations of bioreactor culture to examine the phenotypic evolution of the seeded cell 
population. This chapter provided a more comprehensive analysis than Chapter 4 for MNC 
seeded valves and gave insight into the effects of extended bioreactor culture on the extent of 
scaffold repopulation and cell phenotype. 
Chapter 6 describes the second part of Aim 3, wherein the bioreactor conditioning for 
MSC seeded heart valves was explored. In this chapter, conditioning parameters were identified 
for increasing recellularization of MSC seeded heart valves using non-physiologic forces. After 
cell seeding, heart valves were conditioned under negative/positive cyclic pressure cycles and 
hypoxic/normoxic conditions. As the last step in the pathway to the TEHV, the design of chapter 
6 serves as a culmination of previous chapters. The results from this chapter suggest a bioreactor 
conditioning protocol that may be used to further enhance the recellularization of valve scaffolds.  
Finally, Chapter 7 provides concluding remarks regarding the body of work as a whole. It 
summarizes the key findings from the previous chapters and then presents a recommended 
protocol for developing a TEHV based on those findings. Lastly, an opinion on the future 
directions of heart valve tissue engineering is discussed. 
Overall, the work conducted in the current thesis provides innovative, potential solutions 
to overcome key challenges still facing clinical realization of the TEHV. Specifically, TEHV 
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development has been hindered by the safety concerns of using decellularized valves as tissue 
engineering scaffolds and in the difficulty of establishing a phenotypically appropriate cell 
population throughout the entire valve structure. The work described herein offers a 
characterization of the effects of a decellularization protocol, provides evidence of cellular 
repopulation of decellularized valve scaffolds, and proposes recommended bioreactor 
conditioning protocols to further increase valve recellularization. While the design of this thesis 
followed the pathway to developing a TEHV, certain aspects fell outside the scope of the project, 
which include in vivo functional implant testing. Therefore, although the work presented in this 
thesis did not lead to the complete development of a TEHV, it provides many valuable leads for 
advancing the field of heart valve tissue engineering and approaches the challenge of valvular 
heart disease with a focus on the clinical translation of an ideal heart valve replacement.   
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CHAPTER 2: RECELLULARIZATION OF DECELLULARIZED HEART VALVES; 
PROGRESS TOWARDS THE TISSUE ENGINEERED HEART VALVE* 
2.1 Abstract 
The tissue engineered heart valve (TEHV) portends a new era in the field of valve 
replacement. Decellularized heart valves are of great interest as a scaffold for the TEHV due to 
their naturally bioactive composition, clinical relevance as a stand-alone implant, and partial 
recellularization in vivo. However, a significant challenge remains in realizing the TEHV: 
assuring consistent recellularization of the entire valve leaflets by phenotypically appropriate 
cells. Many creative strategies have pursued complete biological valve recellularization, however 
identifying the optimal recellularization method, including in situ or in vitro recellularization and 
chemical and/or mechanical conditioning, has proven difficult. Furthermore, while many studies 
have focused on individual parameters for increasing valve interstitial recellularization, a general 
understanding of the interacting dynamics is likely necessary to achieve success. Therefore, the 
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purpose of this review is to explore and compare the various processing strategies used for the 
decellularization and subsequent recellularization of TEHVs.  
2.2 Introduction 
Valvular heart disease continues to be a global cause of morbidity and mortality 
worldwide.38 Approximately 2.5% of the US population suffers from aortic heart valve disease, 
and that value skyrockets to 13.2% for the population ≥75 years old.61, 121 There are many 
etiologies for heart valve disease, including congenital defects, rheumatic fever, infective 
endocarditis, and valve calcification, yet after medical therapy is exhausted, the multiple options 
for repair or replacement each have limitations. The annual number of patients requiring heart 
valve surgery is estimated at 290,000 globally, and as the world population continues to grow 
and age, that number is expected to triple in the next five decades to over 850,000.185 Despite 
decades of pursuing the ideal heart valve prosthetic, such a valve still does not exist. Mechanical 
valves have poor hemocompatability, requiring a lifetime of anticoagulation therapy. Xenogeneic 
bioprosthetic valves and biological valves such as homografts lack durability and often require 
replacement in ~10 years due to calcification and/or degeneration.21, 72, 149 Children are even 
more restricted in the suitable options for heart valve replacement, and although pediatric 
patients represent only a subset of the total heart valve replacement population, the clinical need 
for an ideal pediatric valve is far greater.70 The complications inherent to each class of valve 
substitute currently available for clinical use are amplified in children, which can necessitate 
reoperation in as little as 2-5 years. The current standard valve replacement for children is the 
cryopreserved allograft, yet this is not without problems due to the shortage of available grafts 
and patient-valve size mismatch. Most importantly, no current replacement option allows for 
somatic growth after implantation, necessitating multiple reoperations in children and impacting 
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surgical strategies such as timing, sequence of surgeries, serial valve selections, etc.70 Therefore, 
there is a significant unmet clinical need for a truly successful heart valve replacement option, 
especially for pediatric patients.  
Tissue engineering is a promising approach that may lead to novel constructs that will 
satisfy this unmet need and overcome the limitations of current valve prosthetics. The tissue 
engineered heart valve (TEHV) will be constructed using a combination of a porous scaffold, a 
cell population, and signaling factors and has the potential to provide 1) excellent 
hemodynamics, eliminating the need for anticoagulation therapy, 2) active tissue remodeling, 
preventing degeneration and 3) growth characteristics, preventing the need for reoperation.  
The two primary types of valve scaffolds for the TEHV are natural scaffolds, such as 
decellularized tissue or biological materials, and synthetic constructs fabricated from degradable 
polymers.22 Each type has inherent benefits and challenges, but decellularized heart valves are of 
significant interest. Decellularized heart valves are composed of biological materials that can 
positively impact cell differentiation and serve as building blocks during the remodeling 
process.77, 100 Additionally, decellularized valves do not necessitate complete biodegradation and 
often maintain the mechanical anisotropy of the native valves from which they are derived.5, 32, 97, 
101, 173 Decellularized heart valves have been more clinically relevant than polymeric valves thus 
far, as they have been implanted as stand-alone valve substitutes and as TEHVs in animals and 
humans, albeit with mixed results.45, 48-51, 131, 133, 154, 179 However, decellularized heart valves are 
not without their limitations. Decellularized valves require human or animal tissue for 
manufacture, which is limited in supply, and necessitates cryopreservation for storage. Freeze-
drying of biologic heart valves has been explored to facilitate long-term storage; however, 
freeze-drying leads to collapse of the ECM structure and disruption of biomolecules. Research 
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with lycoprotectants may overcome this limitation in the future.177 Additionally, the success of 
decellularized heart valves is highly reliant upon the decellularization process and the potential 
immune response following implantation.  
On the other hand, man-made scaffolds, fabricated from synthetic or biological materials, 
do not require donor tissue but have struggled to recreate the macro and micro valve anatomy 
and mechanical anisotropy.5 Fabricated scaffolds must also undergo complete biodegradation in 
synchrony with the production of extracellular matrix to remain functional. Fabricated or 
synthetic scaffolds have been used as a TEHV in animals, but have seen far less use clinically 
than decellularized valves.93, 184 Therefore, decellularized valve scaffolds have the greatest 
potential for expeditious development of a the TEHV due to the regulatory history, long clinical 
experience with homografts, as well as a deep research focus by many groups.31, 45, 70 
Before the TEHV is realized, a primary challenge must be overcome: the establishment 
and growth of a physiologically appropriate cell population within the leaflet tissue. In pursuit of 
this aim, researchers have employed numerous strategies for recellularization. From these 
strategies the two main approaches that have emerged are in vitro recellularization, the 
traditional tissue engineering approach, and in situ recellularization, also known as guided tissue 
regeneration.22, 117 However, despite the many strategies that have been employed, it is uncertain 
which has the greatest potential for success and reliable recellularization of the TEHV has yet to 
be realized. Therefore, the purpose of this review is to explore and compare the various 
processing strategies used for the decellularization and subsequent recellularization for tissue 
engineered heart valves.  
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2.3 Heart valve decellularization 
In the simplest terms, decellularization is the process of removing cellular (including 
nuclear) material from the extracellular matrix (ECM) of biological tissues. The remaining ECM 
provides a semi-porous scaffold that retains the complex geometry of the native tissue and is 
composed of natural components that provide cues for cell migration and differentiation, 
resulting in constructive remodeling.36, 60, 100 Despite the clinical use of decellularized tissue for 
more than a decade, it is only within the last 5 years that quantifiable minimum criteria defining 
adequate decellularization have been generally accepted in the field.36 These include, 1) <50 ng 
dsDNA per mg ECM dry weight, 2) <200 base pair DNA fragment length and 3) the lack of 
visible nuclear material in tissue sections stained with DAPI or H&E.36 These criteria lay out 
basic metrics to be met as endpoints for decellularized tissues, since ineffective decellularization 
can affect the immunological response through macrophage polarization and inhibit the 
constructive remodeling outcome.7, 8, 89 While decellularization does preserve the geometry of 
the native tissue, it has been shown to affect the structure and protein composition, often in a 
negative manner, depending on the decellularization methods used.36 Additionally, methods of 
decellularization differ in their effectiveness to remove antigens from the ECM scaffold, such as 
cellular and nuclear material, as well as lipids and carbohydrates which can also function as 
antigens.180 Methods of decellularization include the use of detergents, biologic agents, and 
physical forces. Extensive details on methods of decellularization and the effects on general 
tissue can be found in the reviews by Crapo et al.,36 and Gilbert.60 
2.3.1 Methods for heart valve decellularization 
In the context of heart valve decellularization, additional consideration must be given to 
the effects of processing on the mechanics of the heart valve leaflets. Healthy heart valves, 
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particularly the aortic and mitral valves, which control systemic blood flow, are under extreme 
environmental demands. They experience ~100,000 loading cycles per day, equating to ~3 
billion cycles in an average lifetime.22 These physiological forces must be considered during 
heart valve decellularization since the process can affect the structural and mechanical properties 
of the remaining extracellular matrix. Furthermore, the effect decellularization has on the 
extracellular matrix is process specific (Table 2.1; Figure 2.1).  
Detergent valve decellularization. Of the various decellularization methods, the most 
common utilize detergents for the removal of cells. Ionic and non-ionic detergents are effective 
decellularization agents because they are able to solubilize cell membranes, lysing the cells and 
dissociating DNA. The anionic detergents sodium dodecyl sulfate (SDS) and sodium 
deoxycholate (SD) are often used in valve decellularization and have proven effective in 
removing cells and DNA from the extracellular matrix, however prolonged chemical exposure 
during decellularization has been shown to disrupt collagen fiber structure in valve leaflets.19 The 
disruption in the ECM leads to an associated deterioration of mechanical properties, observed 
through increased areal strain and decreased flexural stiffness.101 This is despite preservation of 
the primary structural proteins found in valves: glycosaminoglycans (GAGs), collagen, and 
elastin fibers (Figure 2.1f). SDS is also particularly difficult to completely remove from the 
tissue and residual detergents can adversely affect cell adhesion and repopulation.194 Non-ionic 
detergents, such as Triton X-100, have also proven effective at cell and DNA removal. In 
addition to cell removal, Triton X-100 has been shown to delipidize tissue, reducing the 
concentration of GAGs (Figure 2.1h). GAGs are often attributed to the viscoelastic behavior of 
tissue and indeed, following decellularization with Triton X-100, a decrease in the stress 
relaxation of valve leaflet tissue has been observed.32, 173 Researchers have also successfully 
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employed multi-detergent decellularization strategies. Studies using a combination of Triton X-
100 and SD reported complete cell removal with less damage to the valve extracellular matrix, 
when compared to other methods.87, 190 However, neither study employed mechanical testing 
analysis of the decellularized leaflets and only described the extracellular matrix preservation 
using qualitative histologic methods. A combination of osmotic shock, Triton X-100, and the 
anionic detergent N-lauroylsarcosine sodium (NLS) salt has been used to successfully 
decellularize (>97% dsDNA removal) both pulmonary and aortic heart valves from a variety of 
species, including ovine, porcine, and human.32, 131, 173 The elastin and collagen components of 
the extracellular matrix were preserved, yet a loss of GAGs associated with Triton X-100 was 
observed. Biaxial mechanical testing indicated increased areal strain, increased peak stretch 
ratios, and decreased stress relaxation for ovine pulmonary valves.32 Interestingly, the same trend 
was observed for ovine aortic valves, yet no change in the areal strain or peak stretch ratio was 
observed in human aortic valves.173 The authors speculated that the species-specific effect of 
identical decellularization methods was the result of a loss of collagen crosslinking components 
and an initial higher cellularity in the ovine valves.173 
Enzyme valve decellularization. Enzymatic agents such as nucleases or trypsin have also 
been utilized in valve decellularization to breakdown biologic molecules and facilitate cell 
removal. Nucleases cleave nucleic acid sequences into shorter segments, expediting their 
removal from the extracellular matrix and the inclusion of nucleases, such as DNases or RNases, 
in a decellularization process is so commonplace their use was not specified in Table 2.1. 
Trypsin is another common enzyme used in valve decellularization. Trypsin, a serine protease, 
hydrolytically cleaves proteins and is used to digest cellular proteins in the decellularization 
process. However, the fibrous structural proteins of the valve extracellular matrix have limited 
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resistance to trypsin cleavage and are often affected as well. Decellularization of heart valves 
using trypsin often results in visible histologic damage to the extracellular matrix as well as large 
alterations to valve mechanics (Figure 2.1c). Compared to detergents, trypsin decellularization is 
slower to remove cells, causes greater disruption to the elastin and collagen structure, but has a 
better preservation of GAGs.63, 101, 157 Complete cell removal by trypsin alone actually requires 
lengthy decellularization protocols and the prolonged exposure has been shown to disrupt the 
remaining extracellular matrix beyond practical use.145  
Miscellaneous valve decellularization. Additional creative strategies for valve 
decellularization have been explored, with varying levels of success. Osmotic shock can be used 
to lyse cells; however, osmotic shock by itself is ineffective at removing the hydrophobic cell 
membranes and remnants and is therefore not recommended as the sole decellularization 
technique.116, 157 It is often used in combination with detergent or enzymatic based methods as an 
initial step, reducing the required detergent/enzyme concentrations an/or exposure times.32, 157, 194 
Mechanical forces such as pressure gradients can also aid in decellularization, as perfusion of 
decellularizing solutions through the valve conduit has been shown to increase the removal of 
cellular material from the valve wall compared to immersion protocols.151 Glycol radiation, using 
a polyethylene glycol detergent and gamma irradiation, has proven effective, resulting in >92% 
DNA removal in the valve cusps while not affecting ultimate tensile strength and collagen 
content.122 Additionally, the gamma irradiation effectively removed the galactose-α(1,2)-
galactose (α-Gal) epitope and the porcine endogenous retrovirus.122 Decellularization by 
sequential antigen solubilization is another effective method for the removal of cellular and 
antigeneic material from xenogeneic tissues.180 Based on shared physiochemical properties, 
antigens are removed by sequential solubilization techniques targeting hydrophilic and lipophilic 
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proteins.181, 182 Using this method, researchers have demonstrated the successful decellularization 
of bovine pericardium and porcine aortic heart valve leaflets.130, 181, 182 In addition to the removal 
of cellular material, sequential antigen solubilization also successfully removes the α-Gal and 
major histocompatibility complex I (MHC I) antigens while preserving the structural and 
mechanical properties of the native, untreated tissue.130, 180 Another unique approach to 
decellularization utilizes supercritical fluid solution of carbon dioxide and ethanol as a cell 
extraction medium.143 The high permeability and high transfer rate of the supercritical fluid 
makes this an effective method, resulting in a visible lack of cell nuclei and a 90% reduction in 
phospholipids, the primary component of cell walls. However, a stiffening and dehydration of 
the ECM has also been observed, likely attributed to the high ethanol exposure.143 
2.3.2 Clinical use of decellularized heart valves  
In vivo animal models using stand-alone decellularized valves have seen success, with 
subject survivability out to nine months with patent, functioning valves.13, 46 However, clinical 
studies using stand-alone decellularized valves have seen only mixed results. In clinical practice, 
xenogeneic valves would be preferred to allogeneic valves due to the scarcity of human tissue, 
yet clinical experience using xenograft, decellularized valves has not been encouraging. The 
initial iteration of the SynerGraft valve (Cryolife Inc., Kennesaw, GA), a porcine xenograft, 
showed promising preliminary results in adults, but elicited a severe immune response and 
catastrophic failure in children.62, 154 Subsequent studies identified the presence of ECM 
associated antigens, particularly the α-Gal epitope, following processing.86 AutoTissue (Berlin, 
Germany) has developed the other clinical xenograft, the Matrix P line of decellularized porcine 
pulmonary valve replacements, using a sodium deoxycholate decellularization method. This 
valve line has been CE certified since 2004. Both positive and negative clinical outcomes have 
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been reported with freedom from reoperation ranging broadly from 48% at 19 months to 90% at 
4 years.95, 176 Overall, decellularized xenogeneic valves have performed equivalent to, or worse, 
than standard cryopreserved allografts, though advances in decellularization protocols or better 
pre-implant conditioning may increase efficacy.   
On the other hand, clinical experience with decellularized human allografts has been 
more successful, with three options currently available worldwide. The CryoValve SG valve is 
the decellularized human allograft from CryoLife Inc. Comparisons between the CryoValve SG 
and standard cryopreserved allografts have not yet found a clear benefit from SynerGraft 
decellularization.14, 23, 96, 139 It is speculated that the CryoValve SG valve may be more durable, 
though longer follow up studies are still necessary to verify these claims.14, 23, 96, 139, 153, 168 During 
a 2014 FDA panel to discuss the classification of decellularized valves, CryoLife presented data 
indicating a 93% freedom from reoperation at 10 years in patients using the CryoValve SG.37 
Other studies using the CryoValve SG have reported freedom from valve dysfunction at 
approximately 85% at 5 years or 75% at 10 years.96, 139 A multi-institutional review by Bibevski 
et al.17 observed decreased freedom from valve dysfunction and re-intervention in SynerGraft 
valves compared to cryopreserved homografts. However, it is worth noting that within their 
study, the mean follow-up time was only 5 years and in comparing the SynerGraft and 
cryopreserved homograft groups, patients receiving SynerGraft valves were significantly older, 
received significantly larger valves, and more often underwent valve replacement as part of a 
Ross procedure.17 It is not yet clear whether the durability of the allogeneic version of the 
SynerGraft valve will be significantly prolonged compared to more classical homografts when 
HLA-ABO donor recipient matching is optimized and critical conflicts avoided. The other two 
clinical uses with decellularized human allografts have seen relative success observing positive 
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early and midterm results. Haverich et al. has implanted 131 decellularized allografts since 2005 
and they have observed 100% freedom from explant at 10 years follow-up (compared to 84% 
freedom from explant for cryopreserved allografts).28, 142 Da Costa et al. have also seen 
encouraging results using decellularized aortic allograft replacements, the first of its kind, and 
has reported 100% freedom from reoperation of the graft at 3 years, although early hospital 
mortality was 7%.39 Despite the early success by Haverich and Da Costa using decellularized 
allografts, long term results are not yet available (10-20 years), which is the crucial time when 
the majority of cryopreserved grafts fail. Additionally, without the presence of a viable cell 
population within the valve leaflets, the decellularized valves are anticipated to suffer the same 
valve dysfunction fate as standard cryopreserved valves. However, it is worth noting that all 
three groups using decellularized allografts report an increased freedom from valve dysfunction 
or replacement compared to standard cryopreserved allografts.17, 28, 39, 96, 139, 142 
2.3.3 Limitations of decellularized heart valves  
Thus far, complete autologous recellularization of implanted decellularized heart valves 
has not been realized (see Guided Tissue Regeneration section). Autologous recellularization of 
decellularized valves has been limited to the valve wall with only endothelial recellularization 
observed on the leaflet surface (Figure 2.2). This is far superior compared to cryopreserved 
valves, which undergo massive degeneration and leukocyte infiltration throughout the valve as 
evident in Figure 2.2. However, the fact that recellularization of decellularized valves is limited 
to the valve surface is problematic since the leaflet is the primary location of valve dysfunction 
in implanted cryopreserved valves. Without a viable cell population capable of ECM remodeling 
inside the valve leaflet, decellularized heart valves are anticipated to undergo the same fate as 
cryopreserved valves and ultimately suffer from valve degeneration.70 Decellularized valves are 
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an important improvement above the standard cryopreserved allograft due to reduced 
antigencity, but without restoration of the cell population within the interstitium of the leaflet and 
the ability for matrix repair and remodeling, the decellularized valve likely will not be the sought 
after “ideal” heart valve. Therefore, additional processing strategies must be employed to 
encourage recellularization of the entire valve, including the distal portions of the leaflet.   
2.4 Recellularization and conditioning 
Ultimately, the recellularization of a tissue engineered valve should mimic the cell 
population of a native valve, which is made up of valvular endothelial cells (VECs) and valvular 
interstitial cells (VICs).41 VECs provide a non-thrombotic monolayer over the valve surface, 
which plays a key role in valve hemodynamics.25 VICs are active in the remodeling of the 
extracellular matrix (ECM) of the valve ensuring both tissue durability and growth 
characteristics.105 Together, these cell populations create a non-thrombotic, durable, living valve. 
One of the primary challenges to realizing the TEHV is the recellularization of both VICs and 
VECs to create a physiologically appropriate cell population. There is evidence of a strong 
relationship between the two cell types, as VECs have been shown to regulate VICs toward a 
more native-like phenotype when in co-culture compared to VICs in isolated culture.25 However, 
the exact pathways of valve repair and interaction between the two populations remain largely 
unknown. Further complexities are introduced since cell populations differ between valves in the 
heart, so a recellularization method may need to be optimized for each valve type.41 Fortunately, 
the challenge of recellularization is lessened since there is strong evidence that following 
implantation, properly prepared valves have the potential for partial recellularization by native 
cells, particularly re-endothelialization along the valve surface.13, 39, 48, 75, 131, 133 As demonstrated 
in Figure 2.2, re-endothelialization occurs across all valve surfaces while interstitial 
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recellularization is limited to the valve wall and sinus. Therefore, the remaining challenge lies in 
repopulating the distal leaflet interstitium with VIC-like cells. 
Native VICs have been sub-classified into 5 distinct phenotypes, primarily quiescent 
VICs (qVICs) and activated VICs (aVICs).105 qVICs are the dominant cell phenotype within the 
valve leaflet during normal valve function and it is believed they help maintain homeostasis 
through marginal matrix production and degradation. During valve injury or abnormal stress, 
qVICs become stimulated by VECs to become aVICs, which actively produce and degrade 
extracellular matrix for valve remodeling.26 aVICs are more easily identified than qVICs with a 
myofibroblast-like phenotype that is characterized by positive expression of alpha-smooth 
muscle actin (αSMA).105 Following injury repair and valve remodeling the aVICs are eliminated 
by apoptosis. However, if the activation signals persist or there is dysfunction in the apoptotic 
process the aVICs can become osteoblastic VICs (obVICs), which promote angiogenesis, 
chronic inflammation, fibrosis, and calcification leading to valve disease.105 aVICs are therefore 
responsible for both valve remodeling and the potential for clinical valve disease. Many heart 
valve recellularization studies use aVICs, or αSMA positive cells, as the target phenotype for 
successful recellularization, since aVICs are more easily identified by αSMA and are responsible 
for valve remodeling. However, it is unknown if qVICs will ultimately replace the aVIC 
population and there is a lack of information on the potential for obVIC differentiation. Since 
initial recellularization is still a primary challenge, no studies have yet investigated the long-term 
fate of seeded cells, but it must be considered in the future. Regardless, progress in valve 
recellularization has been made and two main recellularization approaches have emerged: in situ 
recellularization and in vitro recellularization. Within these two approaches a number of creative 
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strategies have been employed to address initial cellular repopulation of the decellularized heart 
valve over the past two decades. 
2.4.1 In situ recellularization 
In situ recellularization of heart valves relies upon the natural regenerative capabilities of 
the host to repopulate a valve scaffold. In contrast to the typical tissue engineering paradigm, this 
approach does not attempt to create living tissue ex vivo. Instead, it aims to encourage the tissue 
healing and remodeling process through the implantation of a biomimetic scaffold capable of 
stimulating host cell recruitment and self-regeneration. For this reason, the decellularized valve 
scaffold is well suited, compared to polymer valve scaffolds, as it provides the chemical and 
mechanical cues of a natural heart valve. The two general approaches for in situ recellularization 
are implantation of stand-alone decellularized valves or implantation of chemically modified 
valve grafts. 
Tissue guided regeneration. The most obvious, and most attempted, approach to in situ 
recellularization, has been the implantation of stand-alone decellularized valve grafts without any 
further chemical or mechanical modification. This approach has come to be known as tissue 
guided regeneration. As mentioned previously, decellularized valve grafts have been implanted 
in animal and clinical applications with varying results in terms of survival and growth (see 
Clinical Use of Decellularized Heart Valves). In this section, the focus is the in situ 
recellularization of the implanted valve scaffolds (Table 2.2).  A more thorough review on the 
tissue guided regeneration of heart valves is available by Iop et al.76 
Currently, the in situ autologous recellularization of implanted decellularized valves is 
limited and variable. As mentioned previously, many studies have observed complete re- 
endothelialization and recellularization of the valve wall up to the leaflet base, yet the distal 
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subsurface leaflet remains mostly acellular. This prevents tissue growth and remodeling in the 
valve leaflets, ultimately leading to valve degeneration. James et al. reported an exception to this 
limited recellularization using a mouse model.79 At 3 months implant, they observed a thickening 
of the decellularized mouse leaflets and repopulation by αSMA+ cells, though by 6 months the 
leaflets appeared normal and the number of αSMA+ cells decreased.79 This may be the first study 
demonstrating a state of valve remodeling after implant transitioning into a quiescent, healthy 
state. While the study by James et al. is significant, the implant model presents challenges for 
clinical translation and the recellularization success is likely due to the thinness of the mouse 
leaflets, expediting cell infiltration.79 Additionally, it appears that leaflet recellularization 
typically decreases as higher order animals are used as implant models (Table 2.2). Furthermore, 
it appears that if the decellularized replacement valve is more robust than the original, native 
valve, the recellularization of the leaflet is better. For example, porcine valves implanted in 
canines led to good recellularization, as did porcine aortic valves implanted in a porcine 
pulmonary valve model.75, 78 
The in situ recellularization of decellularized valves in clinical use has been less 
successful than in pre-clinical studies. Decellularized allografts have functioned better than 
decellularized xenografts, as previously mentioned; however, no evidence has been presented 
demonstrating successful in situ autologous recellularization. Biopsies of the valve conduit taken 
from decellularized allografts during non-valve related reoperation in humans have shown 
repopulation of the conduit, though such recellularization is in accordance with similar animal 
studies.39, 48 During the FDA panel meeting in 2014 to re-evaluate decellularized heart valve 
classification, CryoLife Inc. presented results of their explanted decellularized allografts.37 The 
explanted valves had partial recellularization of the distal conduit but an absence of cellularity in 
20 
 
the decellularized leaflet up to 11 years in vivo.37 Leaflet repopulation was demonstrated during 
clinical use of the Matrix P line of valves, a decellularized xenograft; however, the repopulating 
cells appear to be inflammatory rather than phenotypically appropriate valve cells.95, 127, 138, 176   
Chemical conditioning for in situ recellularization. As autologous recellularization of 
decellularized valves is limited, a number of studies have investigated the use of chemical 
conditioning, or other chemical modifications, before implantation to increase valve 
recellularization (Table 2.3). This approach applies cytokine or signaling molecules to modulate 
the healing response of the host. Specifically, conditioning can be applied that is targeted at 
increasing cell attachment/migration, decreasing the immune response, increasing biologic 
activity, or increasing mechanical integrity. One approach designed to increase cell attachment 
has been the pre-implant conditioning of decellularized valves with fibronectin (FN), either alone 
or in combination with another growth factor.6, 57, 122 In all examples, the valves treated with 
fibronectin performed better than the respective decellularized or cryopreserved control valve 
groups.6, 57, 122 Fibronectin treatment alone led to increased recellularization of the luminal side 
of the treated graft in a small animal model, though no information was given on specific leaflet 
recellularization.6 Fibronectin in combination with stromal cell derived factor 1α (SDF-1α), 
increased the surface and interstitial leaflet recellularization of valves implanted in sheep, as well 
as decreased the calcification, pannus formation, and immune response.57 Fibronectin plus 
hepatocyte growth factor (HGF) was used to achieve good recellularization in situ.94 Ota et al. 
treated decellularized porcine aortic valves with FN+HGF and after one month implantation in 
canines they observed great recellularization of the valve cusps with gene expression of vimentin 
comparable to native valves.122 
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Another approach using chemical conditioning and in situ recellularization has 
investigated the conjugation of antibodies onto decellularized valve scaffolds to encourage in situ 
cell attachment. Antibody conjugation is an interesting method because it allows for selective 
attachment for the cell phenotype of interest. One group has explored conjugating CD133 
antibodies onto decellularized valve scaffolds with the purpose of selectively targeting 
hematopoietic stem cells and endothelial progenitor cells from circulating blood.83, 179 After 3 
months implantation in the RVOT of sheep, the antibody-conjugated valves showed increased 
recellularization throughout the leaflet compared to non-conjugated and cell seeded controls, 
including a vWF+ surface cell layer and an aSMA+ cell population in the leaflet interstitial 
tissue.83 Additionally, explanted valves showed an increase in collagen, glycosaminoglycan, and 
MMP-9 concentrations compared to non-conjugated valves, indicating both matrix production 
and remodeling.83 A follow up study found that CD133+ cells were present by 3 days implant, 
but from 30 to 90 days most cells were CD133-, aSMA+, and VIM+, demonstrating the transition 
and differentiation of the cell population from progenitor cell adhesion to mature valve like cells 
(Figure 2.3).179  However, the increased expression of aSMA+ cells, compared to native controls, 
is noteworth since aSMA indicates an aVIC phenotype that may lead to valve disease.179  
Another chemical conditioning strategy has been employed that aims to restore the 
mechanical properties of the decellularized scaffold and to make the ECM more hospitable for 
recellularization. This chemical treatment was accomplished by normalizing tissue pH, 
rehydrating the collagen helix moisture envelope, compacting collagen fibrils, and restoring 
soluble proteins by treating decellularized valves in a conditioning solution composed of citric 
acid, hyaluronic acid, lauryl alcohol, and species-specific protein.32, 71, 131, 132 Biomechanical 
evaluation revealed that the conditioning solution restored the stress relaxation behavior toward 
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that of the native valve properties.32 In an ovine allograft valve implant model, the conditioning 
process led to better hemodynamic performance, compared to cryopreserved and decellularized 
valves implanted without conditioning.131, 132 Improved re-endothelization and matrix 
recellularization was observed following conditioning, though the interstitial sub-surface 
repopulation was limited to the proximal portion of the leaflet.131, 132 Similar results were 
observed using a baboon model and conditioned human valves to simulate human paradigms.71 
Re-endothelialization and cusp base recellularization was observed in conditioned human valves 
after 26 weeks, as well as a decrease in class I and class II antibody production compared to 
cryopreserved valves, indicating reduced antigenicity.71 In all of the above-mentioned animal 
studies, the conditioned valves performed better than the decellularized and cryopreserved valve 
controls, indicating they may function better clinically than the current standards of care. 
However, because the distal portions of the leaflet do not completely recellularize, the potential 
for a lifelong valve replacement without full leaflet active ECM remodeling is likely limited.  
2.4.2 In vitro recellularization 
In vitro recellularization, the other proposed method of recellularization for tissue 
engineered heart valves, typically follows the traditional paradigm in tissue engineering in which 
cells are introduced on to a scaffold that is then subjected to in vitro conditioning. This approach 
relies upon using an appropriate cell source and providing conditioning signals to drive cell 
proliferation and differentiation in a bioreactor. The exact mechanisms that modulate valve cell 
phenotype are not clear, but there is evidence supporting the role of both mechanical and 
biochemical cues. In vitro recellularization leverages these cues to drive a seeded cell population 
into a mature cell population. The approaches that have been explored using in vitro cell seeding 
can be broken down into three groups, those that did not use any further conditioning, those that 
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applied mechanical conditioning, and those who applied chemical conditioning. Numerous cell 
sources have been explored for heart valve tissue engineering including VICs, VECs, 
mesenchymal stem cells (MSCs), bone marrow mononuclear cells (MNCs), myofibroblasts 
(MFs) smooth muscles cells (SMCs), endothelial cells (ECs) and endothelial progenitor cells 
(EPCs). A more thorough review on the seeding cell sources for heart valve tissue engineering is 
available by Jana et al.80  
In vitro seeding without conditioning. Early work in the field of in vitro cell seeding of 
heart valves investigated the effect of seeding under static culture conditions without added 
mechanical or chemical conditioning (Table 2.4). Some of these first efforts studied the potential 
for leaflet repopulation by isolating the decellularized leaflets and statically seeding cells in 
culture flasks or well plates. A primary objective of this work was re-creating a healthy 
endothelial layer; therefore, seeded endothelial cells were often used in these studies.18, 63, 135 
Endothelial cell seeding resulted in a confluent monolayer of cells on the leaflet surface that 
stained positive for vWF, but lead to little to no cell penetration into the leaflet. Interestingly, the 
study by Rieder et. al. found that the decellularization protocol and chemicals used greatly 
affected the re-endothelialization of decellularized leaflets, with SDS having cytotoxic effects 
and Triton X-100 leading to the best endothelial coverage.135 The value of ex-vivo (and 
especially under static conditions) endothelial seeding seems low since proper decellularization 
and pre-implant conditioning seems to encourage autologous re-endothelialization (presumably 
effected by circulating endothelial progenitor cells). In addition, without an interstitial cell 
population, in vitro endothelial cell layers typically delaminate and are rapidly lost under 
physiologic flow conditions. 
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Other studies investigating cell seeding on isolated leaflets have attempted to repopulate 
the leaflet interstitium using fibroblast-like cells such as cardiac stromal cells (CStCs) and 
neonatal dermal fibroblasts with moderate success.40, 94, 191 Dainese et al. seeded isolated leaflets 
with CStCs and observed up to 90% of native cellularity within 50 µm of the leaflet edge, yet 
they observed only 30% of native cellularity in the inner leaflet regions.40 These studies 
demonstrate the efficacy of introducing cells onto decellularized leaflet samples and they led to 
the seeding of intact decellularized valves. Kim et al.90 and Steinhoff et, al.161 both seeded 
myofibroblasts and endothelial cells onto decellularized pulmonary valves and subsequently 
implanted them into animal models without further in vitro conditioning. Kim et, al. used an 
allogeneic model and seeded canine MFs and ECs onto decellularized canine pulmonary valves 
and implanted them in the pulmonary position of dogs.90 Steinhoff et, al. used a xenogeneic 
animal model and seeded ovine MFs and ECs onto decellularized porcine pulmonary valves 
before implanting them in the pulmonary position of sheep.161 Neither group used chemical or 
mechanical conditioning before implantation, but allowed 6-7 days of static culture after seeding 
for cell adhesion and proliferation.90, 161 Following the longest implant periods evaluated, both 
studies demonstrated complete endothelialization and partial recellularization of the leaflet 
interior, though notably less than compared to native leaflet tissue.90, 161 
An interesting study by Vincentelli et al. compared the efficacy of MSCs and MNCs for 
heart valve tissue engineering by directly injecting the cells into the arterial wall and annulus of 
decellularized valve scaffold, followed immediately by implantation in lambs.175 After 7 days in 
vivo, the injected cells in both groups had scattered throughout the matrix and host cells were 
also observed. At 4 months, both cell groups showed re-endothelialization but had markedly 
different recellularization responses. The MNC seeded valves had thickened and retracted 
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leaflets with calcified nodules and a high presence of CD68+ cells. The MSC seeded valves had 
thin leaflets partially recellularized with aSMA+ cells and showed no signs of calcification. 
While MSC seeding elicited a more favorable in vivo response in this study, it is worth noting 
that the applicability of MNCs towards heart valve tissue engineering has been explored more 
recently using polymeric scaffolds in which seeded MNCs induced an inflammation-mediated 
recellularization response in vivo.55, 178 Considering the potential for regenerative paracrine 
signaling by seeded MNCs, it is not entirely clear if the CD68+ inflammatory cells present in the 
MNC seeded valves in the study by Vincentelli et al. were exhibiting an M1 or M2 inflammation 
response, or if they would eventually be replaced by VIC-like cells. However, the condition of 
the leaflets and the presence of calcified nodules in the MNC seeded valves was not 
encouraging.175 
In vitro seeding and mechanical conditioning. Mechanical conditioning of tissue 
engineered heart valves utilizes bioreactors and mechanical stimulation with the goal of 
achieving a mature cell population in vitro (Table 2.5). Physiologic conditions of high fluid shear 
and pressure have been shown to encourage the VEC and VIC phenotypes, support cell 
proliferation, and encourage extracellular matrix remodeling.1, 9, 114, 115, 134, 169, 186 Mechanical 
conditioning in bioreactors can simulate the physiological forces of heart valves and drive the 
differentiation and proliferation of seeded cells down the appropriate pathways.  
Using a dynamic bioreactor, Lichtenberg et al. explored the effects of mechanical 
conditioning after seeding pulmonary heart valves with vascular endothelial cells.103, 104 They 
demonstrated that culturing seeded valves under physiological pulmonic conditions (2.0 L/min, 
60 bpm, 25 mmHG mean system pressure) can lead to complete re-endothelialization; however, 
care should be taken when introducing the seeded valve scaffolds to increased shear stress.104 
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Rapid increases in the pulsatile bioreactor flow (0.1 L/min to 2.0 L/min; 0.35 L/min increases) 
led to significant interruptions of the endothelium.103 Conversely, a stepwise, gradual increase in 
pulsatile flow (0.1 L/min to 0.5 L/min; 0.1 L/min increases) resulted in a nearly complete 
endothelial layer.103 These studies showed no recellularization of the leaflet interior, though it 
was not expected since they seeded endothelial cells. A study by Schenke-Layland et, al. also 
investigated physiologic mechanical conditioning on valve recellularization.144 Myofibroblasts 
were seeded onto trypsin decellularized porcine pulmonary valves and cultured under pulmonic 
conditions (3.0 L/min, 60 bpm, 60/40 mmHg), followed by subsequent seeding with endothelial 
cells. After culture, the tissue engineered leaflets were very well recellularized, to an extent 
comparable with native valves. Cells repopulating the leaflet interior were αSMA+ and VIM+ 
while the cells on the leaflet surface were vWF+. After recellularization and conditioning, tissue 
engineered valves were also mechanically more similar to native valves than their decellularized-
only counterparts. Indeed, the only noticeable difference between the tissue engineered valves 
and native valves was the presence of αSMA+ cells throughout the tissue engineered leaflets, 
likely due to the seeded myofirbroblasts. While these results are promising, the high αSMA 
expression is indicative of aVICs, which are responsible for tissue remodeling but their 
prolonged activation can also lead to valve disease.105 
A different approach using mechanical conditioning under non-physiological conditions 
has been investigated as a means of repopulating the interstitium of the decellularized leaflet. 
Converse et al. studied the effects of cyclic negative and positive pressure on the 
recellularization of decellularized valves seeded with bone marrow derived MSCs.34 After 
seeding with MSCs, the valves were either cultured in a static bioreactor for 24h, conditioned in 
negative cyclic pressure (5 to -20 mmHg) for 72 h, or conditioned at the same negative cyclic 
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pressure for 72 h followed by an additional 10 days conditioning at positive pressure up to 50 
mmHg. Static cultured resulted in clumping of the cells on the valve surface and minimal cell 
infiltration. Mechanical conditioning under negative pressures resulted in a more even 
distribution of cell coverage on the surface of the leaflet and limited infiltration of cells into the 
interstitium of the leaflet. Valves subjected to a combination of negative and positive pressure 
conditioning exhibited further improved cell coverage and displayed moderate cell infiltration, 
though still less than native. The repopulated interior cells stained positive for CD90, CD29, 
HSP47, VIM, and αSMA. Biaxial mechanical testing also revealed that increased culture under 
positive pressure resulted in mechanical properties more similar to cryopreserved valves.34 
Despite encouraging bench-top studies, mechanically conditioned, in vitro seeded valves 
implanted in animal and pediatric models have only seen moderate recellularization success.85, 171 
Tudorache et al. seeded ovine aortic valves with ovine endothelial cells followed by pulsatile 
flow conditioning up to 1.0 L/min over the course of a week.171 After conditioning, the tissue 
engineered valves showed a complete endothelial layer on the leaflet surface though no 
interstitial cells were present. The conditioned valves were implanted in the descending aorta of 
sheep for three months, at which time all valves exhibited normal function. A complete 
endothelial layer was observed, as expected, however there was very minimal leaflet interstitial 
recellularization.171 In this study, mechanical conditioning resulted in endothelialization in the 
bioreactor, yet the benefit remains unclear since implanted decellularized valves will re-
endothelialize autologously, especially in sheep.131, 133 One case study investigated pediatric 
clinical use of mechanically conditioned tissue engineered valves. Cebotari et al. implanted 
tissue engineered valves in two pediatric patients using decellularized human pulmonary valve 
scaffolds seeded with autologous MNCs isolated from peripheral blood.27 After seeding, the 
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valves were cultured in a continuous perfusion bioreactor using a very low flow rate (15 
mL/min) for 21 days.27 Pre-implant histology revealed a confluent monolayer of cells along the 
leaflet surface with markers positive for endothelial cell types. At 3.5 years of follow up, both 
patients had recovered normally and had experienced somatic growth, valve annulus growth, and 
no signs of degradation, stenosis, or cusp thickening. These are highly encouraging results; 
however, the sample size is very limited and no further follow up data has been provided so the 
long-term outcome remains unclear.   
In vitro seeding and chemical modification. Another common approach to increase the 
recellularization of in vitro seeded tissue engineered heart valves has been to chemically modify 
the decellularized valve scaffolds prior to seeding (Table 2.6). Chemical modification utilizes 
cytokines, chemokines, growth factors, antibodies, and polymers to support phenotype-specific 
cellular attachment, bolster valve mechanics, and drive cell differentiation. 
As discussed previously, decellularization can have deleterious effects on the mechanics 
of the valve leaflet ECM. Chemical crosslinking has been explored as a means of improving the 
structural and mechanical integrity of the decellularized ECM. Conventional crosslinking 
methods using glutaraldehyde block immunogenic antigens, yet glutaraldehyde is also cytotoxic 
preventing cellular ingrowth and therefore is not appropriate for recellularizing valve scaffolds. 
Other crosslinking methods have been explored using procyanidin, quercetin, and 
nordihydroguaiaretic acid (NDGA), which have been found to improve the mechanics of the 
valve leaflets and are not cytotoxic at low concentrations.107, 192, 193 After crosslinking, the treated 
leaflets had increased ultimate tensile strength (UTS) and elastic modulus compared to untreated 
decellularized leaflets and in some cases greater than comparable fresh leaflets or glutaraldehyde 
treated leaflets.107, 192, 193 The recellularization potential after leaflet crosslinking remains largely 
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unknown however, as only NDGA treated valves have been briefly seeded with ECs for 24h, 
though in that time ECs showed adhesion and proliferation on the crosslinked leaflets.107  
Other chemical modifications that can bolster the mechanical integrity of valve leaflets 
are the incorporation of polymers into the decellularized valves to create hybrid valve scaffolds. 
These hybrid valves have improved mechanical properties compared to decellularized valves and 
the polymer additions can act as a transport mechanism for drug delivery. The biodegradable 
polymer poly(3-hydroxybu-tyrate-co-4-hydroxybutyrate) (P3/4HB) has been applied to 
decellularized porcine aortic valves through impregnation into the tissue or electrospinning onto 
the valve surface.68, 160 Hybrid valves created through P3/4HB electrospinning followed by 
seeding with MSCs under static conditions had a greater maximum load carrying capacity, 
ultimate tensile strength, and elastic modulus than their decellularized-only counterparts; 
however, recellularization was similar between groups and limited to the leaflet surface.68 
Impregnated P3/4HB hybrid valves also had increased biomechanics and could support the 
culture of mouse myofibroblasts, human myofibroblasts, and human endothelial cells, but only 
on the valve surface.160 A more common polymer for creating hybrid valves is polyethylene 
glycol (PEG) because it is highly hydrophilic, water soluble, and has active functional groups 
that facilitate peptide conjugation.42, 73, 123, 195, 196 Two groups have investigated modifying 
decellularized porcine aortic valve leaflets with PEG conjugated with TGF-β1, VEGF, and/or 
RGD.42, 73, 195, 196 They found that PEGylation of decellularized valves resulted in mechanical 
properties similar to native valves and that conjugation of various peptides increased surface 
recellularization after seeding with rat myofibroblasts or human umbilical cord vascular 
endothelial cells.42, 195, 196In fact, in all studies the PEG-peptide modified valves showed greater 
surface cell density than valves treated with PEG only or decellularized control valves; however, 
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none of the PEG-peptide modified valves resulted in repopulation of the leaflet interstitium.42, 195, 
196 
Another group has explored chemical modification of decellularized valves by applying 
polyelectrolyte multilayers (PEM) composed of heparin plus VEGF, chitosan, or SDF-1α.187, 188, 
197 Decellularized porcine aortic valves treated with PEM of heparin-chitosan or heparin-VEGF 
were subsequently seeded with endothelial progenitor cells and it was observed that both PEM 
coatings improved hemocompatability, showing decreased platelet adhesion and activation.187, 188 
Although seeding with endothelial progenitor cells did not result in leaflet interstitial 
recellularization, valves modified with heparin-chitosan were able to support an EC population 
while valves modified with heparin-VEGF actually had better adhesion, proliferation, and 
migration of ECs compared to decellularized control valves.187, 188 Zhou et al. applied a PEM of 
heparin-SDF-1α to decellularized rat aortic valves prior to seeding with rat bone marrow MSCs 
and observed increased proliferation and migration of MSCs on the modified scaffolds.197 Zhou 
et al. also implanted unseeded, heparin-SDF-1α modified valves in rats and observed luminal re-
endothelialization of the aortic wall; however, there was no indication of leaflet 
recellularization.197 
Other efforts involving chemical modification of in vitro seeded decellularized valve 
scaffolds have aimed at increasing the adhesion of both the seeded cells and host cells in vivo. 
Theodoridis et al. coated decellularized ovine pulmonary valves in CCN1, a matricellular protein 
associated with cell adhesion, proliferation, and differentiation, before seeding them with ovine 
ECs and implanting them in sheep.170 At explant, the modified valves had greater cell surface 
coverage and partial interstitial recellularization by VIM+ and αSMA+ cells.170 Similarly, Ye et 
al. conjugated decellularized porcine aortic valve leaflets with an anti-human CD90 antibody and 
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then cultured them in a shear flow bioreactor with media containing an MSC population.189 The 
modified leaflets had a greater cell population distributed evenly across the surface than the un-
modified controls samples.189 These approaches demonstrate that conjugation of peptides and 
antibodies can increase the adhesion of cells onto valve surfaces. However, this approach has not 
yet resulted in the complete repopulation of the leaflet interior. Increasing surface cell density 
through chemical modification may encourage cell infiltration to a small degree, but other 
chemokines may be required to repopulate the entire leaflet.  
Decellularized valves have also been treated with fibronectin (FN) before in vitro cell 
seeding. FN has been shown to promote differentiation into a VIC phenotype by human MSCs 
and to reduce the formation of calcific nodules by VICs, particularly in combination with 
vascular endothelial growth factor (VEGF).64, 74 Individual decellularized leaflets treated with 
FN showed only moderate recellularization when seeded with VICs or MSCs, though 
immunohistochemistry revealed appropriate differentiation into the correct cell phenotypes 
(surface cells were vWF+ and interstitial cells were αSMA+ and VIM+).16, 77 Dohmen et al. 
treated decellularized porcine pulmonary valves with FN, seeded them with autologous ovine 
endothelial cells, and implanted them in the pulmonary position of sheep for 6 months.47 At 
explant, FN-treated/EC seeded valves had a complete EC monolayer throughout the valve and 
good internal recellularization of the leaflet, while valves treated with FN but not seeded had 
only a partial EC layer and minimal leaflet recellularization.47 The same group also performed a 
small clinical study using the same in vitro seeding and FN treatment approach. Between 2000 
and 2002, 11 patients underwent pulmonary valve replacement with a tissue engineered 
pulmonary heart valve treated with ProNectin F (a synthetic FN alternative) and seeded with 
autologous ECs.49-51 At 10 years follow up, there was a 100% survival rate and transthoracic 
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echocardiography showed patent and functioning valves in all patients.50 At 3 months, one 
patient required a non-related re-operation, during which a small biopsy was taken from the 
conduit of the tissue engineered heart valve.48 Histology of the biopsy revealed repopulation of 
the conduit wall by CD31+ and vWF+ surface cells and fibroblast-like interstitial cells.48 
2.5 Discussion and future directions 
Many challenges have been encountered in the pursuit of a TEHV. In the context of 
engineering a viable TEHV using a decellularized valve scaffold, the most pressing challenge is 
achieving recellularization of the entire valve, including distal portions of the leaflet, with an 
appropriate cell population. Upon analysis of the various recellularization strategies that have 
been employed, it is apparent that all approaches are not equally effective. Chemical 
conditioning with fibronectin has been one of more successful approaches and has lead to 
increased leaflet recellularization in both in situ and in vitro studies.6, 47, 49-51, 57, 122 Other 
chemical treatments that target increased cell adhesion, including conjugation of CD133 and 
CCN1 to the decellularized scaffold, have led to increased recellularization of the leaflet surface 
and the leaflet interstitium by phenotypically appropriate cells.83, 170, 179 Mechanical conditioning 
has a positive effect on recellularization in general, although the most effective parameters for 
mechanical conditioning have yet to be determined and may vary by valve position. 
Conditioning parameters of pressure and flow similar to native in situ conditions seem to be the 
most obvious choice, yet mechanical conditioning at pulmonary conditions has had mixed results 
and conditioning using non-physiological forces has also resulted in limited recellularization.34, 
85, 103, 104, 144, 171 Complicating matters, the cell population within the TEHV must ultimately 
mimic that of the native valve. Justifiably so, αSMA is often used as the marker of choice to 
evaluate the appropriateness of scaffold repopulation since aVICs express αSMA during the 
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remodeling of valve extracellular matrix, and matrix remodeling is a basic requirement for a 
functioning TEHV.  However, as discussed previously, the prolonged expression of αSMA and 
activation of VICs can lead to valve fibrosis, inflammation, and calcification.105 As evidenced 
above, several groups have shown excellent scaffold repopulation by αSMA+ cells, but the cell 
population should ultimately transition to a quiescent state. The study by James et al. provided 
one example of this successful transition in a decellularized valve graft implanted in a mouse 
model, however similar results have not yet been observed in larger animal implant models.79 
One of the crucial tasks in proving the safety of the TEHV will be proving that a seeded cell 
population that is initially αSMA+ is capable of transitioning into a quiescent state after valve 
remodeling is complete.  
Successful strategies have been employed for both of the two main approaches for heart 
valve recellularization (in situ & in vitro) and have resulted in recellularization of the interstitial 
tissue of the distal leaflet. In particular, the studies by Ota et al.,122 Jordan et al.,83 Iop et al.,77 
and Schenke-Layland et al.144 demonstrate good recellularization of an appropriate valve cell 
phenotype using a variety of methods. However as we continue to progress the field of heart 
valve tissue engineering, we must be mindful of the potential clinical and regulatory challenges 
associated with successful recellularization strategies. Ex vivo cell seeding maintains the ability 
to directly influence cell infiltration by the choice of the seeding cells and by applying bioreactor 
conditioning parameters through mechanical or biochemical means. But, the same bioreactor 
conditioning associated with relatively complete in vitro recellularization requires lengthy valve 
and cell culture, limiting the potential for off-the-shelf availability and clinical relevance. Short 
term in vitro seeding protocols have numerous practical advantages (e.g. sterility) but are 
challenging in assuring target recellularization populations are achieved. In either case, in vitro 
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seeding will have associated regulatory challenges with assuring correct lineage and phenotype 
stability of the seeded and subsequent proliferated cells, particularly if MSCs or other stem cells 
are used. Therefore, the future direction of heart valve tissue engineering may follow the 
paradigm of guided tissue regeneration and in situ recellularization. That is, the greatest 
possibility for success lies in developing bioengineered scaffolds and conditioning methods to 
create ‘smart’, bioactive heart valves that harness the patient’s own regenerative capabilities to 
recellularize the construct after implantation. The inherent elegance of in situ recellularization is 
the simplification between the TEHV product (manufacture, distribution, inventory, and patient 
allocation) and the clinical event (actual treatment of individual patients.) It is worth noting that 
there are still significant regulatory hurdles associated with in situ recellularization since many of 
the signaling molecules may be pro-neoplastic and may cause difficulties in sterilization. Lastly, 
it is worth noting that the two recellularization approaches of in vitro and in situ are not mutually 
exclusive and the benefits of both may be leveraged. For example, short term seeding of a ‘pilot’ 
cell population in vitro may provide the signaling cues necessary to induce complete valve 
repopulation by host cells in situ. Such approaches have already realized recellularization 
success in vascular tissue engineering and with polymeric heart valve scaffolds.137, 178  
As discussed previously, decellularized heart valve scaffolds are of significant interest 
moving forward with the tissue engineered heart valve. However, other scaffold options are 
being explored that may soon over-come the limitations of decellularized valves. One such 
scaffold is a polymeric valve under development by XELTIS, a European based company that 
started the first clinical trial evaluating a synthetic, biodegradable scaffold in October 2016.129, 183 
The XELTIS valve is a non-cell seeded scaffold that allows host cell repopulation and new tissue 
formation. This valve is promising because of the unlimited supply of a synthetic valve, though 
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long-term follow up studies are necessary determine the success of the XELTIS valve implants. 
Another noteworthy scaffold option comes from decellularizing ‘man-made’ engineered tissue. 
For example, Tranquillo et al. have created valve and leaflet shaped collagen scaffolds by 
seeding fibrin gels with dermal cells followed by decellularization.164-166 These engineered 
tissues show potential for both in situ recellularization in sheep and in vitro recellularization after 
seeding with MSCs.164-166 Similar to synthetic scaffolds, these engineered scaffolds have 
potential for unlimited supply but further studies are needed to ensure clinical safety. Until then, 
the decellularized heart valve is still the scaffold currently in the best position to move forward 
as a clinically useful TEHV. As advances continue in materials science and in the understanding 
of heart valve structure, the challenges facing synthetic and engineered scaffolds may be 
overcome and an artificial scaffold may one day be preferred for bioengineered valve 
replacements with the attendant manufacturing advantages. However, the timeline for that reality 
is uncertain and decellularized valve scaffolds have the greatest potential for the expeditious 
development of a TEHV due to the regulatory history, long clinical experience with homografts, 
as well as a deep research focus by many groups. 31, 45, 70 Utilizing the decellularized heart valve 
as a tissue engineering scaffold offers advantages in terms of both immediate function and 
overall safety, as the worst case scenario results in a valve similar to the homograft for which the 
natural history is well known and clinical advantages are appropriate for specific patient 
populations. 
In addressing the challenges associated with the TEHV, researchers must be mindful of 
the ultimate goal: improving the clinical management of congenital heart defects and other 
structural valve diseases.  Success in the laboratory does not necessarily equate to successful 
translation to clinical practice.  While the regulatory guidelines for non-viable prosthetic valve 
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substitutes are well defined, the guidelines for FDA approval of a viable combination device 
(cells + scaffold) such as a TEHV are evolving and no such construct has yet been approved. 
Valve functional safety will certainly be paramount; however, assurance of consistent 
recellularization with phenotypically appropriate cell populations could be more challenging to 
demonstrate in vivo and non-destructively, potentially necessitating new technologies for 
analyzing recellularization. Ultimately, the challenge remains regarding scaffold repopulation 
and the success of the TEHV may be reliant upon developing new performance markers, 
including in vitro cell population monitoring, not just performance monitoring by 
echocardiography and traditional MRI methods. Thus, successful heart valve tissue engineering 
strategies will require elegant science to meet the design criteria of the TEHV, survive regulatory 





CHAPTER 3: SPECIES-SPECIFIC EFFECTS OF AORTIC VALVE 
DECELLULARIZATION† 
3.1 Abstract 
Decellularized heart valves have great potential as a stand-alone valve replacement or as 
a scaffold for tissue engineering heart valves. Before decellularized valves can be widely used 
clinically, regulatory standards require pre-clinical testing in an animal model, often sheep. 
Numerous decellularization protocols have been applied to both human and ovine valves; 
however, the ways in which a specific process may affect valves of these species differently have 
not been reported.  In the current study, the comparative effects of decellularization were 
evaluated for human and ovine aortic valves by measuring mechanical and biochemical 
properties. Cell removal was equally effective for both species. The initial cell density of the 
ovine valve leaflets (2036 ± 673 cells/mm2) was almost triple the cell density of human leaflets 
(760 ± 386 cells/mm2; p < 0.001). Interestingly, post-decellularization ovine leaflets exhibited 
significant increases in biaxial areal strain (p < 0.001) and circumferential peak stretch (p < 
0.001); however, this effect was not observed in the human counterparts (p > 0.10).  This 
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species-dependent difference in the effect of decellularization was likely due to the higher initial 
cellularity in ovine valves, as well as a significant decrease in collagen crosslinking following 
the decellularization of ovine leaflets that was not observed in the human leaflet. 
Decellularization also caused a significant decrease in the circumferential relaxation of ovine 
leaflets (p < 0.05), but not human leaflets (p > 0.30), which was credited to a greater reduction of 
glycosaminoglycans in the ovine tissue post-decellularization. These results indicate that an 
identical decellularization process can have differing species-specifc effects on heart valves.  
 
3.2 Introduction 
None of the current treatment options for heart disease requiring valve replacement are 
ideal, including mechanical, bioprosthetic, and biological (primarily cryopreserved homograft) 
valves.  Mechanical valves run the risk of embolism and require a lifetime of anti-coagulation 
therapy.117, 140 Bioprosthetic and homograft valves have a limited lifespan due to structural 
degradation, calcification, and immunological inflammation.70, 106, 117, 140 These complications are 
compounded in children, resulting in multiple revision surgeries throughout the patient’s life. 
Decellularized heart valve options possess great potential as a valve replacement option and/or as 
a scaffold for tissue engineering. As a stand-alone valve substitute, the design of decellularized 
valves is well proven and the acellular nature reduces the immunological response and host 
rejection. However, in clinical application decellularized valves have been met with varying 
levels of success, with decellularized allogeneic valves performing better than xenogeneic 
valves.27, 28, 56, 62, 119, 127, 154 Decellularized valves are a promising scaffold for the tissue 
engineered heart valve (TEHV) due to excellent, intrinsic hemodynamic function and 
structure.117 The TEHV conceptually would combine the optimal hemodynamic performance of 
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the homograft valve with early active tissue remodeling, perhaps allowing for somatic growth 
after implantation.56, 99, 133 However, before decellularized valves are used as stand-alone 
replacements or TEHV scaffolds, the effects of the decellularization process must be fully 
understood.32, 65, 117 
Decellularization has been shown to affect the mechanical and biochemical properties of 
human, ovine and porcine valve tissue; however, the species-specific effects of decellularization 
have not been elucidated due to differences in tissue processing protocols.32, 81, 101 Species-
specific differences in native valve tissue have already been reported between ovine, porcine, 
and aged, human valve leaflets.111 Martin et al. found there are significant mechanical 
differences between the three species and qualitatively observed less collagen type I and collagen 
alignment in the ovine leaflets.111 These reported findings warrant a comparative analysis of 
decellularization across species, as species-specific differences in the effect of decellularization 
may have down-stream consequences.   
The effects of decellularization on the valve extracellular matrix are highly dependent on 
the individual decellularization protocol.36 A study by Liao et al. measured the biaxial 
mechanical and structural effects of three different decellularization protocols on porcine aortic 
valves.101 All three decellularization protocols were found to increase leaflet extensibility, 
though to differing degrees, with the Triton X-100 process having the greatest effect.101 Other 
studies have also compared the effects of different decellularization methods, yet they have 
found that processes using Triton X-100 or other detergents caused the least harm to the 
extracellular matrix, while methods using the enzymatic agent trypsin caused the most harm.87, 
116, 157, 172 We have previously investigated the effects of a low concentration, multi-detergent 
decellularization process on the biaxial, mechanical properties of ovine heart valve leaflets and 
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found an increase in leaflet extensibility and areal strain along with a reduction in relaxation 
following decellularization.32, 34 It was proposed that the increase in leaflet extensibility was due 
to an increased mobility of collagen fibers.101 However, it remains unclear whether other factors 
contribute to changes in mechanical behavior following decellularization. Taken together, these 
reports indicate that the mechanical and biochemical behavior of a decellularized leaflet is 
dependent upon the decellularization protocol and therefore each decellularization protocol 
should be analyzed and validated for the species and tissue that it will ultimately process. 
The end-goal of characterizing decellularized tissue is to develop a fundamental 
understanding of tissue composition and properties, which may, in turn, facilitate clinical 
translation. However, regulatory guidelines require pre-clinical testing in animal models. Sheep 
are considered the regulatory standard for valve implantation due to the similar cardiac and 
growth characteristics of the ovine model to human children59, yet due to species- transplantation 
antigen mismatch it is not useful to implant human valves in sheep. Therefore, good scientific 
practice requires characterizing pre-implant decellularized human and ovine valves. Previous 
studies have investigated the effects of decellularization on ovine valve tissue and the 
performance of those valves in sheep.131-133 However, to our knowledge, no studies have 
evaluated the comparative effects of equivalent decellularization protocols between ovine and 
human valves. The ovine valve model was designed to test calcific degradation of glutaraldehyde 
crosslinked bioprosthetic valves, thus the similarities to human hosts for evaluating other 
biological valves is less well understood. Therefore the purpose of this study is to compare the 
effects of a multi-detergent decellularization process on human and ovine aortic valves. The 
underlying causes for changes in the mechanical behavior of the extracellular matrix (ECM) 
were evaluated using histology, collagen crosslinking analysis, and biochemical content assays.  
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3.3 Materials and Methods 
3.3.1 Tissue preparation 
Ovine aortic valves were obtained from juvenile sheep under approved IACUC protocols 
and in accordance with Guide for Care and Use of Laboratory Animals (National Institutes of 
Health Publication No. 85-23). Ovine samples were cryopreserved 72 h after harvest to simulate 
clinical tissue handling methods. Human aortic valves were obtained from a tissue banking 
facility (LifeNet health, Virginia Beach, VA) from male donors aged 16-26 years old. All 
samples were stored in cryopreserved state until use. The cryopreservation procedure was 
modeled after clinical tissue handling protocols. Briefly, samples were frozen in a cryoprotectant 
(RPMI w/10% FBS and 10% DMSO) at 1 °C min-1 using a controlled rate freezer (2100 Series, 
Custom BioGenics Systems, Romeo, MI) before being stored in a cryofreezer at -180 °C. 
Cryopreserved valves were selected as the standard comparison against decellularized valves 
since cryopreserved valves are used clinically and are the closest to in-situ native valves that can 
be easily obtained.  In total, seven ovine cryopreserved, six ovine decellularized, six human 
cryopreserved and six human decellularized aortic heart valves were used to complete this study. 
3.3.2 Valve decellularization 
Ovine and human aortic valves were thawed from cryopreservation and decellularized 
using a reciprocating osmotic shock and non-ionic detergent wash protocol similar to that 
described previously.133 Under continuous mild shaking, valves were immersed in a series of 
solutions including, hypertonic salt solution (HSS), 0.05% Triton X-100 (Sigma-Aldrich), 
deionized water, N-lauroylsarcosine sodium salt (Sigma-Aldrich), and Benzonase® (EMD 
Chemicals, Gibbstown, NJ). Afterwards, organic soluble material was extracted via recirculating 
sterile water through ion exchange resins (Amberlite, Sigma-Aldrich; Mixed Bead Resin TMD- 
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8, Sigma-Aldrich; Dowex Monosphere, Supleco) for 40 hours. Following decellularization the 
valves were cryopreserved using the procedure described above. The effectiveness of 
decellularization was determined via histologic imaging and double-stranded DNA (dsDNA) 
analysis. Assays for dsDNA were performed using the Quant-it Kit, High Sensitivity (Invitrogen, 
Carlsbad, CA) and measured using a fluorescence plate reader (Synergy HT, Bio-Tek 
Instruments Inc., Winooski, VT) at 486/528 nm excitation/emission wavelengths. dsDNA 
content was calculated as ng mg-1 of wet tissue. 
3.3.3 Biaxial mechanical testing 
The quasi-static and time dependent mechanical behavior of cryopreserved and 
decellularized, human and ovine valve leaflets were measured using planar biaxial mechanical 
testing, using methods similar to those previously described.32 Leaflets were dissected from their 
regional position (left coronary (LC), right coronary (RC), or non-coronary (NC)) and a 9 x 6 
mm rectangular specimen was cut from the belly region of the leaflet. The rectangular samples 
were then attached to tissue grips using small fishing hooks and line, with four attachment points 
per side. The tissue grips were submerged in phosphate buffer saline (PBS) at 37 °C and 
mounted on a four motor biaxial test system (LM1 TestBench, Bose, Eden Prairie, MN) such that 
the loading axes aligned with the circumferential and radial directions of the sample.  
Equibiaxial loading was performed on cryopreserved and decellularized leaflet samples 
(n = 9). Ovine specimens were loaded to tensions of 30 N m-1 using a rise time of 10 s and 
human specimens were loaded to 60 N m-1 using a rise time of 10 s. A lower tension was used on 
ovine samples to prevent failure at attachment points based on previous experience.32 Specimens 
were preconditioned for 10 loading cycles prior to data collection. Strain was measured using a 
digital video extensometer. Peak stretch ratios were calculated from strain data in the 
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circumferential (λCpeak) and radial (λRpeak) directions. Anisotropy ratios (λRpeak/ λCpeak) were also 
calculated for each specimen.  Areal strain was used as a measure of net extensibility and was 
calculated from equibiaxial data as (λCpeak x λRpeak – 1) x 100%. Following quasi-static testing, all 
samples underwent relaxation testing. Samples were loaded to the same equibiaxial tension used 
previously at a rate of 8 mm s-1 along the radial axis. The displacement rate along the 
circumferential axis was adjusted so the overall rise time of both axes was equal. Specimens 
were held at a constant displacement and allowed to relax for 1000 s, while load data was 
collected.  Relaxation data is reported as per cent relaxation at multiple time points (i.e., 1, 10, 
100 and 1000 s).  Additionally, the time after initial loading at which differences in relaxation 
between cryopreserved and decellularized became statistically significant was determined.  It is 
worth noting that the same specimens used for mechanical testing were also utilized for GAG, 
collagen, elastin analysis.  Between tests, the specimens were stored at -80 °C. 
3.3.4 Biochemical Assays 
The effects of decellularization on the leaflet extracellular matrix were evaluated using 
biochemical assays, specifically by measuring the collagen, elastin, sulfated glycosaminoglycan 
(sGAG), and total protein concentrations. Collagen and total protein concentrations were 
measured using the QuickZyme Total Collagen Assay and QuickZyme Total Protein Assay, 
respectively (QuickZyme Biosciences, Leiden, The Netherlands). Samples (~15 mg, n = 9) were 
prepared by overnight hydrolysis in 6M HCl at 90 °C. The resulting hydrolysates were used for 
the collagen and total protein assays, as well as for collagen cross-linking analysis. The collagen 
and total protein assays used colorimetric quantification to measure the hydroxyproline and free 
amino acid concentrations, respectively. Samples were analyzed using a UV/Vis 
spectrophotometer (VERSAmax, Molecular Devices) at 570 nm. Elastin and sGAG 
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concentrations were measured using commercially available assay kits (Fastin Elastin Assay and 
Blyscan Sulfated Glycosaminoglycan Assay; Biocolor). Tissue samples for elastin and sGAG 
assays (~15 mg, n=9 each) were processed according to manufacturer protocols and the results 
quantified colorimetrically using a UV/Vis spectrophotometer at 513 nm and 656 nm, 
respectively. Total protein content is reported as µg mg-1 of wet tissue. Collagen, elastin, and 
sGAG content are reported as fraction of total protein and as µg mg-1 of wet tissue. 
3.3.5 Collagen Cross-linking 
The degree of collagen crosslinking in the human and ovine leaflets, for both 
cryopreserved and decellularized samples, was analyzed by measuring the mature enzymatic 
collagen crosslinks by the biomarkers pyridinoline (PYD) and deoxypyridinoline (DPY).91 PYD 
and DPY are hydrophilic amino acid derivatives released by digestion to amino acids.  PYD and 
DPY have a quaternary amine (pyridinium) and three carboxylic acid functional groups and are 
frequently measured by cation ion pair reverse phase chromatography with fluorescence 
detection. A modification of the general ion pair method has been adapted for reverse phase 
liquid chromatography and mass spectrometry (LCMS).91 The ion pair agent, in this case 30 mM 
sodium salt from octane sulfonic acid, was put into each sample.  When injected, each sample 
“refreshes” the amount of ion pair bound to the stationary phase of the C18 column for consistent 
retention times. Separation was done in isocratic mode with 90% 0.1% acetic acid and 10%  
CH3CN on a Hypersil BDS C18 column (3 µ, 2.1 mm × 100 mm) using a Waters Acquity 
Classic UPLC (Waters Corp., Milford MA). The injection volume was 20 ul and the column 
operated at 320 ul/min with the first 4 minutes of eluent diverted away from the source.  
Following separation, compounds were detected using a “triple” quadrupole mass spectrometer 
(Quattro Ultima Micromass Ltd. Manchester UK) operating in positive-ion mode with the mass 
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analyzers tuned to 0.8u FWHH. Cone voltage and collision induced dissociation conditions for 
precursor/product ion pairs were determined by post column mixing of standards infused at 
UPLC elution conditions. The conditions were 1) PYD m/z 429> 82 and 2) DPY m/z 413> 84, 
both with a cone voltage of 45 V, a collision energy of 35 V, and 150 ms dwell time.  The 
retention times were 6.8 minutes for both compounds. Calibration curves were generated by 
pooling partial aliquots from all samples in a batch and spiking with PYD/DPY standards 
(Quidel, San Diego CA USA) at 4 concentrations in the 100s of pg/ul range. Samples for all 
groups were taken from the hydrolysates used in the collagen concentration assay. The 
hydrolysate samples were dried overnight under N2 flow then stored at -20 °C until use, at which 
point they were reconstituted in H2O. Then, the ion pair agent was added after pooled sample 
segregation.  Remnant hydrolysis salts, amino acids, etc., did not suppress signal compared to 
standards with hydrolysis. PYD and DPY concentrations are reported as ng µg-1 of collagen.  
Note that a second set of valves was used for collagen cross-linking analysis.  Additional 
collagen analysis was performed on these valves.  Therefore, the collagen contents used for 
normalization of cross-linking compounds correspond directly to the valves used for cross-
linking analysis.  
3.3.6 Histology 
Human and ovine valve leaflet samples for histology were dissected and sectioned along 
the radial plane. Hematoxylin and eosin (H&E) staining was used to evaluate leaflet architecture 
and cell removal. Following H&E staining, cellularity of the cryopreserved ovine (n=12) and 
human (n=6) leaflets was determined by counting the cells in a calculated area using Axiovision 
software. Cell density was measured at the base, middle, and tip region of the leaflet and an 
average for the whole leaflet was calculated. Leaflets were also stained with Movat’s 
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pentachrome to evaluate the ECM biochemical structure and collagen architecture.  
3.3.7 Statistical Analysis 
To determine the effect of decellularization within each species, statistical comparisons 
were made between the cryopreserved and decellularized samples of that species.  A statistical 
comparison was also made for the initial cellular density between human cryopreserved and 
ovine cryopreserved samples in an effort to elucidate a possible reason for differences in effect 
observed between species.  Normality within groups was determined by the Shapiro-Wilk test. 
Data between cryopreserved and decellularized groups was evaluated with parametric (Student’s 
t-test) and non-parametric (Mann-Whitney Rank Sum Test) methods as appropriate (SigmaStat 
3.5, Systat Software, Inc., Chicago, IL.). Differences between groups were considered 
statistically significant at p < 0.05. Error values reported as the standard deviation of the mean.  
3.4 Results 
3.4.1 Decellularization and Histology 
For all decellularized samples, dsDNA content was below the detection limit of 0.007 
ng/mg wet tissue, indicating a >99.9% reduction in nuclear material from both human and ovine 
leaflet tissue. Effective decellularization is further supported by histologic acellularity observed 
in all regions of both human (Figure 3.1) and ovine (Figure 3.2) decellularized valve leaflets. The 
lamellar structure of the leaflet was preserved following decellularization; however, the 
extracellular matrix was more porous due to the removal of cells (Figure 3.1 C, D and Figure 3.2 
C, D).  
The average number of cells in cryopreserved tissue was measured by leaflet region 
(Figure 3.3). Both ovine and human leaflets had a significantly greater density of cells in the tip 
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of the leaflet compared to the base and the middle. Overall leaflet averages indicated that the 
cellular density in the ovine leaflet was nearly three-fold that measured in the human leaflet, with 
2036 ± 673 and 760 ± 386 cells/mm2 in ovine and human tissues, respectively (p < 0.001). 
3.4.2 Planar biaxial mechanical testing 
The mechanical behavior of ovine and human aortic valve leaflets was highly anisotropic 
under biaxial loading (Figure 3.4).  Mechanical testing revealed several species-specific effects 
of decellularization (Figure 3.5). As determined by equibiaxial testing, decellularized ovine 
leaflets exhibited a statistically significant increase in areal strain compared to cryopreserved 
samples (p < 0.001), while no significant difference was measured in human samples (p = 0.11). 
Decellularized ovine leaflets had an areal strain of 158.1 ± 15.4% while cryopreserved ovine 
leaflets exhibited 124.5 ± 19.7%. Decellularized and cryopreserved human leaflets exhibited 
areal strains of 93.3 ± 12.3% and 84.0 ± 11.3%, respectively. Ovine leaflets also exhibited a 
significant increase in the circumferential peak stretch ratio of decellularized leaflets compared 
to cryopreserved leaflets (p < 0.001). Ovine leaflets had a circumferential peak stretch ratio of 
1.36 ± 0.07 and 1.22 ± 0.06 for decellularized and cryopreserved samples, respectively. No 
significant change in circumferential peak stretch ratio was seen in human samples (p = 0.23). 
Human leaflets had a circumferential peak stretch ratio of 1.16 ± 0.08 and 1.10 ± 0.08 for 
decellularized and cryopreserved samples, respectively.  There was also no significant difference 
in the radial peak stretch ratio between decellularized and cryopreserved leaflets for ovine (p = 
0.28) or human (p = 0.73) samples. Ovine radial stretch ratios for decellularized and 
cryopreserved samples were 1.90 ± 0.11 and 1.84 ± 0.14, respectively, and human radial stretch 
ratios were 1.66 ± 0.07 and 1.65 ± 0.07, for decellularized and cryopreserved respectively.  
Ovine cryopreserved and decellularized leaflets exhibited anisotropy ratios of 1.51 ± 0.14 and 
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1.41 ± 0.12, respectively; however, the difference was not statistically significant (p < 0.11).  
Human cryopreserved and decellularized leaflets exhibited anisotropy ratios of 1.49 ± 0.16 and 
1.44 ± 0.13, respectively; however, as with the ovine samples, the difference was not statistically 
significant (p = 0.43).  
Relaxation testing revealed that decellularization effected the time-dependent behavior of 
leaflet; however, the effect was more pronounced in the ovine leaflet (Figure 3.6, Figure 3.7). 
Decellularization caused significantly decreased relaxation of valve leaflets in both ovine and 
human tissues in the radial direction at 1000 s (p < 0.001 ovine; p = 0.04 human). Ovine 
decellularized and cryopreserved leaflets respectively exhibited 25.8 ± 1.7% and 30.7 ± 2.9% 
relaxation in the radial direction at 1000 s, while human decellularized and cryopreserved leaflets 
respectively exhibited 25.9 ± 1.1 % and 27.7 ± 2.0%. However, in the circumferential direction, 
only ovine tissue exhibited a significant decrease in relaxation at 1000 s (p < 0.01). Ovine 
leaflets exhibited 26.9 ± 2.0% and 31.53 ± 2.9% relaxation in the circumferential direction at 
1000 s for decellularized and cryopreserved samples, respectively. No significant change in 
circumferential relaxation was observed in human tissue (p = 0.21).  At 1000 s, human tissue 
exhibited circumferential relaxation of 25.6 ± 1.2% and 27.1 ± 3.3%, for decellularized and 
cryopreserved samples respectively.  Statistically significant differences in relaxation between 
decellularized and cryopreserved ovine leaflets emerged 2 and 4 s after initial loading in the 
radial and circumferential specimen directions, respectively.  In the radial specimen direction at 
2 s, cryopreserved and decellularized ovine leaflets exhibited 16.9 ± 2.9% and 14.3 ± 1.9 
relaxation, respectively (p = 0.04).  In the circumferential specimen direction at 4 s, 
cryopreserved and decellularized ovine leaflets exhibited 19.7 ± 2.9% and 17.2 ± 1.4 relaxation, 
respectively (p = 0.04).  These differences in ovine samples remained statistically significant 
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throughout the remainder of relaxation period (p < 0.03); however, a statistically significant 
difference in relaxation of human samples in the radial direction did not emerge until 100 s after 
initial loading (Figure 3.7).   
3.4.3 Biochemical Assays 
The decellularization process was found to slightly affect the biochemical composition of 
the extracellular matrix of the valve leaflets (Table 3.1). Collagen, the primary structural protein 
of the leaflet matrix, was not significantly altered by decellularization in ovine or human samples 
(p = 0.59; p = 0.39, respectively). Interestingly, decellularization did cause a significant decrease 
in the elastin concentration of human leaflets (p < 0.05), yet there was no significant change in 
ovine leaflets (p = 0.84). The concentration of sGAGs was also significantly decreased in 
decellularized samples for both ovine and human tissues (p<0.01; p < 0.001, respectively). The 
reported differences in sGAG content between decellularized and cryopreserved samples 
represent an 89.6% reduction for ovine leaflets and a 57.4% reduction for human leaflets. 
Overall, there was no significant change in total protein concentration of the leaflet samples for 
either human or ovine specimens after decellularization. 
3.4.4 Collagen Cross-linking 
The concentration per collagen of the mature collagen cross-links PYD and DPY was 
measured in the human and ovine cryopreserved and decellularized leaflet samples (Figure 3.8). 
Following decellularization, the concentration of DPY and PYD remained relatively unchanged 
in the human leaflets. The concentration of PYD in the human leaflets measured 0.17 ± 0.03 ng 
µg collagen-1 for decellularized samples and 0.18 ± 0.03 ng µg collagen-1 for cryopreserved 
samples (p = 0.70). The concentration of DPY in the human leaflets was 0.06 ± 0.03 ng µg 
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collagen-1 and 0.07 ± 0.01 ng µg collagen-1 for decellularized and cryopreserved samples, 
respectively (p = 0.43). Interestingly however, the ovine leaflets experienced a significant 
decrease of both collagen crosslinking markers after decellularization. Ovine leaflets had a PYD 
concentration of 0.21 ± 0.08 ng µg collagen-1 and 0.31 ± 0.06 ng µg collagen-1 for decellularized 
and cryopreserved samples, respectively (p < 0.01), and a DPY concentration of 0.02 ± 0.004 ng 
µg collagen-1 and 0.1 ± 0.006 ng µg collagen-1 for decellularized and cryopreserved sample, 
respectively (p < 0.05).  
3.5 Discussion 
3.5.1 Mechanical Effects of Decellularization 
The primary purpose of the tested decellularization process is removal of cellular and 
nuclear material from the scaffold. At this, it was highly effective for both ovine and human 
aortic valve leaflets. In both species, the double stranded DNA content of the decellularized 
leaflets was lower than the detection limit of 0.007 ng/mg wet tissue, indicating greater than 
99.9% removal of double stranded DNA. Decellularization was confirmed by H&E staining 
which showed no evidence of cells or nuclear material in the resulting extracellular matrix of 
human or ovine leaflet tissue.  
The decellularization process was equally effective at removing nuclear material from 
both human and ovine valves, yet decellularization also resulted in changes in mechanical 
behavior of ovine valve leaflets, as we have observed previously for ovine pulmonary valve 
leaflets 32. Equibiaxial and time dependent mechanical testing of the decellularized ovine leaflets 
revealed increased areal strain and circumferential stretch ratio, along with significantly 
decreased relaxation in both specimen directions, compared to the cryopreserved leaflet; 
however, the level anisotropy remained unchanged (Figure 3.5, Figure 3.7). For the human aortic 
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valve leaflet, only a significant decrease in relaxation in the radial specimen direction was 
observed.  Differences before and after decellularization in the relaxation behavior of the ovine 
leaflet were reflected in the relaxation curves; however, this was not the case for human sample, 
likely due to the overall magnitude of the change (Figure 3.6, Figure 3.7).  Statistically 
significant differences in relaxation between cryopreserved and decellularized leaflet tissue also 
emerged much more rapidly in ovine samples, compared to human samples.  This illustrates a 
key finding of this study that, while the human and ovine valves underwent the same 
decellularization process, the mechanical behavior of the ovine aortic valve leaflet was affected 
more extensively.  
Direct statistical comparisons were not made between the mechanical properties of ovine 
and human tissues in part because different tension levels were used for the two cohorts and also 
because the effect of decellularization within a given species is determined by comparing the 
cryopreserved and decellularized samples of that particular species.  However, to gain a better 
understanding of the relationship in mechanical behavior between the human and ovine leaflets, 
stretch ratio and areal strain values for human leaflet tissues at a tension of 30 N/m were 
determined from the tension-stretch data (Table S1).  As expected based on the tension-stretch 
curves (Figure 4a), stretch ratios and areal strain at 30 N/m were very similar to those at 60 N/m 
(p > 0.44), and as at a tension of 60 N/m, there were no statistically significant differences 
between cryopreserved and decellularized samples at a tension of 30 N/m.  
3.5.2 Biochemical makeup of the ECM 
Collagen, the primary structural protein of the valve leaflets, and the total protein content 
of the leaflets remained unchanged after decellularization indicating other factors were 
responsible for the change in leaflet mechanical properties in ovine samples (Table 3.1). 
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However, a significant decrease in sulfated GAGs was measured in decellularized samples. The 
loss of the bulky GAGs from the ECM may open the leaflet architecture and allow greater 
freedom of rotation of the collagen fibers owing to the increase in areal strain. However, a study 
by Eckert et al. used enzymatic digestion to test the biomechanical properties of GAGs in 
porcine aortic valve leaflets and it was found that the loss of GAGs had no effect on peak stretch 
during biaxial tensile testing.53 Therefore, it is unlikely that the loss of GAGs contributed 
significantly to the changes in areal strain and peak stretch ratio of ovine leaflets in the current 
study. A reduction of GAG content has been linked to decreased relaxation.20, 32, 102, 112 In the 
current study, decreases in relaxation were observed in both human and ovine leaflets following 
decellularization; however, the changes were more extensive, and emerged more rapidly, in 
ovine tissue. This corresponded to a larger reduction in GAG content in ovine samples, 
compared to human.  Seemingly contrary to these results, the study by Eckert et al. reported no 
change in the time-dependent tensile properties of their porcine valve leaflets after the enzymatic 
removal of GAGs.53 However, their study evaluated changes in hysteresis of the stress-strain 
relationship during cyclic loading. Therefore Eckert’s results and those from this study are not 
directly comparable.  In this study, significant differences in per cent relaxation were observed at 
2-4 s after initial loading.  While still longer than the cardiac cycle, the speed with which these 
differences emerged suggests that GAG retention during decellularization may be an important 
consideration. 
3.5.3 Collagen Crosslinking 
The trivalent collagen crosslinks PYD and DPY are the mature products of lysyl oxidase-
mediated crosslinking.128 Both compounds are primarily found in bone collagen, but they are 
also present in a number of soft tissues, including heart valves.2, 11, 128 Aldous et al. found that 
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during the fetal-to-neonatal transition of bovine, the concentration of these mature crosslinks 
increased in aortic valve leaflets as the transvalvular pressure increased, indicating collagen 
remodeling and maturation in response to higher loads.2 In another study. Balguid et al. found a 
direct correlation between the concentration of PYD and DPY in human valve leaflets and the 
circumferential modulus of elasticity.11 In the current study, decellularization resulted in a 
significant decrease in PYD and DPY in ovine aortic valve leaflets; however, no significant 
changes were observed in human tissue. This species-dependent effect on collagen crosslinking 
likely contributed to the dissimilarities observed in the mechanical behavior between species. It 
isn’t entirely clear why ovine valves were more susceptible to a loss of PYD and DPY 
crosslinks; however, all ovine valves were from juvenile sheep and human valves were from 
donors 16-26 years of age. There is evidence that the amount of collagen crosslinking increases 
with age88, 163, which favors crosslinking in the human valves. Interestingly however, the PYD 
concentration measured in this study was greater in the ovine valves. Though it does not appear 
that age affected the concentration of collagen crosslinking, the age of the valves may effect 
crosslinking stability. “Mature” collagen has been thought to have stronger molecular bonds 
which has consequences such as less protein remodeling and stiffer collagen rich tissues. 
Furthermore, human valve leaflets are almost twice as thick as ovine leaflets and the 
decellularization process may have a greater effect on the thinner ovine leaflets.141 It is also 
possible that the loss of collagen crosslinks is entirely a species-specific effect.  
3.5.4 Cell density and cell loss 
The number of cells per mm2 in the cryopreserved ovine leaflets was nearly triple the 
amount of cells per mm2 found in cryopreserved human leaflets. The measured difference in 
cellularity may partially be related to the previously mentioned age discrepancy between ovine 
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and human groups rather than purely species-specific. After decellularization, no cells were 
found in valve leaflets of either species. Valve interstitial cells (VICs) have been mechanically 
characterized by microaspiration and found to have their own effective elastic modulus that 
correlates with transvalvular pressure115 and viscoelastic properties.113 The contractility of VICs 
is thought to be too low to affect valve mechanics during normal valve function115, and it is 
doubtful the cells provide significant structural stability during tensional loading. However, Liao 
et al. previously reported increased extensibility of porcine aortic valve leaflets following 
decellularization and attributed the changes to increased collagen fiber motility, reasoning that 
the loss of cells and other key proteins opens up the leaflet architecture allowing more freedom 
of movement of collagen fibers.101 Additionally, VICs interact with the surrounding ECM 
through integrin-mediated adhesions, which act to transfer local micromechanical forces to the 
cells.30 Therefore, the integrin binding of the VICs likely function as attachment points between 
collagen fibers, restricting their rotation and providing greater structural stability. It is proposed 
that following decellularization, the vacant regions of missing cells and the loss of cellular 
attachment between collagen fibers leads to greater collagen fiber rotation. Thus, the higher 
initial cellularity of the ovine valves likely also contributed to the discrepancy in post-
decellularization mechanical properties. These results imply that the VICS within the aortic 
valve leaflet may provide greater structural support than previously believed, not by conveying 
their own mechanical properties but instead in the interaction between VICs and ECM 
components. 
3.5.5 Insight for in vivo implantation 
Taken together, the results of this study show a species-specific response to 
decellularization. After decellularization, ovine aortic leaflets displayed a greater change in 
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biaxial stretch behavior compared to their human counterparts. The underlying cause for the 
species-specific response in biaxial stretch is likely a contribution of multiple factors: including a 
loss of collagen crosslinking and greater initial cellularity in ovine valve leaflets. Additionally, 
ovine leaflets underwent more extensive changes in relaxation post-decellularization, which 
corresponds to larger GAG reduction. These results stand as a firm reminder that the ovine 
animal model is only a model, and that studies performed in sheep or using ovine tissue may not 
translate perfectly to clinically studies. However, the ovine model remains an important 
regulatory pre-clinical animal model due to its similar calcification and immune response 
analogous especially to valve replacement in pediatric patients. Since human valves cannot be 
implanted in sheep, the characterization of decellularized valves post-processing from both 
species provided by this study is essential. The success of in vivo ovine valve replacement 
studies using decellularized valves has been shown and our own decellularization protocol has 
been validated by in vivo studies using similarly decellularized valves implanted in juvenile 
sheep.131-133 While the ovine model provides crucial calcification information, it is also worth 
considering other animal models especially if unanticipated in-vivo results occur that are at 
variance with in-vitro predictions of performance. Porcine valves are more anatomically and 
mechanically similar to humans and the papio model allows implantation of human valves.71, 141 
Ultimately, the sheep model remains the gold standard for assessing vulnerability to calcification 
while also providing estimates of pro-thrombotic and pro-inflammatory propensities before 
moving into clinical trials. The combination of relevant bench assays and the sheep chronic 
implant model likely provides a useful and sufficient preclinical testing regimen. 
3.5.6 Study Limitations 
This study is not without limitation. While planar biaxial testing has emerged as a 
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popular method for evaluating the mechanical behavior of the heart valve leaflet, test 
methodologies remain unstandardized.  The reference configuration for strain monitoring in this 
study was selected as the unloaded state prior to specimen preconditioning, as reported 
previously.32 Others have selected a reference state either after the application of a small pre-
load151 or after specimen preconditioning.111 Thus, the mechanical properties reported here are 
not necessarily directly comparable to those reported by other authors.  However, in the context 
of this comparative study, the methodology selected for biaxial testing does permit comparisons 
to be drawn between cryopreserved and decellularized tissues. Different strategies have also 
been reported for specimen attachment to the biaxial test apparatus (i.e., hooks, springs, clamps).  
Hooks, which inherently create stress-concentrations at the discrete attachment points, were 
selected for the current study. This could result in non-uniform relaxation across the leaflet; 
however, we note that we did not visually observe evidence of transient deformation at the 
attachment points (e.g., gaps in the tissue developing over time) over the course of relaxation 
experiments. Moreover, because the same number of attachment points per side, per specimen 
were used over the course of the study, any effect would be consistent across all specimens 
tested.  The placement of tissue attachment points is also important in biaxial testing.155 Care was 
taken to place hooks as uniformly as possible across leaflet samples to minimize this potential 
source of error. We also note that the loading rate used for relaxation testing was lower than the 
physiologic rate; however, Doehring et al. found only moderate strain-rate dependence in the 
relaxation of heart valve leaflet tissue.44 Additionally, Stella et al. reported no strain-rate 
sensitivity in leaflet membrane strain energy under biaxial loading.162 Thus, given the 
comparative nature of this study, the methods used here were useful in determining differences 
in relaxation following decellularization. Finally, the standard deviation in biochemical test data 
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was high in some cases. This may be due to sampling, coupled with regional variation in leaflet 
composition. Variability could likely be reduced through the use of larger samples for each 
individual assay; however, the methods used here permitted the direct evaluation of multiple 
biochemical properties on each leaflet sample subjected to biaxial testing.       
3.6 Conclusion  
This study identifies key differences in the effects of decellularization on human and 
ovine aortic valves. Decellularization resulted in effective cell removal for both human and ovine 
aortic valve leaflets. Ovine leaflets exhibited significant changes in mechanical properties that 
were not observed in human leaflets. Further analysis identified a number of underlying causes 
including the loss of collagen crosslinking and greater initial cellularity in ovine leaflets 
compared to human. This species-specific response to decellularization highlights the importance 
of validating decellularization protocols for the species and tissue for which it is intended as well 






CHAPTER 4: COMPARISON OF CANDIDATE CELL POPULATIONS FOR THE 
RECELLULARIZATION OF TISSUE ENGINEERED HEART VALVES‡ 
4.1 Abstract 
Heart valve tissue engineering may provide improved treatment for valvular heart 
disease, yet development of a tissue engineered heart valve (TEHV) has been limited by 
incomplete recellularization of the valve leaflets. In this study, we compare the leaflet 
recellularization potential of candidate cell populations after seeding onto decellularized heart 
valves and two weeks of bioreactor conditioning. Four cell populations were tested: bone 
marrow mononuclear cells (MNC), 5 million bone marrow mesenchymal stem cells (MSC), 10 
million bone marrow mesenchymal stem cells (MSC2), and valve interstitial cells (VIC). MSC2 
valves demonstrated the best recellularization of the interstitial leaflet tissue as well as an 
appropriate cell phenotype, mechanical properties, and biochemical composition. MSC valves 
exhibited similar leaflet repopulation, yet had decreased mechanical and biochemical properties. 
MNC seeding resulted in minimal recellularization of the leaflet, though an additional time point 
group found cells present after three days, which seemed to disappear at two weeks. VIC seeding 
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Comparison of Candidate Cell Populations for the Recellularization of Tissue Engineered Heart 
Valves, Cellular and Molecular Bioengineering, Submitted Dec. 23, 2017. 
59 
 
resulted in cell clumping on the leaflet surface and poor recellularization. The results of this 
study suggest mesenchymal stem cells are a preferred cell population for TEHV recellularization 
and demonstrate the ability for repopulation of the distal valve leaflet.   
 
4.2 Introduction 
Valvular heart disease remains a significant cause of morbidity and mortality worldwide, 
particularly for pediatric patients with congenital valve defects.70 The current options for valve 
replacement, including mechanical valves, bioprosthetic valves, and cryopreserved allografts, all 
have associated limitations and cannot provide the necessary remodeling or growth after 
implantation.70 Therefore, pediatric patients requiring valve replacement often undergo multiple 
revision surgeries throughout their lifetime.70 The tissue engineered heart valve (TEHV) may be 
the ideal solution for heart valve replacement acting as a one-time intervention to create living, 
functional tissue capable of growth and remodeling.70  
However, a number challenges remain before realizing the TEHV. Primarily is the 
difficulty in establishing a phenotypically appropriate cell population within the valve leaflet 
tissue. Native heart valves are populated by two cell phenotypes, valve endothelial cells on the 
luminal surfaces and valve interstitial cells (VICs) within the tissue matrix. Decellularized heart 
valves implanted as bioprosthetic replacements in human and animal models have shown 
complete re-endothelialization of the luminal surfaces and partial recellularization of the valve 
interstitial tissue including the conduit and leaflet base.48, 131 However, despite the presence of 
endothelial cells, the distal free-edge of the valve leaflets exhibit an absence of VIC 




Over the years, various methodologies for cell seeding using multiple cell sources have 
been explored.80, 174 Using endothelial cells, myofibroblasts, or VICs from arterial, venous, or 
leaflet tissue avoids cell phenotype mismatch with the native valve; however, obtaining 
homologous cells for clinical use is problematic.66, 104, 161 Bone marrow derived mesenchymal 
stem cells (MSCs) and mononuclear cells (MNCs) have received interest as a potentially patient-
specific cell source. MSCs are an attractive option because of their differentiation potential 
toward a VIC lineage and their immunomodulatory capabilities.35, 52, 158 However, the 
preparation MSC populations prior to seeding can be a time consuming procedure.124 MNCs are 
of interest due to their potential for rapid migration and inflammation-mediated native cell 
recruitment through paracrine signaling.137, 178 
Despite the variety of cell sources for heart valve seeding, there have been very few 
direct comparisons between cell populations to evaluate the potential for valve recellularization. 
One of the only comparisons (Vincentelli et al.) utilized a direct injection technique to transplant 
ovine MNCs or MSCs into the annulus and arterial wall of decellularized porcine pulmonary 
heart valves before implantation into sheep.175  After 4 months in vivo, the MNC injected group 
displayed thickened leaflets, increased pressure gradients, calcification, and the presence of 
inflammatory cells.175 The presence of the inflammatory cells may be in line with the 
inflammation-mediated recellularization described previously by MNCs, although the other 
reported results are not encouraging and suggest a classical inflammatory response. The injection 
of expanded MSCs did not elicit this negative response and a limited number of α-actin positive 
cells were observed in the leaflet.175 However, cells cannot be clinically localized directly within 
the leaflet using this method due to the potential of damage to the delicate tissue.  
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Therefore, the purpose of this investigation is to provide a direct comparison between 
seeding cell populations for their TEHV recellularization potential. MNCs, MSCs, and VICs, 
were tested for their ability to repopulate the interstitial leaflet tissue of decellularized heart 
valves following in vitro bioreactor conditioning. To better evaluate the MSC seeded groups, two 
seeding concentrations were tested, leading to a total of four tested cell populations. Although 
not clinically practical, VICs were included as a positive control for cell phenotype analysis. It 
was hypothesized that valves seeded with MSCs at the higher concentration would lead to 
significantly higher recellularization of the leaflet tissue compared to other groups.  
4.3 Methods 
4.3.1 Tissue and tissue processing 
Ovine aortic valves were harvested from juvenile sheep under approved IACUC 
protocols and in accordance with Guide for Care and Use of Laboratory Animals (National 
Institutes of Health Publication No. 85-23). Harvested valves were cryopreserved using a 
procedure modeled after clinical tissue handling protocols. Valve were frozen at 1 °C min-1 using 
a controlled rate freezer (2100 Series, Custom BioGenics Systems) then stored at -180 °C. Valve 
decellularization was performed as described previously.133 Briefly, the valves were thawed and 
subjected to reciprocating osmotic shock, followed by detergent (Triton X-100, sodium-lauroyl 
sarcosine) and enzymatic (Benzonase®) washes to remove cellular material. Extraction of 
organic material was performed using recirculating water and ion exchange resins. After 
decellularization, the valves were again cryopreserved as described and stored at -180 °C until 
seeding. 
4.3.2 Seeding cell populations 
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The decellularized ovine aortic valves were randomly divided into four groups for 
seeding: human MNCs (MNC group), human MSCs at a dose of either 5 million (MSC group) or 
10 million (MSC2 group) cells per valve, or human VICs (VIC group). Cell populations for MNC 
and MSC seeded valves were isolated from 25 mL human bone marrow aliquots obtained from a 
commercial source (Lonza) using a bone marrow filter system (Kaneka).98 For MNC seeding, the 
entire mononuclear cell population was isolated from bone marrow and used for valve seeding. 
For seeding with MSC populations, mononuclear cells were filtered from bone marrow and the 
mesenchymal stem cell fraction was isolated through cell culture until sufficient cells were 
available. VICs were isolated from human aortic valve leaflets. Briefly, aortic valve leaflets were 
dissected, minced, and placed in a cell culture flask to allow the outgrowth of VIC cells. After 
sufficient proliferation, VICs were cryopreserved and stored at -180 °C 
4.3.3 Valve seeding and conditioning 
For each cell seeding group, the tissue engineered heart valves were seeded following 
established protocols.34 Decellularized valves were thawed from cryopreservation and sutured 
onto tissue grips. The seeding cell population for each group was then suspended in 10 mL of 
media and seeded into the lumen of the valve which was mounted in a static bioreactor chamber 
containing 200 mL valve media (DMEM F12 (Life Technologies) and 10% human serum 
(Sigma-Aldrich)). After cell seeding, all groups underwent the same bioreactor conditioning 
protocol starting with 24h of static culture (37 °C, 5% CO2) to allow cell adhesion. Valves were 
then transferred to a dynamic bioreactor chamber containing 500 mL valve media and were 
conditioned for 24h under cyclic negative pressure (-20 to 5 mmHg), followed by 24h of cyclic 
low positive pressure (-5 to 20 mmHg), and finally 2 weeks of cyclic high positive pressure (-5 
mmHg to 120 mmHg).34 A media change was performed on all valves after 1 week of high 
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positive pressure, wherein half of the bioreactor media (250 mL) was removed and replaced with 
250 mL of fresh valve media. Following bioreactor conditioning, the valves were removed and 
dissected for analysis, including histology, immunohistochemistry (IHC), real time PCR (rt-
PCR), biomechanical testing, and biochemical analysis.  
After analysis of the MNC group revealed minimal cell infiltration, an additional sub-
group was added which was seeded similarly and then conditioned in the bioreactor for only 3 
days (MNC short) (24h static, 24h negative pressure cycles, and 24h high pressure cycles). The 
purpose was to elucidate temporal changes in the cell population, since previous experience has 
seen moderate leaflet recellularization with seeded MNCs.33 After conditioning, the MNC short 
term valves were analyzed by histology, IHC, and PCR. MNC short valves were not included in 
the mechanical or biochemical analyses since significant changes were not expected so quickly. 
4.3.4 Histology, IHC, & PCR 
Samples for histology were sectioned along the radial plane of each leaflet from the 
valves of each group. Hematoxylin and eosin (H&E) staining was used to evaluate repopulation 
of the decellularized valve leaflets, specifically by the presence of cells within the leaflet tissue 
and on the leaflet surface. Protein expression of the seeded cells was evaluated by IHC. 
Unstained slides were blocked in 10% normal goat serum for 1 hour before overnight incubation 
at 4 °C with 1:100 diluted primary antibodies. The primary antibodies (Abcam) targeted alpha 
smooth muscle actin (aSMA), heat shock protein 47 (HSP47), vimentin (VIM), CD90, CD68, 
CD271, CD34, and CD45. Fluorescent secondary antibodies (Alexa Fluor 488 or Alexa Fluor 




Gene expression in the cell populations prior to seeding and after 2 weeks of conditioning 
was analyzed by rt-PCR. Pre-seeding cell samples were taken immediately before seeding. Post-
seeding tissue samples were isolated from each leaflet during valve dissection and immediately 
frozen in liquid nitrogen before being pulverized. Tissue samples from each leaflet of the valve 
were combined to form one sample to measure overall gene expression across the valve. RNA 
was isolated using the RNeasy Micro Kit (Qiagen) and then reverse transcribed to cDNA using 
the High Capacity cDNA Reverse Transcription Kit (Invitrogen). rt-PCR (7300 RT-PCR system, 
Applied Biosystems) was performed using a custom phenotyping array (TaqMan, Life 
Technologies). PCR data is conveyed as the relative fold change in gene expression of the cells 
from tissue samples compared against the matched pre-seeding cell population. Data is presented 
as the mean relative fold change of all valves within a group (n=3) with standard deviation error 
bars.  
4.3.5 Mechanical testing 
The mechanical behavior of the leaflet tissue from the MNC, MSC, MSC2, and VIC 
groups was measured by biaxial loading. MNC short seeded valves were not tested. Biaxial 
mechanical testing was performed in phosphate buffered saline at 37 °C using methods described 
previously.32 Rectangular specimens (9 x 6 mm, n=9) were cut from the middle belly region of 
each leaflet and mounted onto a four motor equibiaxial loading system (LM1 TestBench, Bose 
ElectroForce) with the radial and circumferential directions of the sample aligned to the loading 
axes. Samples were then loaded to an equibiaxial tension of 30 N/m with a rise time of 10s and 
the peak stretch ratios were calculated from strain data in the circumferential (λCpeak) and radial 
(λRpeak) directions. Areal strain was used as a measure of net extensibility and was calculated 
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from stretch data as (λCpeak x λRpeak – 1) x 100%. Results were compared against biaxial 
mechanical data previously reported from cryopreserved and decellularized valves.173 
4.3.6 Biochemical analysis 
The sulfated glycosaminoglycan (GAG), collagen, and total protein concentrations of the 
extracellular matrix of seeded valves was measured using colorimetric assays. GAG 
concentration was measured using the Blyscan Sulfated Glycosaminoglycan Assay (Biocolor). 
Tissue samples (approx. 15 mg; n=9) were processed according to manufacturer protocols and 
the results were measured using a spectrophotometer at 656 nm. Collagen concentration was 
measured using the QuickZyme Total Collagen Assay (QuickZyme Biosciences). Samples 
(approx. 15 mg, n = 9) were prepared by overnight hydrolysis in 6M HCl at 90 °C and the 
hydroxyproline concentration was measured using a UV/Vis spectrophotometer at 570 nm. Total 
protein concentration was measured using the QuickZyme Total Protein Assay (QuickZyme, 
Biosciences) and used the same hydrolysates that were prepared for collagen quantification. The 
GAG, collagen, and total protein concentrations are reported as µg mg-1 of wet tissue and are 
compared to previously reported values from cryopreserved and decellularized valves.173 
The production of signaling molecules such as cytokines and chemokines from the cells 
of the seeded tissue engineered valves was quantified using a multiplex (Luminex) assay in 
accordance with manufacturer protocols. Media samples (n= 3 to 6) were taken at the end of 
bioreactor conditioning (2 weeks of high positive pressure) and frozen at -80°C until use. The 
multiplex assay identified the media concentration of FGF-2, IL-10, IL-6, MCP-1, MIP-1α, MIP-
1β, TNFα and VEGF.  
4.3.7 Statistical analysis 
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Statistical analysis was performed by ANOVA, and post-hoc comparisons were made 
using the Tukey test or the Kruskal-Wallis test for parametric and non-parametric data, 
respectively. Differences were considered statistically significant at p < 0.05. 
4.4 Results 
4.4.1 Tissue Processing 
 As demonstrated previously, the decellularization process resulted in complete removal 
of cells from the valve tissue while preserving the overall architecture of the extracellular matrix 
(data not shown).32, 173 Following cell seeding and bioreactor conditioning, the valves in all 
groups had a normal appearance with complete and functional leaflets.  
4.4.2 Histology 
H&E staining of the seeded valve groups revealed differing levels of recellularization 
after two weeks of bioreactor culture (Figure 1).  MNC seeded valves had minimal 
recellularization with isolated cells present only on the surface of the leaflet while the interstitial 
matrix remained acellular (Figure 1 A,E). MSC seeded valves showed recellularization of the 
leaflet matrix with a high density of cells within the leaflet matrix, though multilayered clumps 
of cells were present on the leaflet surface (Figure 1 B,F). It is worth noting that the 
recellularization was limited to the distal region of the leaflet, while the mid and base of the 
leaflet had very little cells present within the leaflet or on the surface. MSC2 seeded valves 
showed similar recellularization to the MSC group and interestingly appeared to have less cell 
clumping present on the valve surface (Figure 1 C,G).  Again, the recellularization of the MSC2 
group was primarily within the distal leaflet region. Valves seeded with VICs showed high 
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cellularity and clumping of cells on the valve surface but very little to no cellular infiltration into 
the leaflet interstitium (Figure 1 D,H).  
4.4.3 Cell phenotypes 
The protein expression of the seeded cells on the tissue engineered valve leaflets was 
evaluated by IHC (Figure 2). Cells from the MNC group were notably negative for αSMA and 
CD90, but showed slight positive expression of HSP47, VIM, and CD68 (Figure 2 A,E,I). The 
MSC and MSC2 groups had similar protein expression and stained positive for αSMA, HSP47, 
VIM, and CD90, though the MSC2 group appears to have greater protein expression (Figure 2 
B,F,J;C,G,K) . The cells of the VIC group were positive for HSP47, CD90, and VIM while 
interestingly remained negative for αSMA, the classical marker pattern for activated VICs 
(Figure 2 D,H,L). 
The gene expression of the cells from the seeded heart valves was measured by rt-PCR 
and evaluated as the relative fold change compared to the respectively matched, pre-seeded cell 
population (Figure 3). Valves from the MNC seeded group showed an up-regulation of the 
myofibroblast marker αSMA (ACTA2), stem cell type markers (ITGB1, SERPINH1, THY1), 
and markers of extracellular matrix remodeling (COL1A1, MMP1). MNC seeded valves also 
showed a general down-regulation of immune cell markers (CD14, CD163, CD4, IFNG, 
PTPRC) with the exception of CD206, a marker for M2 macrophages. The cells from the MSC 
group showed relatively small changes in gene expression with a general down-regulation in 
immune cell gene markers (CD14, CD163, CD4, PTPRC). The relative gene expression of 
MSC2 valves was generally similar to the MSC valves, though a greater up-regulation of MMP1 
was observed. The VIC group displayed an interesting gene expression profile with slight up-
regulation of MMP1 but down-regulation of ACTA2 and COL1A1.  
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4.4.4 Mechanical Analysis 
 Biaxial testing of the tissue engineered leaflets revealed significant differences in the 
areal strain and directional stretch ratios between the cell seeding groups (Table 1). The 
collected data were compared to previously reported data for cryopreserved and decellularized 
ovine aortic valve leaflets, which act as a positive and negative control respectively.173 
Interestingly, the areal strains of MNC leaflets were most similar to cryopreserved leaflets (i.e. 
with native cells) when compared to the other tested groups, and significantly different than 
decellularized (p = 0.006), MSC (p = 0.021) and VIC (p = 0.045) groups; no significant 
differences were found in circumferential or radial stretch ratios between MNC valves and other 
groups. On the other hand, MSC seeded leaflets appeared to be most mechanically similar to 
decellularized leaflets when compared to other groups and were found to have significantly 
greater areal strain (p = 0.024) and circumferential stretch (p = 0.004) than cryopreserved 
leaflets. Leaflets from the VIC seeded group revealed no significant differences between the 
cryopreserved and decellularized groups, though the average properties of the VIC leaflets was 
much closer to those of the decellularized leaflets. Similarly, no significant differences in 
mechanical properties were found between the MSC2 group and the cryopreserved or 
decellularized groups, however the areal strain and circumferential stretch ratio of the MSC2 
group was medial to the control groups.  
4.4.5 Biochemical Analysis  
The concentrations of GAG, collagen, and total protein in the seeded valve leaflets were 
measured and compared to previously reported data for cryopreserved and decellularized ovine 
aortic leaflets (Table 2).173 The previously reported data indicated a significant loss of GAG 
between cryopreserved and decellularized samples. However, no other significant differences 
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were found in GAG concentration between other groups in this study. The average GAG 
concentration of all tissue engineered leaflets was within the bounds of the reported 
cryopreserved and decellularized concentrations. Conversely, the concentration of collagen was 
similar between cryopreserved and decellularized groups, yet all tissue engineered groups (MNC, 
MSC, MSC2, and VIC) had a significantly increased collagen concentration than either control 
group (p < 0.05). The total protein concentration in all cell seeded groups was greater than either 
cryopreserved or decellularized groups, although only the MSC2 group was significantly 
different (p < 0.05).  
The production of cytokines by the seeded valves was measured by analyzing the culture 
media after the two week culture period using multiplex assays (Figure 4). Cytokines were 
measured to estimate the potential for inflammation and/or cell recruitment. The selected 
cytokines represent a mix of classic inflammation signaling proteins representing an M1 
macrophage response (IL-6, MIP-1α, MIP-1β, TNFα) and an assortment of tissue repair 
signaling proteins associated with an M2 macrophage response (FGF-2, IL-10, MCP-1, VEGF). 
Of the cytokines measured, IL-6, MCP-1 and VEGF were produced to the greatest concentration 
by all cell seeded groups. VIC seeded valves produced an exceptionally high amount of IL-6 
compared to other valves, and a significantly greater amount than MNC or MSC seeded valves (p 
< 0.05). Similarly, VIC seeded valves produced more MCP-1 than the other seeded groups, and a 
significantly greater amount than MSC or MSC2 seeded valves (p < 0.05). The highest VEGF 
concentration was produced by MSC2 seeded valves, though there was no significant difference 
between any groups and there was a large variance within the MSC2 samples. FGF2 production 
was relatively similar across all groups. Of the classic inflammatory signaling proteins, MNC 
valves produced higher concentrations compared to other groups. IL-10 production was greatest 
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in MNC valves and was significantly greater than the MSC group (p < 0 .05). MIP-1α and MIP-
1β was also greatest in the MNC valves and significantly greater than the MSC2 group (p < 0.05). 
TNFα is not included in Figure 4 because it was below the detection limit (2.15 pg/mL) in all 
but one MNC sample, which had a TNFα concentration of 5.81 pg/mL. 
4.5 Discussion 
4.5.1 MNC Valve Seeding 
Valves in the MNC group exhibited surprisingly minimal leaflet recellularization. The 
lack of recellularization is particularly unexpected due to the seemingly positive effect that MNC 
seeding had on the mechanical and biochemical properties. MNC valves exhibited mechanical 
properties most similar to cryopreserved valves (i.e. native control) compared to the other groups 
and the increased collagen in MNC valves compared to decellularized valves indicated an active 
cell presence during bioreactor culture. Furthermore, previous experience within our group has 
seen the establishment of pilot cell populations within the leaflet matrix after only three days 
when seeding with MNCs.33 To investigate the short-term fate of the MNC seeded cells within 
this study, three additional decellularized ovine aortic valves were seeded with human MNCs 
and cultured in the bioreactor for three days (MNC short). Interestingly, histology of the MNC 
short group revealed a cell population present within the leaflet matrix (Figure 5 A-D). The cells 
were located only within the fibrosa layer of the leaflet and were not continuous, but appeared in 
small clusters along the length of the leaflet. IHC staining revealed the cells stained positive for 
CD68, CD34, or CD45 (Figure 5 E-H). rt-PCR of the MNC short valves was similar to the MNC 
two week conditioned valves, except for a general up-regulation of classic inflammatory genes 
compared to the pre-seeding population, specifically CD163, CD14, and TNFα.  
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Taken together, the MNC short and MNC valves show an evolving cell phenotype and 
population throughout the bioreactor culture period. Following MNC seeding, recellularization 
readily occurs within the fibrosa layer by macrophages, leukocytes, and hematopoietic cells. As 
bioreactor culture continues, those cells likely migrate or undergo cell death leading to isolated 
cells on the leaflet surface by two weeks. The cells remaining at two weeks were positive for 
CD68, HSP47, and VIM, indicating a mix of macrophage and fibroblastic phenotypes. The 
fibroblastic cells likely originate from the proliferation of the small population of stem cells 
found within bone marrow.3 The evolving cell phenotype is supported by the rt-PCR data that 
shows an up-regulation of the ACTA2, SERPINH1, and THY1 genes in the MNC valves 
compared to the pre-seeding cells, although it is worth nothing there was no positive staining for 
CD90 or CD271 during IHC. Despite the proliferation of the stem cell population, after two 
weeks of bioreactor culture the leaflet interstitial tissue remained acellular indicating cell 
proliferation was not occurring quickly enough to repopulate the leaflet. Therefore, MNC 
seeding and two weeks of bioreactor culture is an impractical approach for in vitro TEHV 
recellularization as a stand-alone method.  
An alternative approach may be seeding MNCs to establish a pilot cell population that 
can stimulate autologous recellularization in situ. Weber et al. demonstrated seeded MNCs are 
capable of inducing an inflammation-mediated recellularization response in polymeric heart 
valve scaffolds.178 Roh et al. further identified that the mononuclear cells produce the signaling 
cytokine MCP-1, which induces the recellularization response.137 In this study, we found the 
MNC valves produced moderate amounts of MCP-1. Although cytokine production was not 
measured for MNC short valves, it was demonstrated that MNCs can rapidly establish within the 
leaflet tissue and may be producing signaling cytokines much earlier than measured here. Future 
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investigations should investigate the temporal cytokine production of MNC seeded valves and 
the potential for autologous cell recruitment in situ. 
4.5.2 MSC and MSC2 Valve Seeding 
Seeding with MSCs led to the most successful recellularization of the interstitial matrix 
of the decellularized leaflets. Surprisingly, the difference in the seeding cell concentrations, 5 
million cells for the MSC group versus 10 million cells for the MSC2 group, did not lead to 
greatly differing degrees of recellularization (Figure 1). In fact, no significant differences were 
directly measured between the MSC or MSC2 groups by any metric in this study. However, a 
number of dissimilarities can be inferred based on the significant differences measured between 
other groups. For example, the areal strain and circumferential stretch ratio of MSC valves was 
similar to decellularized valves and significantly different than cryopreserved valves, indicating 
that cell seeding in the MSC group had little to no effect on the mechanical properties. 
Alternatively, the MSC2 group showed statistically similar mechanical properties to both 
decellularized and cryopreserved valves, indicating MSC2 seeding had a small effect on 
mechanical properties. The concentrations of GAGs, collagen, and total protein was also similar 
between MSC and MSC2 group, yet MSC2 had significantly more total protein than either 
decellularized or cryopreserved valves, signifying increased protein production. IHC revealed 
similar protein expression between the MSC and MSC2 groups, yet the staining intensity appears 
greater in the MSC2 group. Comparing the MSC and MSC2 groups indicate it is advantageous to 
seed with the higher concentration of MSCs.  
Overall, these results suggest seeding with MSCs leads to better recellularization of 
TEHV compared to MNCs after two weeks of bioreactor culture. MSCs have shown great 
potential as a cell source for heart valve tissue engineering, due in part to their pluripotent 
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differentiation and naturally myofibroblastic phenotype similar to native VICs.52 Additionally, 
MSCs possess immunomodulatory capabilities that may help reduce inflammation.35, 158 
However, the use of MSCs may raise some concerns since their multi-lineage potential can lead 
to the differentiation of adverse phenotypes, including osteoblasts, chondrocytes, and/or 
adipocytes.52 Before the clinical application of MSC seeded devices can be realized, the 
underlying factors leading to cell differentiation in valve tissues must be understood and 
controlled so as to avoid adverse differentiation.  
4.5.3 VIC Valve Seeding 
Due to the difficulty in obtaining a patient matched VIC population, seeding TEHVs with 
autologous VICs is not a clinically viable solution. Despite this, the VIC group was included in 
this study under the expectation that VIC seeded valves would lead to moderate recellularization 
and provide an internal positive control for cell phenotype analysis. However, the VIC group of 
valves showed surprisingly minimal recellularization of the leaflet interstitial tissue and cells 
remained clumped on the leaflet surface. Also surprising was the lack of αSMA expression by 
the cells in the VIC group.105  
Valve interstitial cells in a healthy, native valve remain quiescent (qVIC) until damage or 
injury to the valve requires repair, at which point they become activated (aVICs) and are 
identified by their expression of αSMA.105 aVICs are responsible for remodeling the extracellular 
matrix and αSMA is often used as a marker for the VIC phenotype in tissue engineering 
applications since matrix remodeling is a basic requirement for a functioning TEHV. After 
repairing valve damage, aVICs should return to a quiescent state, but it is worth noting that 
prolonged VIC activation is linked to valve disease including fibrosis, inflammation, and 
ultimately calcification.105  
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In this study, we found VIC seeded valves did not express αSMA. We expected the 
seeded VICs to express an activated phenotype and begin remodeling the decellularized matrix, 
yet it appears the VICs remained quiescent. The apparent qVIC phenotype may explain the lack 
of cell infiltration in the VIC group since the cells may not have produced matrix remodeling 
proteins, such as MMPs, which would break down surrounding tissue matrix. The extracellular 
matrix of the valve leaflets appears compact and cells may be unable to infiltrate the leaflet 
without the expression of matrix remodeling proteins. Hof et al. similarly reported an absence of 
cellular infiltration after seeding VICs onto decellularized leaflet tissue due to the presence of a 
compact basement membrane.67 To increase the penetrability of the leaflets, Hof et al. performed 
laser perforation or enzymatic digestion by trypsin and found laser perforation treatment led to 
marginal cell infiltration while trypsin treatment led to increased infiltration.67 However, trypsin 
digestion led to structural alterations in the leaflet matrix, and is therefore not a clinically viable 
treatment option for decellularized valves.67 In addition to the clinical impracticality of seeding 
valves with autologous VICs, the results of this study, and others, suggest that VIC seeding leads 
to poor recellularization of the leaflet tissue and is likely not applicable for the TEHV.   
4.5.4 Limitations 
While this study provides fundamental information regarding candidate cell populations 
for heart valve seeding, it is not without limitations. For example, the in vitro nature of this study 
eliminates the tissue healing milieu that is expected in vivo. As such, a number of factors could 
not be included in this study which may change the recellularization potential of the cell 
populations, including paracrine and endocrine signaling, the presence of local tissue repair cells, 
and possible inflammatory responses. Therefore, the results of this study are simply guidelines, 
and set the stage for future in vivo experiments to further elucidate TEHV recellularization. 
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Additionally, this study only investigated most groups at an arbitrary time point of two weeks. 
As evidenced by the MNC short group, recellularization likely changes throughout the culture 
period and future studies should investigate the time response curve of cell populations to further 
enhance recellularization.  
 
4.6 Conclusion 
This investigation was designed to provide a direct comparison of candidate cell 
populations for heart valve tissue engineering. We compared four different cell populations for 
their ability to repopulate the distal leaflet of decellularized heart valves after two weeks of in 
vitro bioreactor culture. We found that seeding with MSCs at a higher concentration delivered 
the best results as demonstrated by recellularization of the interstitial leaflet tissue, cell 
phenotype, mechanical properties, and biochemical analysis. Seeding with MSCs at a lower 
concentration exhibited similar leaflet repopulation, yet the mechanical and biochemical analysis 
were not as encouraging. MNC seeding led to minimal recellularization though an additional 
time point group demonstrated a cellular presence at only three days. VIC seeding resulted in cell 
clumping on the leaflet surface but poor recellularization of the interstitial tissue. These results 
confirm the hypothesis that of the tested groups, MSCs are best suited for bioreactor ex vivo 




CHAPTER 5: EXTENDED BIOREACTOR CONDITIONING OF MONONUCLEAR 
CELL SEEDED HEART VALVE SCAFFOLDS§ 
5.1 Abstract 
The tissue engineered heart valve may be the ideal valve replacement option but still 
must overcome challenges in leaflet recellularization. This study sought to investigate the 
potential for leaflet matrix restoration and repopulation following MNC seeding and extended 
periods of bioreactor conditioning. Human aortic heart valves were seeded with MNCs and 
conditioned in a pulsatile bioreactor for 3 days, 3 weeks, or 6 weeks. The results of this study 
determined that an MNC population can be readily localized within the leaflet tissue in as little 
as 3 days. Furthermore, as extended bioreactor condition continued to the 3 week and 6 week 
time points the MSC sub-fraction within the larger MNC population proliferated and became the 
predominant cell phenotype. However, repopulation of the leaflet interstitium was less extensive 
than anticipated. Valves in the 6 week time point also exhibited retracted leaflets. Thus, while the 
3 week bioreactor conditioning period used in this study may hold some promise, a bioreactor 
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conditioning period of 6 weeks is not a viable option for clinical translation due to the negative 
impact on valve performance.   
5.2 Introduction 
Heart valve disease is a common cause of global morbidity with etiologies ranging from 
congenital to degenerative.61 Although a variety of options are available for heart valve 
replacement, including mechanical valves, bioprosthetic xenografts and cryopreserved 
homografts, the ideal heart valve substitute has yet to be developed.70 The tissue engineered heart 
valve (TEHV) offers great potential as a permanent valve substitute for disorders requiring valve 
replacement, overcoming the limitations of the other replacement options. This is particularly 
true for the pediatric population for which an initial intervention using a living, growing valve 
would eliminate the need for multiple revision surgeries and catheter interventions as the child 
matures.70 However, logistical and regulatory challenges have hindered the development of a 
clinically useful TEHV, including the selection of an appropriate cell line for scaffold 
repopulation. The ideal cell source should 1) be patient specific and readily available in the 
clinical setting, 2) require minimal manipulation prior to scaffold seeding and 3) offer the 
potential for phenotypically appropriate scaffold repopulation, either through direct proliferation 
of the seeded cells (prior to or following implantation) or through chemotactic recruitment of 
autologous cells (following implantation).66, 80, 103 
Traditional approaches to heart valve tissue engineering have generally employed 
extended periods of cell culture and valve conditioning in custom bioreactors with the aim of 
creating end-stage living tissue ex vivo before theoretical or animal implantation. These 
approaches have used numerous cell types and sources including endothelial cells and 
myofibroblasts, often isolated from arterial, venous or leaflet tissue.66, 110, 147, 161 Despite varying 
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degrees of success in the research arena, clinical application of these cell sources is challenged 
by donor site morbidity from cell harvest.  Bone marrow mesenchymal stem cells (MSCs) are an 
alternative option for valve seeding providing autologous cells with pluripotent differentiation 
capabilities.52 However, considering the low proportion of MSCs within bone marrow (0.002-
0.02%), lengthy periods of in vitro cell expansion are required prior to valve seeding to ensure 
adequate cell coverage.3 
Another option, bone marrow derived mononuclear cells (MNCs), are beginning to 
receive interest as a candidate for scaffold seeding. A group of European researchers has 
reported on the seeding of polymeric heart valve scaffolds with MNCs using fibrin as a cell 
carrier.55, 146, 178 This strategy relies on the migration of seeded cells from the fibrin carrier into 
the polymer scaffold after implantation, followed by further recruitment of autologous cells 
through a paracrine signaling mechanism. Four weeks after implantation of these scaffolds in 
primates, seeded MNCs were no longer present; however, the presence of autologous endothelial 
and interstitial cells was observed.55, 146, 178 Work by Roh et al. provides further evidence that a 
“pilot” population of MNCs may act to recruit autologous cells, as the authors reported that 
MNCs seeded on polymeric vascular grafts prior to implantation in mice were no longer 
detectable after only one week in vivo, though overall cellularity was maintained due to the 
infiltration of autologous monocytes followed by scaffold repopulation with host smooth muscle 
cells and endothelial cells.137 
Of particular interest when seeding with MNCs is the persistence of MNC 
subpopulations, such as MSCs, macrophages and leukocytes, throughout extended conditioning 
periods. Since MSCs are commonly isolated from bone marrow through cell culture, it is 
possible that MNC seeding and extended culture will lead to expansion of the MSC population, 
79 
 
effectively skipping traditional cell culture methods. Additionally, all afore mentioned studies 
seeding with MNCs have used animal implant models to assess the potential for autologous 
recellularization, yet the outcome of a seeded MNC population throughout extended ex vivo 
valve conditioning remains unknown.  Therefore, the purpose of this study is to investigate the 
fate of a MNC population seeded onto decellularized heart valves over an extended period of ex 
vivo processing. We have previously shown the ability to localize an MSC population into the 
leaflet matrix of a decellularized valve scaffold using a novel bioreactor and pressure 
conditioning. Using similar methods, it is expected that the seeded MNCs in this study will 
localize within the leaflet tissue of the decellularized valves and extended conditioning will lead 
to proliferation of the MSC population.  
5.3 Methods 
5.3.1 Tissues and tissue processing 
Human aortic valves were obtained from a tissue banking facility (LifeNet Health) and 
stored in a cryopreserved state until use. The cryopreservation procedure is modeled after clinical 
tissue handling protocols and freezes the valves at 1 °C min-1 using a controlled rate freezer 
(2100 Series, Custom BioGenics Systems) before being stored in a cryofreezer at -180 °C. 
Decellularization was performed as described previously.133 Briefly, aortic valves were subjected 
to reciprocating osmotic shock, followed by detergent (Triton X-100, sodium-lauroyl sarcosine) 
and enzymatic (Benzonase) washes to remove cellular material. Extraction of organic material 
was performed using recirculating water and ion exchange resins. After decellularization, the 




5.3.2 Cells and valve seeding 
Human bone marrow was obtained from a commercial source (Lonza) and the 
mononuclear cell fraction was isolated using a bone marrow filter system (Kaneka).98 The 
decellularized valves were thawed from cryopreservation and then seeded with the entire 
mononuclear fraction isolated from the bone marrow using an established protocol.34 Briefly, 
isolated mononuclear cells were suspended in 10 mL of media and seeded into the lumen of the 
valve which is mounted in a static bioreactor chamber containing valve media (DMEM F12 (Life 
Technologies) and 10% FBS). After introduction of the cells, the seeded valve was incubated in 
static culture (37 °C, 5% CO2) for 24h to allow cell adhesion.  
5.3.3 Valve bioreactor conditioning 
After 24h static culture, the seeded valve was transferred to a pulsatile bioreactor 
chamber containing valve media and the assembly was placed in a linear actuator to create cyclic 
positive and negative pressure profiles within the bioreactor chamber. In all groups, the valves 
were cultured in a cyclic negative pressure profile (-20 to 5 mmHg) for 2 days, after which the 3 
day group (1 day static + 2 days negative; n = 6) of valves were removed from culture and the 
valve leaflets were dissected for analysis. The remaining two groups were then switched to 
cyclic positive pressure profile (-5 to 50 mmHg) and cultured for an additional 18 days (3 week 
group; n = 6) or 39 days (6 week group; n = 3) before dissection and analysis. Upon dissection, 
samples from the valve leaflets were designated for mechanical testing and biochemical assays 
or histology, immunohistochemistry (IHC), and real-time PCR (rt-PCR) analysis.  
5.3.4 Histology, IHC, and PCR 
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Samples for histology were sectioned along the radial plane of the leaflets from the 3 day, 
3 week, and 6 week conditioned valves. Hematoxylin and eosin (H&E) staining was used to 
evaluate repopulation of the decellularized valve leaflets, specifically by the presence of cells 
within the leaflet tissue and on the leaflet surface. Movat’s Pentachrome staining was used to 
evaluate the biochemical composition of the leaflet extracellular matrix. Protein expression of 
the seeded cells was evaluated by IHC. Unstained slides were blocked in 10% normal goat serum 
for 1 hour before overnight incubation at 4 °C with 1:100 diluted primary antibodies. The 
primary antibodies (Abcam) targeted alpha smooth muscle actin (aSMA), heat shock protein 47 
(HSP47), CD29, CD90, CD45, CD34, CD68, and vimentin (VIM). Fluorescent secondary 
antibodies (Alexa Fluor 488 or Alexa Fluor 594, Life Technologies) were then incubated for 1 h 
followed by nuclear counterstaining (DAPI; Life Technologies). 
Gene expression was measured by rt-PCR analysis was evaluated as the relative fold 
change in gene expression compared to the pre-seeding cell population. Cell samples were taken 
immediately before valve seeding and tissue samples from each leaflet were taken during valve 
dissection and frozen in liquid nitrogen. The leaflet tissue from each valve was combined to form 
one sample (n=3 per group) to indicate the gene expression across the valve. The frozen tissue 
was pulverized and the total RNA was isolated using the RNeasy Micro Kit (Qiagen) 
accompanied by DNase digestion (DNA-freeTM kit, Invitrogen). The RNA was then reverse 
transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Invitrogen). rt-
PCR (7300 RT-PCR system, Applied Biosystems) was performed using a custom phenotyping 
array (TaqMan, Life Technologies). PCR data is conveyed as the relative fold change in gene 
expression between the matched, pre-seeding cell population and the cell population in the valve 
after bioreactor conditioning.  
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5.3.5 Mechanical Testing 
The mechanical behavior of the leaflet tissue from the 3 day group and 3 week group of 
tissue engineered valves was measured using biaxial loading. The 6 week group of tissue 
engineered valves was not included for mechanical testing due to the lack of coaptation between 
leaflets. Biaxial mechanical testing was performed using methods described previously.32 
Rectangular specimens (9 x 6 mm, n=9) were cut from the belly region of each leaflet and 
mounted on a four motor equibiaxial loading system submerged in phosphate buffered saline at 
37 °C (LM1 TestBench, Bose ElectroForce). Samples were mounted so that the loading axes 
were aligned with the radial and circumferential directions of the sample. All samples were then 
loaded to an equibiaxial membrane tension of 60 N/m using a rise time of 10 sec. The directional 
peak stretch ratios were calculated from strain data in the circumferential (λCpeak) and radial 
(λRpeak) directions. Areal strain was used as a measure of net extensibility and was calculated 
from equibiaxial data as (λCpeak  x λRpeak – 1) x 100%. Results were compared against previously 
reported biaxial mechanical data from cryopreserved and decellularized valves.173 
5.3.6 Biochemical 
The collagen and sulfated glycosaminoglycan (GAG) concentrations of the tissue 
engineered leaflet extracellular matrix from the 3 week group and 6 week group was measured 
using colorimetric assays. The QuickZyme Total Collagen Assay (QuickZyme Biosciences) was 
used to measure the collagen concentration. Samples (approx. 15 mg, n = 9) were prepared by 
overnight hydrolysis in 6M HCl at 90 °C then prepared following the manufacturers protocol. 
The hydroxyproline concentration was measured using a UV/Vis spectrophotometer 
(VERSAmax, Molecular Devices) at 570 nm. The GAG concentration was measured using the 
Blyscan Sulfated Glycosaminoglycan Assay (Biocolor). Tissue samples (approx. 15 mg, n=9) 
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were processed according to manufacturer protocol and the results were measured using a 
UV/Vis spectrophotometer at 656 nm. The collagen and GAG concentrations are reported as µg 
mg-1 of wet tissue. 
5.3.7 Statistical Analysis 
Statistical analysis of normally distributed data was performed using one-way analysis of 
variances (ANOVA) (SigmaStat 3.5, Systat Software, Inc.) and post-hoc comparisons between 
groups were performed using the Holm–Sidak test. Differences were considered statistically 
significant at p < 0.05. Error values are reported as the standard deviation of the mean. 
5.4 Results 
5.4.1 Tissue Processing and Valve Seeding 
As observed in previous studies, decellularization resulted in complete removal of cells 
from the valve tissue while preserving the overall extracellular matrix architecture (data not 
shown).173 Following MNC cell seeding and bioreactor conditioning, the gross appearance of the 
aortic valves in the 3 day group and 3 week group was normal with functional leaflets capable of 
coaptation. Valves in the 6 week were incompetent due to retracted leaflets, though otherwise 
appeared normal.  
5.4.2 Histology 
Extended conditioning in the bioreactor of the MNC seeded heart valves led to 
differences in the recellularization of the valve leaflets, as seen by histology (Figure 1). Three 
day processing (1 day static and 2 days negative pressure) led to localization of cells within the 
interior of the leaflet tissue, though no cells were present of the surface of the leaflet (Fig. 1A,B). 
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After three weeks processing (1 day static, 2 days negative pressure, 18 days positive pressure), 
cells were still present within the leaflet tissue as well as on the surface of the leaflet  (Fig. 
1D,E). The cells on the surface of the 3 week group were often multilayered and clumped 
together. After six weeks of bioreactor conditioning (1 day static, 2 days negative pressure, 39 
days positive pressure) there was a decrease in the number of cells within the leaflet tissue, 
though more cells were present on the leaflet surface (Fig. 1G,H). Similar to the 3 week group, 
the cells on the surface of the leaflets in the 6 week group were multilayered and clumped 
together. Movat’s Pentachrome staining revealed the preservation of collagen, GAG, and elastin 
within the ECM for all bioreactor conditioning time points (Fig. 1C,F,I). Additionally, there was 
evidence of collagen production by the seeded cells in the 6 week group (Fig. 1I).  
5.4.3 Protein and Gene Expression 
IHC revealed a changing cell phenotype with extended periods of bioreactor conditioning 
(Figure 2). Previous work has shown that a MNC population isolated from bone marrow initially 
consists of macrophages, leukocytes, hematopoietic stem cells, and a small population of 
mesenchymal stem cells (MSCs) 3. In this study, the cells on the 3 day group of seeded valves 
had protein expression that closely resembled the profile expected from isolated MNCs. 
Specifically, cells seeded on the 3 day group had positive expression of CD34 and CD68, partial 
expression of αSMA, HSP47, and VIM, and notably were negative for CD29 and CD90 (Fig. 
2A-E). As the duration of bioreactor conditioning increased to 3 weeks the protein expression 
began to more closely resemble a MSC population (Fig. 2 F-J).  Compared to the 3 day group, 
the 3 week group had increased expression of αSMA, CD90, and CD34 with decreased 
expression of CD68. The protein expression in the 6 week group further resembled an MSC 
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population with a high expression of HSP47, greater expression of αSMA, CD90, and VIM, and 
decreased expression of CD68 and CD34 (Fig. 2 K-O). 
Gene expression by rt-PCR analysis agreed with the changing phenotype observed by 
IHC (Figure 3). The cells in the 3 day group showed up regulation of immune responsive cells 
compared to the initial seeding population (ANPEP, CD14, CD44, CD68, ICAM1, and PTPRC) 
and little to no up regulation of MSC or VIC related markers. However, with increased 
bioreactor conditioning the valves in the 3 week and 6 week groups had generally increased 
regulation of the MSC or VIC related markers compared to the seeding population (ACTA2, 
ITGB1, MCAM, NT5E, SERPINH1, and THY1). Additional gene markers were not displayed in 
Figure 3 because they had no expression in either the cells or the tissue. These include ADIPOQ, 
CD19, CD34 and TNF which were expressed in the seeded cell populations, but was not 
expressed by any of the valve groups. Additionally, ITGA11 and MMP1 were expressed by the 3 
week valves, but had no expression in the corresponding cell populations at the time of seeding.  
 
5.4.4 Mechanical Testing 
Mechanics of the tissue engineered heart valve leaflets from the 3 day and 3 week groups 
were compared against each other and against leaflet samples from cryopreserved and 
decellularized human aortic valves (Figure 4).173 Leaflets from the 6 week group of tissue 
engineered valves were not included for mechanical testing due to incompetence in the leaflets 
after bioreactor culture. The areal strain of the valve leaflets from the 3 day group was 90.63 ± 
11.90% and the peak stretch ratios were 1.14 ± 0.08 and 1.67 ± 0.12 in the circumferential and 
radial directions, respectively. Valve leaflets from the 3 week group of tissue engineered valves 
had an areal strain of 106.30 ± 19.46% and peak stretch ratios of 1.18 ± 0.09 and 1.74 ± 0.10 in 
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the circumferential and radial directions, respectively. The only significant difference between 
groups in the measured areal strain was between the cryopreserved and 3 week group (p = 
0.012). All other groups were statistically similar (p > 0.05) and no significant differences were 
measured between groups in the directional peak stretch ratios (p > 0.05). 
5.4.5 Biochemical Analysis 
Biochemical assays measured the collagen and GAG concentration from valves in the 3 
week and 6 week groups, and those results were compared against previous results from 
cryopreserved and decellularized valves.173 The 3 day group was not expected to exhibit matrix 
remodeling in such a short time and was therefore excluded.  Cell seeding with MNCs and 
extended bioreactor conditioning did not have a significant effect on the biochemical 
composition of the decellularized heart valve leaflets (Table 1). The collagen concentration 
between all groups was found to be statistically similar (p > 0.05). As previously reported, 
decellularization causes a loss of GAGs within the leaflet tissue and a significant decrease in 
GAG concentration is found between decellularized and cryopreserved samples. Seeding with 
MNCs and extended bioreactor conditioning did not have a significant effect on the GAG 
concentration since no significant difference was found between decellularized and tissue 
engineered valves (p > 0 .05). Additionally, the cryopreserved valves retained a significantly 
greater GAG concentration than the tissue engineered valves from the 3 week group (p < 0.001) 
and 6 week group (p < 0.001).  
5.5 Discussion 
The purpose of this study was to investigate the fate of MNCs isolated from bone marrow 
seeded onto decellularized heart valve scaffolds. Specifically, we sought to evaluate the 
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persistence of sub-populations such as MSCs, macrophages and leukocytes on and within the 
valve leaflet following extended periods of bioreactor conditioning. Since MSCs are commonly 
isolated from bone marrow through cell culture, it was expected that MNC seeding and extended 
conditioning will lead to expansion of the MSC population, effectively skipping traditional cell 
culture methods. 
The results of this study yielded both expected and unexpected outcomes. As expected, 
MNCs can be quickly localized into the leaflet matrix. There is evidence of MNC seeding 
leading to rapid recellularization in situ, and we now have evidence that such rapid 
recellularization can occur in vitro.55 It was also expected that extended bioreactor processing 
would lead to proliferation of the MSC sub-population from the seeded MNCs. This was 
demonstrated by the increased expression of MSC associated genes following extended periods 
of bioreactor conditioning in both the 3 week and 6 week processing groups. Conversely, 
macrophage markers were generally down-regulated with increased processing times. This effect 
was also observed by IHC staining, which identified CD34, CD45, and CD68 positive cells in 
the three day group indicating a mixed cell population of hematopoietic stem cells, leukocytes, 
and macrophages. On the other hand, cells in the 3 week and 6 week groups showed positive 
expression of CD90, CD29, aSMA and HSP47 indicating a population of MSCs and/or 
myofibroblasts. The positive expression of CD34 during extended bioreactor conditioning may 
also indicate proliferation of the hematopoietic stem cell population, although there is evidence 
that MSC populations may also express CD34.150 
Despite proliferation of the MSC population, recellularization of the leaflet matrix 
following extended bioreactor conditioning was not as extensive as expected. Areas of interstitial 
repopulation were observed at both the 3 and 6 week time points; however, a cellularity similar 
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to that of the cryopreserved leaflet was not achieved, and areas devoid of cells were observed. 
The majority of the cells present on the seeded valves following 3 weeks and 6 weeks of 
bioreactor conditioning were located on the surface of the leaflet. While MSC proliferation 
occurred during extended bioreactor processing, extensive localization of MSCs within the 
leaflet interstitium did not occur. Additionally, valve incompetency due to leaflet retraction was 
observed for these valves. Therefore, the use of long (i.e., 6 weeks) periods of bioreactor 
conditioning following MNC seeding is likely not a clinically viable heart valve tissue 
engineering strategy.   
MNC seeding and bioreactor processing did not seem to have a significant effect on the 
mechanics or biochemical properties of the seeded heart valves. The directional strain ratios of 
all groups remained similar and the 3 week processing group actually displayed an increase in 
areal strain. Because the mechanics of valves processed for 6 weeks were clearly compromised, 
we did not perform biaxial mechanical testing for this group, as three additional human aortic 
valves would have been required and no information regarding the clinical feasibility would have 
been gained. Biochemical analysis did not reveal any significant changes between decellularized 
controls and MNC seeded samples; however, it is worth nothing some collagen deposition was 
observed within areas of cell localization on surface of the leaflet fibrosa at the 6 week time 
point (Figure 2I).The absence of any significant mechanical or biochemical changes may be due, 
in part, to the lack of full repopulation of the leaflet interstitium during valve seeding.  
As shown by others, MNC seeded scaffolds have the potential for recellularization in 
situ. Emmert et al. and Weber et al. demonstrated that polymeric heart valve scaffolds seeded 
with MNCs are capable of recellularization by autologous cells in ovine and primate models, 
respectively.55, 178 Roh et al. proposed this occurs through an inflammation-mediated mechanism 
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wherein seeded monocytes attract a population of autologous macrophages which incite a tissue 
healing response.137 The use of MNC seeding onto decellularized scaffolds was explored by 
Vincentelli et al. who injected MNCs or MSCs into the base of the leaflet of decellularized 
pulmonary valves and then implanted into the pulmonary position of juvenile sheep.175 Seven 
days after implantation they observed both groups had seeded cells and recruited host cells 
present within the scaffold, but at final explant the MNC seeded valves exhibited thickened 
leaflets, calcification, and CD68+ macrophage host cells in the arterial wall.175 The results from 
Vincentelli et al. favored the MSC group, yet the presence of macrophage cells may align with 
the inflammation-mediated recellularization mechanism proposed by Roh et al.137, 175 However, 
the calcification and thickened leaflets from their MNC group is troubling. The MSC favored 
results by Vincentelli et al. is further supported by evidence that seeded MSCs release a cocktail 
of immunomodulatory proteins that may facilitate in situ recellularization.12, 175 Therefore, an 
MSC pilot population, such as demonstrated in our three week bioreactor conditioning group, 
may be better suited for valve recellularization compared to a fresh MNC population.  
The results from this study provide implications towards the translation of the TEHV, as 
the mechanism of recellularization, whether in vitro cell proliferation or in situ autologous cell 
recruitment, determines the extent to which the cell-seeded decellularized heart valve must be 
processed prior to implantation. For example, matrix repopulation through an inflammatory-
tissue healing response, in which the seeded cells serve only to attract autologous cells through 
paracrine signaling, would mechanistically facilitate brief ex vivo processing protocols. Here we 
demonstrated the ability to rapidly localize a MNC population into a decellularized leaflet matrix 
within 3 days. On the other hand, recellularization through proliferation and differentiation of the 
seeded population would likely require extended bioreactor processing, though different 
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processing methods should be considered to avoid the observed cell layering on the leaflet 
surface. The work proposed here segues to future large animal studies (e.g., ovine and papio) to 
evaluate, not only matrix repopulation, but also the hemodynamic performance and growth 
potential of intact tissue engineered heart valves processed by these methods.        
While this study focused on extended conditioning of MNC seeded heart valve scaffolds 
in a bioreactor, this creates an inherent limitation such that the in vitro nature eliminates any 
tissue healing response that may be expected in vivo. Therefore a number of factors could not be 
included in this study that could ultimately effect the recellularization of the valve leaflets, 
including paracrine and endocrine signaling, the presence of local tissue repair cells, and possible 
inflammatory responses. The in vivo response fell outside the scope of this study, yet this 
investigation still provides valuable insight into the persistence of sub-populations during 
extended conditioning following MNC heart valve seeding.  
5.6 Conclusion 
This study sought to investigate the potential for leaflet matrix restoration and 
repopulation following MNC seeding and extended periods of bioreactor conditioning. We found 
that an MNC population can be readily localized within the leaflet tissue in as little as 3 days. 
Furthermore, the MSC sub-fraction within the larger MNC population becomes amplified with 
prolonged bioreactor conditioning. The effect of MSC proliferation may eliminate the need for 
the long term pre-seeding culture of MSC populations, although that time is replaced with 
extended bioreactor culture. Repopulation of the leaflet interstitium was less extensive than 
anticipated; however, this alone does not preclude this TEHV processing strategy from clinical 
use, as an incomplete cell population established ex vivo may continue to proliferate after 
implantation or may provide paracrine signaling to promote further autologous recellularization 
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in vivo. Thus, while the intermediate bioreactor conditioning period used in this study (i.e., 3 
weeks) may hold some promise, a bioreactor conditioning period of 6 weeks is not a viable 







CHAPTER 6: EXPLORING NON-PHYSIOLGOIC BIOREACTOR PROCESSING 
CONDITIONS FOR HEART VALVE TISSUE ENGINEERING** 
6.1 Abstract 
Conventional methods of bioreactor conditioning for heart valve tissue engineering have 
led to inconsistent results in cellular repopulation, particularly of the distal valve leaflet. The use 
of non-physiologic conditioning parameters within a bioreactor, such as hypoxia and cyclic 
chamber pressure, may lead to increased and more consistent recellularization. To investigate the 
effects of such bioreactor conditioning parameters, ovine aortic heart valves were seeded with 
mesenchymal stem cells (MSC) and cultured in one of four environments: hypoxia and high 
cyclic pressure, normoxia and high cyclic pressure, hypoxia and negative cyclic pressure, and 
normoxia and negative cyclic pressure. Analysis revealed that hypoxic conditioning led to 
increased cellular infiltration into the valve leaflet tissue compared to normoxic culture. Protein 
expression across all groups was similar, exhibiting an MSC and valve interstitial cell phenotype.  
Gene expression was varied between groups, with cyclic negative pressure conditioning resulting 






** To be submitted as VeDepo M.C., Buse E., Paul A., Hopkins R.A., and Converse G. 
L., Exploring Non-physiolgoic Bioreactor Processing Conditions for Heart Valve Tissue 
Engineering, Annals of Biomedical Engineering, 2018. 
93 
 
in up-regulation of gene markers for an MSC phenotype and matrix remodeling, compared to a 
down-regulation of similar genes for cyclic high pressure conditioning. Taken together, these 
results suggest the use of non-physiologic bioreactor conditioning parameters such as hypoxia 
and cyclic negative pressure to increase the in vitro cellular repopulation of TEHV leaflets.  
6.2 Introduction 
Heart valve tissue engineering may be the ideal solution for patients suffering from 
valvular heart disease and requiring valve replacement.70 The current options for valve 
replacement all suffer from limitations and the pediatric population is particularly impaired by 
the lack of an ideal prosthetic valve substitute.148 Mechanical prosthetic valves have poor 
hemodynamics requiring a lifetime of anti-coagulation therapy and tissue-based prosthetic valves 
are limited by poor durability often requiring re-intervention.148 The tissue engineered heart 
valve (TEHV) can overcome the existing limitations of current replacement options by providing 
a one-time implantation of living tissue capable of optimal hemodynamics, tissue remodeling, 
and growth.  
Unfortunately, clinical realization of the TEHV is still hindered by the difficultly in 
reproducibly establishing a phenotypically appropriate cell population within the tissue 
engineered leaflet matrix. Native heart valve leaflets are primarily populated by valve endothelial 
cells (VECs) on the luminal surface and valve interstitial cells (VICs) within the tissue matrix.105 
Numerous studies have attempted to recreate this two-fold cell phenotype in vitro by seeding 
heart valve scaffolds with a variety of cell populations.174 There is evidence, however, that 
decellularized heart valve matrices will undergo partial autologous recellularization when 
implanted in vivo.39, 47, 48, 131 Specifically, decellularized valves implanted in both human patients 
and ovine models have shown complete re-endothelialization by VECs and partial 
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recellularization by VICs in the valve conduit wall and leaflet base; however, the distal leaflet 
remains acellular.39, 47, 48, 131 This is problematic since tissue growth requires a viable cell 
population throughout the leaflet tissue. Therefore, the challenge of in vitro recellularization 
should focus on recreating a cell population within the distal tip of the valve leaflet matrix. 
One solution that may increase recellularization of the leaflet interstitial tissue is fine-
tuning of bioreactor conditioning parameters. Bioreactor conditioning of tissue engineered heart 
valves can be used to apply mechanical and chemical stimuli to the valve scaffolds to drive cell 
proliferation, differentiation, and ultimately recellularization. Numerous studies have 
investigated conditioning in custom bioreactor systems to increase the recellularization of cell 
seeded heart valve scaffolds.15, 103, 104, 144, 152 Many of these systems employ physiologic 
parameters of pressure and flow rate to mimic a systemic or pulmonary circulation 
environment.103, 104, 144, 152 However, recellularization using these bioreactors has often been 
limited to surface re-endothelialization.103, 104, 152 The localization of cells within the leaflet tissue 
remains challenging. While it is inherently logical to use physiologic parameters for bioreactor 
conditioning to drive cell differentiation, it may be necessary to develop novel conditioning 
parameters to stimulate cell infiltration into the valve leaflet.  
One such solution is hypoxic conditioning, as there is evidence that culturing 
mesenchymal stem cells under oxygen tension can increase cell proliferation and migration.92, 109 
Additionally, in a study by Balguid et. al, polymeric valve scaffolds seeded with venous 
myofibroblasts were cultured in hypoxic conditions and exhibited increased mechanical 
properties compared to scaffolds cultured at normoxic conditions.10 Cyclic champber 
pressurization using positive and negative pressures may also influence recellularization. 
Previous work in our lab has demonstrated partial recellularization of the distal valve leaflet 
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using cyclic positive and negative pressure cycles within the bioreactor.34 Ovine aortic valves 
seeded with human MSCs showed increased recellularization following a combination of 
negative and positive pressure conditioning, compared to negative conditioning only or static 
conditioning.34 However, the experimental design of that study made it impossible to de-couple 
the effects of positive versus negative pressure conditioning with the duration of bioreactor 
culture. Therefore, the purpose of this study was to investigate the effects of hypoxia and 
positive/negative bioreactor conditioning parameters on the recellularization of heart valve 
leaflets. Specifically, the focus is on the repopulation of the distal leaflet tip. It is hypothesized 
that valves cultured under hypoxic and positive pressure conditions will result in the greatest 
recellularization of the distal valve leaflet. 
6.3 Methods 
6.3.1 Tissue and tissue processing 
Ovine aortic valves were harvested from juvenile sheep under approved IACUC 
protocols and in accordance with Guide for Care and Use of Laboratory Animals (National 
Institutes of Health Publication No. 85-23). Harvested valves were cryopreserved using a 
procedure modeled after clinical tissue handling protocols. Valve were frozen at 1 °C min-1 using 
a controlled rate freezer (2100 Series, Custom BioGenics Systems) before being stored in a 
cryofreezer at -180 °C. Valve decellularization was performed as described previously.133 
Briefly, the ovine aortic valves were thawed and then subjected to reciprocating osmotic shock, 
followed by detergent (Triton X-100, sodium-lauroyl sarcosine) and enzymatic (Benzonase) 
washes to remove cellular material. Extraction of organic material was performed using 
recirculating water and ion exchange resins. After decellularization, the valves were again 
cryopreserved using the above procedure and stored at -180 °C until valve seeding. 
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6.3.2 Valve seeding and conditioning groups 
All tissue engineered valves were seeded with bone marrow derived MSCs. MSCs were 
isolated by filtering 25 mL bone marrow aliquots (Lonza) for the mononuclear cell fraction using 
a bone marrow filter system (Kaneka). The mononuclear cells were then put in culture and the 
MSCs were isolated as adherent cells. The cells were then cultured until sufficient numbers were 
available for valve seeding (approx. 10 million cells). MSC populations to be seeded in one of 
the groups using hypoxic bioreactor conditioning were cultured in hypoxic conditions (7% O2, 
5% CO2, 37 °C) while MSCs to be seeded in one of the normoxic bioreactor conditioning groups 
were cultured in normoxic conditions (21% O2, 5% CO2, 37 °C). Two cell populations were 
isolated from a single donor with one of the matched populations being used for a hypoxic 
conditioning group and the other used for a normoxic conditioning group, effectively creating 
matched cell populations that differ based on oxygen tension conditioning. It is worth noting, the 
cells were effectively passage 2 at the time of valve seeding. All tissue engineered heart valves 
were then seeded following established valve seeding protocols.34 The decellularized valves were 
thawed from cryopreservation and sutured onto tissue grips. The seeding cell population for each 
group was then suspended in 10 mL of media and seeded into the lumen of the valve which was 
mounted in a static bioreactor chamber containing 200 mL valve media (DMEM F12 (Life 
Technologies) and 10% human serum (Sigma-Aldrich)). 
 The valves were then randomly divided into one of four groups to evaluate bioreactor 
conditioning parameters (3 valves per group): hypoxic & high pressure (Hyp/HighP), normoxic 
& high pressure (Norm/HighP), hypoxic & negative pressure (Hyp/NegP), and normoxic & 
negative pressure (Norm/NegP). After cell seeding, all valves underwent 24h of static culture (37 
°C, 5% CO2) to allow cell adhesion the valves. Valves were then transferred to a sterile, single 
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use, dynamic bioreactor chamber containing 500 mL valve media and the assembly was placed 
in a linear actuator to create cyclic positive and negative pressure profiles within the bioreactor 
chamber.34 A bioreactor conditioning protocol was then applied for 2 weeks based on the group. 
Valves in the hypoxic groups were cultured at 7% O2 while valves in the normoxic groups were 
cultured at 21% O2 (all valves cultured at 37 °C, 5% CO2). After the 24 hours of static culture, 
valves in the high pressure groups were conditioned for 24h of cyclic negative pressure (-20 to 5 
mmHg), followed by 24h of cyclic low positive pressure (-5 to 20 mmHg), and finally 2 weeks 
of cyclic high positive pressure (-5 mmHg to 120 mmHg). Valves in the negative pressure 
groups were conditioned for 9 days of cyclic negative pressure (-20 to 5 mmHg). A media 
change was performed on all valves after 1 week of conditioning, wherein half of the bioreactor 
media (250 mL) was removed and replaced with 250 mL of fresh valve media. Following 
bioreactor conditioning, the valves were removed and dissected for analysis, including histology, 
cell counting, immunohistochemistry (IHC), real time PCR (rt-PCR), and biochemical analysis.  
6.3.3 Histology & Cell Counting  
Samples for histology were sectioned along the radial plane of each leaflet from each of 
the tissue engineered valves. Hematoxylin and eosin (H&E) staining was used to evaluate 
repopulation of the decellularized valve leaflets, specifically by the presence of cells within the 
leaflet tissue and on the leaflet surface. Recellularization of the tissue engineered valves in each 
group (n = 9) was determined by counting the cells in a calculated area using Axiovision 
software. Cells within the interstitial leaflet tissue were counted but not cells on the leaflet 
surface. Cell density was measured at the base, middle, and tip region of the leaflet. 
6.3.4 IHC & PCR 
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Protein expression of the cells from the tissue engineered valves was evaluated by IHC. 
Unstained slides cut from the samples prepared for histology. The slides were blocked in 10% 
normal goat serum for 1 hour before overnight incubation at 4 °C with 1:100 diluted primary 
antibodies. The primary antibodies (Abcam) targeted alpha smooth muscle actin (αSMA), heat 
shock protein 47 (HSP47), vimentin (VIM), CD90, CD73, and vWF. Fluorescent secondary 
antibodies (Alexa Fluor 488 or Alexa Fluor 594, Life Technologies) were then incubated for 1 h 
followed by nuclear counterstaining (DAPI; Life Technologies). 
Gene expression was analyzed by rt-PCR and was evaluated as the fold change of the 
hypoxic bioreactor conditioning relative to the normoxic bioreactor conditioning, with respect to 
the pressure conditioning. Valves were compared based on the matched cell populations that 
were isolated from a single donor to minimize donor variability. Tissue sections from each 
leaflet were taken during valve dissection and immediately frozen in liquid nitrogen before being 
pulverized. The tissue sections from each leaflet of the valve were combined to form one sample 
to measure the gene expression across the valve. RNA was isolated using the RNeasy Micro Kit 
(Qiagen). The RNA was then reverse transcribed to cDNA using the High Capacity cDNA 
Reverse Transcription Kit (Invitrogen). Real-time PCR (7300 RT-PCR system, Applied 
Biosystems) was performed using a custom phenotyping array (TaqMan, Life Technologies). 
PCR data is conveyed as the relative fold change in gene expression of the cells from the 
hypoxic conditioned groups compared against their respective matched normoxic conditioned 
groups, with respect to pressure conditioning.  
6.3.5 Biochemical analysis 
The sulfated glycosaminoglycan (GAG), elastin, collagen, and total protein 
concentrations of the extracellular matrix from the tissue engineered valve leaflets was analyzed 
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using colorimetric biochemical assay kits. GAG concentration was measured using the Blyscan 
Sulfated Glycosaminoglycan Assay (Biocolor). Elastin concentration was measured via the 
Fastin Elastin Assay (Biocolor). For both the GAG and elastin assays, tissue samples (approx. 15 
mg, n=9) were processed according to manufacturer protocol and the results were measured 
using a UV/Vis spectrophotometer (VERSAmax, Molecular Devices).  at 656 nm and 513 nm, 
respectively. Collagen concentration was measured using the QuickZyme Total Collagen Assay 
(QuickZyme Biosciences). Samples (approx. 15 mg, n = 9) were prepared by overnight 
hydrolysis in 6M HCl at 90 °C and the hydroxyproline concentration was measured using a 
spectrophotometer at 570 nm. Total protein concentration was measured using the QuickZyme 
Total Protein Assay (QuickZyme, Biosciences) and used the same hydrolysates that were 
prepared for collagen quantification. The GAG, collagen, and total protein concentrations are 
reported as µg mg-1 of wet tissue and are compared to previously reported values from 
cryopreserved and decellularized valves.173 
6.3.6 Statistical analysis 
Statistical analysis was performed by ANOVA, and post-hoc comparisons were made 
using the Tukey test or the Kruskal-Wallis test for parametric and non-parametric data, 
respectively. Further statistical comparisons between hypoxic/normoxic groups within a given 
pressure conditioning, particularly for the cell density measurements, were made using the 
Mann-Whitney Rank Sum test. Differences were considered statistically significant at p < 0.05. 
6.4 Results 
6.4.1 Tissue, and tissue processing 
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As reported previously, the decellularization process resulted in complete removal of 
cells from the valve tissue while preserving the overall architecture of the extracellular matrix 
(data not shown).32, 173 Following the two week bioreactor conditioning protocols the valves from 
all groups had a normal appearance and functional leaflets.  
6.4.2 Histology & Cell Counting  
H&E staining of the tissue engineered valve samples revealed the four bioreactor 
conditioning protocols lead to differing degrees of recellularization, particularly with the 
interstitium of the leaflet (Figure 1). Valves in the Hypoxic/HighP group and Hypoxic/NegP 
groups both showed increased cellularity within the leaflet interstitium compared to valves in the 
Normoxic/HighP and Normoxic/NegP group (Figure 1 A,E,C,G). This was particularly true of 
the distal tip of the leaflet which exhibited the greatest cell concentration, while the middle 
region and base of the leaflet showed less cellular infiltration. Valves in the Normoxic/HighP 
and Normoxic/NegP groups exhibited only minimal cellularity within the interstitial leaflet 
tissue, but showed a high degree of cells agglomeration on the leaflet surface (Figure 1 B,F,D,H). 
Similar to the hypoxic groups, the highest cell concentration was at the distal tip of the leaflet 
with decreased cellularity along the leaflet middle and base. These results indicate hypoxic 
conditions increased the recellularization of the leaflet interstitium. Pressure conditioning within 
the bioreactor did not seem to have an obvious effect on recellularization as visualized by 
histology. 
The extent of matrix repopulation within each group was quantified by measuring the cell 
density within the leaflet tissue (Figure 2). As was observed by histology, all groups had an 
increased cellularity at the distal tip of the leaflet compared to the middle or base regions. Since 
the goal of this project was recellularization of the distal leaflet, and measured cell density was 
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greatest within the leaflet tip for all groups, the remainder of the manuscript will focus on the cell 
concentration within the tip region. Valves conditioned under hypoxic conditions had increased 
cell density compared to normoxic conditioned valves. Specifically, the Hypoxic/NegP group 
exhibited generally high levels of recellularization with a median cell density of 116.34 
cells/mm2 within the leaflet tip. The other hypoxic group, Hypoxic/HighP, also exhibited high 
recellularization with one sample showing the greatest maximum recellularization, however the 
results were not consistent leading to a high variance and a median cell density of 58.66 
cells/mm2. The Norm/HighP and Norm/NegP had relatively low recellularization with median 
values of 20.64 cells/mm2 and 26.01 cells/mm2 respectively. Statistical analysis by ANOVA on 
ranks indicated a significant difference was to be expected (p = 0.045), but the post-hoc 
comparison found no significance between individual groups. Further statistical analysis was 
performed using the Mann-Whitney test between hypoxic and normoxic samples within the 
individual pressure conditioning groups (i.e. negative pressure or high pressure). Hypoxia led to 
significantly increased cell density compared normoxic conditioning for both negative pressure 
(p = 0.030) and high pressure (p = 0.042) groups.  
6.4.3 Protein and Gene Expression 
The protein expression of the cells within the tissue engineered valves from the four 
conditioning groups was evaluated using IHC (Figure 3). The protein expression was similar 
between groups with cells from all groups displaying markers indicative of MSC or valve 
interstitial cell (VIC) phenotypes. Specifically, cells from all groups showed positive expression 
for αSMA, HSP47, VIM, and CD90. The Hypoxic/HighP group also exhibited positive 
expression of CD73, another MSC marker, while the other groups did not. None of the groups 
displayed positive expression of the endothelial cell marker vWF.  
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Gene expression of the tissue engineered valves was evaluated by rt-PCR (Table 1).  The 
gene expression was analyzed as the fold change of the tissue engineered valves from each 
bioreactor conditioning group relative to the matched pre-seeded cell population.  Similar to the 
protein expression, the gene expression between groups was relatively similar. VIC-like markers 
within all groups were both up-regulated (VIM) and down-regulated (ACTA2) compared to 
initial seeded cell population, although valves in the normoxic group showed greater down-
regulation of ACTA2. Some of the MSC markers were up-regulated in all groups (CD44, 
ANPEP), but other MSC markers (THY1, ITGB1) exhibited increased expression in negative 
pressure conditioning and decreased expression in positive pressure conditioning. Interestingly, 
markers that indicate extracellular matrix production (HSP47, COL1A1, COL3A3) were all up-
regulated in negative pressure conditioning groups and down-regulated in positive pressure 
conditioning groups, while the marker for extracellular matrix digestion (MMP1) was greatly up-
regulated in all groups except Normoxic/NegP. The cell proliferation marker (MKI67) was 
down-regulated or showed no expression in all groups except Hypoxic/NegP. All groups, even 
valves in the hypoxic groups, showed a down-regulation of the hypoxia marker EPAS1. It is 
possible this was due to the pre-seeding culture of the cell populations in a hypoxic or normoxic 
environment depending on the group of the cell seeded valve. Endothelial markers (vWF, ENG) 
were partially up-regulated in most groups despite no evidence of endothelial cells by protein 
expression. Finally, markers for inflammatory cells (PTPRC, CD14) or signs of adverse 
differentiation (ACAN, ALPL, ADIPOQ) were generally down-regulated in all groups.  
6.4.4 Biochemical analysis 
The concentration of GAG, collagen, and total protein in the extracellular matrix of the 
tissue engineered valves was measured and compared to previously reported values for 
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cryopreserved and decellularized samples (Table 2) [VeDepo ref].  The biochemical analysis 
revealed no differences between the bioreactor conditioning groups. As reported previously, the 
decellularization protocol causes a significant decrease in GAG concentration. However, none of 
the tissue engineered valves had a significantly different GAG concentration than either 
decellularized or cryopreserved controls, indicating some amount of GAG production by the 
seeded cells. On the other hand, the collagen concentration of all tissue engineered valves from 
each group was significantly greater than both the cryopreserved and decellularized controls (p < 
0.05). The concentrations of total protein in the tissue engineered valves revealed no significant 
differences between groups or between the cryopreserved or decellularized controls.  
6.5 Discussion 
The purpose of this study was to investigate the effects of oxygen tension and pressure 
conditioning on the recellularization of tissue engineered heart valve leaflets seeded with MSCs. 
The results demonstrate that the tested bioreactor conditioning parameters can positively affect 
recellularization. Histologic evaluation of the various groups suggested that conditioning valves 
in hypoxic conditions increased recellularization of the interstitial tissue of the distal valve 
leaflet. The positive effect of hypoxic conditioning was confirmed by quantifying the cell density 
within the tip, middle, and base of the leaflet. Valves cultured under hypoxia conditions resulted 
in significantly increased cell density within the leaflet tip compared to normoxia conditions, 
within individual pressure conditioning groups. Gene and protein expression revealed a relatively 
similar cell phenotype of MSC or VIC-like cells within all groups. Biochemical concentrations 
of extracellular matrix proteins were also similar between all groups.  
6.5.1 Effects of cyclic pressure conditioning 
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The use of negative cyclic pressures versus negative and positive cyclic pressures lead to 
similar results in the recellularization of heart valve leaflets. The greatest observable difference 
was measured in the gene expression, where valves conditioned under negative pressures showed 
an up-regulation of MSC and matrix remodeling gene markers compared to a general down-
regulation in valves conditioned at positive pressures. As mentioned, a previous study in our lab 
determined heart valve leaflets conditioned with a low flow, cyclic pressure conditioning 
protocol showed increased recellularization compared to static culture.34 That study used the 
same bioreactor system as was used in the present study. This system uniquely utilizes cyclic 
negative and/or positive chamber pressures within the bioreactor. During the initial development 
of the valve seeding protocols employing this bioreactor, short (i.e., 72 h) periods of negative 
pressure conditioning were found to promote improved matrix repopulation, relative to similar 
periods of positive pressure.34 While the exact mechanism remains unclear, it is theorized that 
the negative pressure cycles increase saturation of the leaflet with cell culture media and/or 
causes increased cell deformation, mimicking diastolic loading.115 However, the present study 
suggested that the benefit of negative pressure conditioning relative to high positive pressure 
conditioning on cellular infiltration is transient, in that the application of extended periods of 
either negative or positive pressure conditioning subsequent to the initial short period of negative 
pressure did not impact the extent of matrix repopulation.  
The more common method of bioreactor conditioning used by many other researchers 
attempts to mimic the physiologic forces of trans-valvular pressure and fluid flow rates 
experienced in situ. Many conventional methods using physiologic conditioning parameters have 
focused on re-endothelialization and therefore demonstrate minimal cellular infiltration into the 
leaflet tissue.103, 104, 152 An exception is the study by Schenke-Layland et al. which seeded 
105 
 
endothelial cells and myofibroblasts onto porcine pulmonary valves followed by pulmonary 
physiologic conditioning (40-60 mmHg trans-valvular pressure and 3 L/min flow rate) in a 
bioreactor for 9 or 16 days.144 The resulting heart valve constructs exhibited repopulation of the 
leaflet tissue by αSMA+ cells within the leaflet and vWF+ cells on the leaflet surface.144 
Conversely, seeded valves cultured under static conditions for identical time periods revealed a 
lack of cellular infiltration and cells remain in clusters around the leaflet surface.144 The 
increased cellular infiltration in the bioreactor cultured group was likely caused by the cyclic 
mechanical conditioning which can promote the production and release of TGF-β1, leading to 
the activation of myofibroblasts and the release of proteolytic enzymes (MMPs).126 However, it 
has been suggested that heart valves can be overly mechanically conditioned, potentially leading 
to fibrosis of the engineered tissue.126 Therefore, mild mechanical conditioning using forces that 
stimulate cellular infiltration, such as a cyclic negative chamber pressure, may offer a safer 
means to achieve TEHV recellularization.   
6.5.2 Effects of oxygen tension 
Oxygen tension had the greatest effect on recellularization in this study. The study was 
specifically designed to mitigate the effects of donor to donor variability, so one hypoxic valve 
and one normoxic valve were generated from the cells of each donor. This allowed us to make 
comparisons between donor-matched hypoxic and normoxic valves for a given pressure 
conditioning protocol (Table 3). As seen in Table 3, hypoxic condition led to an increase in 
distal leaflet recellularization for each matched pair of valves. There was large variance in the 
fold change of positive pressure conditioned valves. One pair of valves exhibited greater than 8-
fold increase due to hypoxic conditioning while the other two pairs of valves exhibited only a 
moderate increase. Conversely, negative pressure conditioned valves experienced at a least a 2-
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fold increase in cell density due to hypoxia. These results suggest synergistic effects on leaflet 
recellularization between hypoxia and negative pressure conditioning. Of particular interest is 
that hypoxia greatly increased recellularization within the distal tip region of the valve leaflets. 
All other regions of valvular tissue (leaflet middle, leaflet base, and conduit wall) have shown 
evidence of autologous recellularization during the implantation of decellularized valves in 
human and animal models. Since the distal leaflet region has previously proven difficult to 
repopulate, the cellular density observed in hypoxic conditioned groups is highly encouraging. 
As the results demonstrate, hypoxic conditioning significantly promotes the cellular 
infiltration of MSCs into the valve leaflet. However, the large variability within the hypoxic 
conditioned groups also indicates the inconsistent nature of TEHV recellularization. As stated 
previously, one of the greatest challenges remaining in heart valve tissue engineering is 
reproducibly establishing a phenotypically appropriate cell population within the leaflet tissue. 
Such inconsistency led to samples within this study demonstrating a level of recellularization 
similar to native leaflets, while other identically treated samples exhibited only marginal cellular 
repopulation. Despite the large variance, hypoxic conditioning still demonstrated a significant 
increase in recellularization of heart valve leaflets seeded by MSCs compared to normoxic 
conditioning, within a given pressure-conditioning group. 
There are extensive reports on the effects of hypoxic culture on MSCs describing how a 
low oxygen concentration can cause cells to proliferate faster, proliferate longer, and better 
maintain an undifferentiated phenotype.24, 54 However, there are fewer studies on the role 
hypoxia may play during tissue engineering and even fewer that focus on hypoxia in heart valve 
tissue engineering.109 This is likely because human heart valves, particularly the mitral and aortic 
valve, do not generally exist in hypoxic conditions in situ. The exception of course, is during pre-
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natal valve development as the uterine environment is hypoxic.4 Amofa et al. described the role 
of changing oxygen levels on heart valve development during the neonatal transition and how 
such changes lead to the GAG-rich valve primordia transforming into tri-layered leaflets.4 They 
further found that hypoxia can promote GAG expression in adult murine valves.4 The latter point 
is of particular interest as our decellularization protocol significantly decreases GAG 
concentration within the leaflet ECM, however hypoxic conditioning of the tissue engineered 
valves within this study did not reveal an increase in GAG production. It is likely that we did not 
observe an increase in GAG production because the tissue engineered valves contained an MSC 
population compared to a VIC/myofibroblast population in native leaflets. GAG production was 
also observed in the study by Balguid et al., in which myofibroblasts were seeded on polymeric 
valve scaffolds.10 They observed GAG production to a level similar to native valves, and despite 
a lower collagen concentration, the resulting mechanical properties were similar to native 
tissue.10 
6.5.3 Limitations 
One of the primary limitations of this study is the smaller sample size within each group. 
Three aortic valves were processed within each group, providing nine leaflets available for 
analysis. While nine samples was adequate to detect the significant effects of hypoxic 
conditioning, the variance within the measured population was still very high. Increasing the 
sample size may provide more information as to the effects of bioreactor conditioning and may 
indicate greater synergistic effects between conditioning parameters that were not identified by 
this study. Another critical consequence of the low sample size is the use of a single time point 
for measurements rather than serial sampling. All tissue engineered valves were processed for 
two weeks based on previous experience with cell seeded valve constructs. However, that time 
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point is largely arbitrary and further work is required to determine the ideal duration of 
bioreactor processing. Despite the limitations, the results of this study provide invaluable leads 
for increasing the recellularization of TEHVs. Future studies should focus on fine-tuning the 
bioreactor conditioning protocol based on hypoxia and a negative pressure waveform.  
6.6 Conclusion 
Adjusting the bioreactor conditioning parameters for cyclic negative/positive chamber 
pressure and oxygen tension resulted in varying degrees of recellularization of MSC seeded 
TEHVs. Conditioning in a low oxygen environment led to increased cellular infiltration into the 
valve leaflet tissue compared to normoxic culture. Cyclic negative pressure conditioning resulted 
in up-regulation of gene markers for an MSC phenotype and matrix remodeling, compared to a 
down-regulation of similar genes for cyclic high pressure conditioning. Taken together, these 
results suggest the use of non-physiologic bioreactor conditioning parameters such as hypoxia 
and cyclic negative pressure to increase the in vitro cellular repopulation of TEHV leaflets. 
Further development of such protocols may increase the reproducibility in TEHV 






CHAPTER 7: CONCLUSION 
Heart valve tissue engineering is a promising approach for the currently unmet need of an 
ideal prosthetic heart valve. However, the TEHV still faces a number of challenges ranging from 
optimal scaffold creation to the lack of consistent recellularization. Therefore, the current thesis 
explored the pathway to the TEHV and addressed challenges associated with scaffold creation 
through decellularization, cell seeding of valve scaffolds, and conditioning seeded scaffolds in a 
bioreactor.  
Decellularized heart valves are a promising scaffold material for the TEHV since they are 
composed of biological materials that can positively impact cell differentiation and may serve as 
building blocks during the remodeling process.77, 100 Additionally, decellularized valves often 
maintain the mechanical anisotropy of the native valves from which they are derived.5, 32, 97, 101, 
173 However, before a decelluarized valve should be used as a TEHV scaffold, the effects of the 
decellulrization process on the valve tissue should be characterized for all applications, including 
the different animal applications in which research will be performed. Therefore, the work in the 
current thesis began with a detailed investigation into the species-specific effects of 
decellulzation on human and ovine aortic heart valves. The tested multi-detergent 
decellularization process lead to cell free scaffolds for both human and ovine heart valves; 
however, decellularization was found to more greatly impact ovine tissue than human tissue. The 
species-specific effects were likely due to increased initial cellularity and a decrease in the 
collagen crosslinking of ovine leaflets. Despite the discovered effects due to decellularization, 
ovine valves were still used throughout the current thesis. The non-human tissue is more easily 
available for research purposes, and more importantly, the sheep model is the preferred FDA pre-
clinical mode. The TEHV will need to be developed first in the ovine model and then translated 
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to clinical practice. Instead, the results from this study are relevant for use outside of the current 
thesis and demand attention during future pre-clinical testing of heart valve devices that 
incorporate decellularized tissue. Since sheep are the FDA preferred pre-clinical regulatory 
model for heart valve replacement, care must be given to the species-specific effects to 
decellularization that were identified here. This is particularly important given the potential 
inherent barrier to the clinical translation of such a ‘combination device’ (prosthetic device + 
biological and cellular components). 
The next phase of the dissertation focused on the introduction of cells into the 
decellularized scaffold. As outlined in Chapter 2, decellularized valves do not completely 
recellularize autologously in vivo. Implanted decellularized valves undergo complete re-
endothelialization as well as partial interstitial recellularization of the leaflet base, but the mid to 
distal leaflet tip remains acellular. Therefore, additional measures must be taken to encourage 
distal leaflet recellularization. Recellularization is proposed to take place by two mechanisms: 
(1) proliferation and differentiation of seeded cells or (2) autologous cell recruitment through the 
release of homing cytokines. The work in Aim 2 of this thesis investigated the capacity for 
leaflet repopulation, and the potential mechanism by which recellularization occurred for four 
cell populations: MNCs, low dose MSCs, high dose MSCs, and VICs. Seeding with MNCs led to 
initial cellular infiltration but minimal recellularization was observed at two weeks. Cytokine 
analysis showed increased expression of MCP-1, an inflammatory cell homing factor that others 
have suggested encourages recellularization through the recruitment mechanism.12, 43, 137, 156. On 
the other hand, MSC seeding at a low or high dose led to high interstitial recellularization, likely 
due to the cell proliferation mechanism. The higher seeding dose of MSCs led to increased 
native-like biochemical and mechanical properties. The increased cell population caused an 
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increased production of extracellular matrix proteins, which in turn likely improved the 
mechanical properties. Therefore, high dose seeding is recommended since it less reliant upon 
cell proliferation. Seeding valves with VICs was surprisingly unsuccessful. Although not 
clinically relevant due to the difficulty in obtaining autologous VICs, the VIC group was 
included under the presumption it would act as a positive control group. However, VICs 
achieved little recellularization, possibly because the cells could not enter an aVIC state 
(indicated by negative αSMA expression) and were not capable of producing matrix remodeling 
proteins to allow infiltration into the valve leaflet.  
The final phase of the thesis was to develop bioreactor-conditioning protocols to increase 
the recellularization of cell seeded valves. Detailed investigations into bioreactor conditioning 
were performed individually for valves seeded with MNCs and MSCs. Bioreactor conditioning 
for MNC seeded valves was focused on the duration of bioreactor culture. The study in Chapter 
4 comparing seeding cell populations indicated a changing cell phenotype in MNC seeded valves 
during the bioreactor culture. As observed in the previous studies, MNCs could be localized 
within the leaflet tissue in as little as three days using a cyclic negative and positive bioreactor 
pressure protocol. After three weeks of culture, an MSC cell population became the dominant 
phenotype as determined by gene and protein expression. As the MSC population grew, cell 
layering on the leaflet surface became more pronounced. Six weeks of culture of MNC seeded 
valves also saw an increase in the MSC population, though leaflet retraction was noted leading to 
incompetency of the valves. Therefore 6 weeks of culture is not recommended for MNC seeded 
heart valves. 
Bioreactor conditioning for MSC seeded valves focused on non-physiologic parameters 
of chamber pressure and hypoxic conditions to increase recellularization into the distal leaflet. 
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The bioreactor parameters were based off of preliminary data and previous studies.33, 34 Hypoxia 
led to significantly increased cell infiltration compared to normoxia, though large variations were 
observed. Due to the donor matched nature of each hypoxic versus normoxic conditioned valve, 
we can see that hypoxic conditions increased recellularization in each donor matched sample. As 
was observed in previous studies, negative pressure conditioning led to slightly more consistent 
recellularization and an increase gene expression markers associated with stem cells and matrix 
remodeling. Surprisingly, positive pressure cycles did not significantly out perform negative only 
as observed previously (converse bioreactor paper). The benefits from cyclic negative chamber 
pressure conditioning are encouraging but the mechanisms behind such benefits remain unclear. 
The negative pressure may cause increased saturation of the interstitial leaflet tissue with culture 
media allowing greater cellular ingrowth. Another possibility is the alternating pressure cycles 
may cause greater cell deformation, which in wound healing models has stimulated smooth 
muscle protein synthesis. Thus, cyclic deformation of the cells may enhance mobility and thus 
the ability to better infiltrate the dense leaflet matrix. Additionally, cell deformation may lead to 
increased production of matrix remodeling proteins, including proteins for matrix production and 
matrix breakdown, as was observed in the negative only conditioned groups from Chapter 7. 
Breakdown of the local matrix may enhance cellular infiltration, while production of structural 
matrix proteins preserves the mechanical properties.  
As this thesis followed the pathway to a tissue engineered heart valve, methodologies 
were identified that may overcome many of the challenges remaining to the clinical realization of 
a TEHV. Therefore, the following protocol is suggested for TEHV development. Heart valve 
decellularization should be performed in a manner that adequately removes cellular and nuclear 
material, without causing structural or chemical damage to the extracellular matrix. The use of 
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trypsin and other aggressive enzymes is a classic example of “over processing” leading to 
structural damage of the valve leaflet.63, 101, 135, 157 The low dose multi-detergent decellularization 
process used in the current thesis resulted in minor mechanical changes for ovine aortic valves, 
though human aortic valves were structurally similar. However, a loss of GAGs was noted for 
both ovine and human valves. Following decellularization, it is recommended to seed the valve 
scaffolds with MSCs isolated from bone marrow to establish a pilot population. MSCs showed 
the greatest cellular infiltration compared to other tested cell sources and the MSCs maintained a 
phenotype similar to native VIC-like myofibroblasts. Finally, a higher dose of MSCs is 
recommended, approximately 10 million cells per valve; thus, an implied cell amplification step 
is necessary to magnify autologous cell harvests. Lastly, it is recommended to optimize 
biological and mechanical conditioning within a bioreactor to increase recellularization of the 
valve leaflets. Specifically, hypoxic conditions and cyclic negative chamber pressures were 
found to be beneficial. Conditioning in a low oxygen environment led to increased cellular 
infiltration compared to normoxic conditioning. Cyclic negative chamber pressures resulted in 
greater expression of matrix remodeling gene markers compared to cyclic positive chamber 
pressures.  
Such a protocol for generating a TEHV is suggested by the results of the sequential 
experiments reported in this thesis. However, there is ample room for improvement and the 
current thesis suggests numerous avenues for further fine-tuning of heart valve tissue engineering 
methodologies. This work focused on the in vitro recellularization of TEHVs. Therefore, the in 
situ response fell outside the scope of this study and thus remains unknown. In considering the 
future directions following the work in this current thesis, in vivo testing of TEHVs developed 
using the previously suggested protocol should be held paramount. Implant studies using the 
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described TEHV will elucidate the functionality of the valve and the host-body response to the 
tissue engineered device. Additionally, in lieu of extended implant studies, wear testing using a 
pulse duplicator may predict the long term functionality. Other options for future work concern 
the mechanism of recellularization. The current thesis was primarily focused on the mechanism 
of cell proliferation due to the in vitro nature of the studies. However, there is promise in 
leveraging in vivo healing capabilities through autologous recruitment driven recellularization. 
There is evidence that the chemo-attractant protein MCP-1 may stimulate inflammation-
mediated recruitment recellularization in polymeric vascular grafts and heart valves.55, 137, 178 The 
current thesis identified MCP-1 production by MNCs seeded on decellularized valves (Figure 
4.4). Further analysis revealed increased MCP-1 production at 3 days and a decreased production 
as bioreactor conditioning continued (Figure 7.1). Therefore, seeding with an initial pilot 
population of MNCs or incorporation of the MCP-1 protein into the decellularized scaffold may 
lead to host cell recruitment and eliminate the need for bioreactor conditioning. Future work 
using these methods should investigate the potential for autologous recellularization by the 
recruitment mechanisms. 
Ultimately, the work conducted in this current thesis provides innovative solutions to 
many of the challenges still facing clinical realization of the TEHV. The work described herein 
offers a species-specific characterization on the effects decellularization, compares numerous 
cell populations for the potential recellularization of decellularized scaffolds, and identifies 
bioreactor conditioning parameters to further increase valve recellularization. Additionally, 
methodologies identified in this thesis, specifically the use of hypoxic and negative pressure 
conditioning, may be applied to other tissue engineering applications to increase recellularization 
by myofibroblast cell types. Such conditioning may benefit any tissue-engineered application but 
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the use for vascular grafts, cardiac tissue, and other cardiovascular devices are of particular 
interest. The end-goal of the current thesis has always been the clinical application of a TEHV 
and the described methodologies were developed to be translatable to the clinic. As demonstrated 
in the current thesis, heart valve tissue engineering methods need to focus on restoring full 
matrix remodeling capacity through complete recellularization of the valve tissue to achieve 
lifelong viability. The bench-to-bedside approach adopted in this thesis offers real, obtainable 
advances for the field of heart valve tissue engineering and draws the reality of an ideal heart 
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Figure 2.1: Effects of various decellularization methods 
(a–d) H&E and (e–h) Movat’s pentachrome staining highlighting the effects of decellularization 
by SDS (b, f), trypsin (c, g), and Triton X-100 (d, h) compared to native tissue (a, e). All three 
methods show effective removal of cellular and nuclear material. SDS slides show preservation 
of leaflet structure and ECM components. Trypsin slides show a “loosening” of the ECM 
network and loss of structural proteins. Triton X-100 slides show good preservation of leaflet 
structure but loss of GAGs from the ECM.  






Figure 2.2: Limited autologous recellularization of cryopreserved and decellularized valves 
in vivo 
H&E-stained sections highlighting the autologous recellularization of decellularized (dAV) and 
cryopreserved (cAV) aortic valves after implantation in sheep. Histology of aortic wall: cAV 
after 3 months (a) and after 9 months (c) with signs of rejection and leukocyte infiltration; dAV 
after 3 months (b) and after 9 months (d) without any signs of rejection and with partial re-
endothelialization and ingrowth of interstitial cells. The same findings are shown in the aortic 
sinus: cAV degeneration after  
3 months (e) and after 9 months (g); dAV sinus without signs of rejection and with partial re-
endothelialization and recellularization of leaflet base after 3 months (f) and even more 
recellularization after 9 months (h). Leaflets from the cAV show massive degeneration and 
destruction after 3 months (i) and after 9 months (k); dAV distal leaflets show partial re-
endothelialization after 3 months (j) and after 9 months (l). (S) shows sinus side of the leaflet.  







Figure 2.3: Recellularization of CD133 conjugated heart valve leaflets 
Immunological staining demonstrating successful recellularization of leaflets from pulmonary 
valves conjugated with CD133 and implanted in the pulmonary position in sheep. Texas Red–
labeled secondary antibodies show αSMA (top row) and vimentin (bottom row), and the nuclei 
are DAPI counterstained. Percentage values are the percent of cells with positive expression 
compared to the total number of cells which represent the mean calculated from all three leaflets. 
Note the high αSMA expression in the tissue-engineered leaflets compared to native leaflets. L 
denotes lumen. * indicates p < 0.05. Scale bars are 100 µm.  
Source: Figure reprinted from Williams et al.179 with permission. Copyright 2015 Springer Science: Journal of 







Figure 3.1: Histology of human aortic valves  
Representative histology of cryopreserved (cryo) and decellularized (decell) human aortic valve 





Figure 3.2: Histology of ovine aortic valves 
Representative histology of cryopreserved (cryo) and decellularized (decell) ovine aortic valve 





Figure 3.3: Cell density of ovine and human aortic valves 
Cells per mm2 of ovine and human cryopreserved leaflets. Cellularity was measured at the base, 
middle, and tip of each leaflet and reported as the mean with SD error bars. The reported 
Average is the mean of all three regions. * Denotes a statistically significant difference between 






Figure 3.4: Tension-stretch curves for human and ovine aortic valves 
Representative tension-stretch curves for human (A) and ovine (B) cryopreserved and 






Figure 3.5: Areal strain and peak stretch ratio of human and ovine aortic valves 
Areal strain (A) and peak stretch ratio (B) of human and ovine, cryopreserved and decellularized 
aortic valve leaflets. Peak stretch ratios were measured along the circumferential and radial axes. 
Mean values are reported and error bars represent standard deviation. * Denotes a statistically 






Figure 3.6: Sample stress relaxation curves from human and ovine aortic valves 
Representative relaxation curves from human (A) and ovine (B) cryopreserved and 






Figure 3.7: Stress relaxation of human and ovine aortic valves 
Relaxation of human (A) and ovine (B), cryopreserved (cryo) and decellularized (decell) aortic 
valve leaflets at 1s, 10s, 100s, and 1000s. Per cent relaxation was measured along both the radial 
(R) and circumferential (C) axes. Mean values are reported and error bars represent standard 







Figure 3.8: Concentration of collagen crosslinking in human and ovine aortic valves 
Concentration of the collagen crosslinking compounds PYD and DPY in human and ovine aortic 
leaflets before and after decellularization. Crosslinking concentration is reported per ug of 
collagen within the leaflet ECM. Mean values are reported and error bars represent standard 







Figure 4.1: Histology of TEHVs seeded with MNC, MSC, MSC2 or VIC populations 
Representative H&E stained sections showing various degrees of recellularization from the four 
groups of the tissue engineered valve leaflets, two weeks post seeding. MNC valves (A,F) 
showed no signs of interstitial recellularization and minimal cells on the leaflet surface. MSC 
valves (B,G) and MSC2 (C,H) valves displayed increased interstitial recellularization of the 
distal leaflet and slight cell clumping on the leaflet surface. VIC valves (D,I) showed no cell 
infiltration and a high degree of cell clumping along the leaflet surface. Positive and negative 
controls (E & J, respectively) are presented as cryopreserved (cryo) and decellularized (decell) 
ovine valve samples. Images within the same processing group (e.g. A & F) are taken from 
separate valves under the same processing conditions to show reproducibility. All images are 





Figure 4.2 IHC staining of TEHVs seeded with MNC, MSC, MSC2 or VIC populations 
Immunohistochemical sections of seeded valve leaflets dual stained for the expression of: cell 
nuclei (blue) (all), αSMA (red) & HSP47 (green) (A-D), VIM (red) & CD90 (green) (E-H), and 
CD68 (red) & CD271 (green) (I-L). MNC leaflets (A,E,I) showed positive expression for HSP47, 
VIM, and CD68. MSC leaflets (B,F,J) and MSC2 leaflets (C,G,K) both showed positive 
expression for HSP47, αSMA, VIM, and CD90, although the MSC2 leaflets appear to have 







Figure 4.3: Gene expression of cells from TEHVs seeded with MNC, MSC, MSC2 or VIC 
populations 
Relative fold change in the gene expression of cells from MNC, MSC, MSC2 and VIC seeded 
heart valves in relation to their respective pre-seeded cell populations. Changes in gene 
expression are displayed as the Log2 of the average relative fold change within a group. Error 






Figure 4.4: Cytokine production of TEHVs seeded with MNC, MSC, MSC2 or VIC 
populations 
Box and whisker plots of cytokine concentrations from the bioreactor media of the tissue 
engineered valve groups, two weeks post seeding. The box boundaries represent the first and 
third quartiles, the horizontal line indicates the median, and the whiskers indicate the maximum 




Figure 4.5: Histology and IHC of short term MNC seeded valves 
H&E (A-D) and IHC (E-H) stained sections of MNC short heart valve leaflets, 3 days post 
seeding. IHC sections were stained for cell nuclei (blue) (E-H), αSMA (red) & HSP47 (green) 
(E), VIM (red) & CD90 (green) (F), CD68 (red) & CD271 (green) (G), and CD34 (red) & CD45 
(green) (H).  H&E staining revealed clusters of cell infiltration into the fibrosa along the length 






Figure 5.1: Histology of MNC seeded TEHVs after extended conditioning 
Representative H&E (A,B,D E,G,H) and Movat’s Pentachrome (C, F, I) images of 3 day (A-C), 
3 week (D-F) and 6 week (G-I) bioreactor conditioned heart valve leaflets. 3 day conditioned 
leaflets exhibited high interstitial recellularization. 3 week and 6 week conditioned valves 
exhibited decreased interstitial recellularization but increased numbers of cells on the leaflet 
surface, often in multi-layered clumps. Images of cryopreserved (J) and decellularized (K) 
human valve sections provide positive and negative control images for recellularization, 
respectively. Movat’s Pentachrome staining demonstrated preservation of leaflet structural 
proteins (collagen, gold; elastin, black; GAG, blue) and evidence of collagen deposition in the 6 





Figure 5.2: IHC of MNC seeded TEHVs after extended conditioning 
IHC stained sections of 3 day (A-E), 3 week (F-J) and 6 week (K-O) bioreactor conditioned heart 
valve leaflets. Sections were stained for αSMA (red) & HSP47 (green) (A,F,K), CD29 (red) & 
CD90 (green) (B,G,L), CD45 (green) & CD34 (red) (C, H, M), CD 68 (red) (D, I, N), and VIM 




Figure 5.3: Gene expression of MNC seeded TEHVs after extended conditioning 
Relative fold change in the gene expression between 3 day, 3 week, and 6 week conditioned 
heart valves in relation to their respective pre-seeded cell populations. Changes in gene 
expression are displayed as the Log2 of the average relative fold change within a group. Error 






Figure 5.4: Mechanical properties of MNC seeded TEHVs after extended conditioning 
Mechanical properties, areal strain and directional peak stretch ratios, of the 3 day and 3 week 
conditioned heart valve leaflets. Previously reported data for cryopreserved (cryo) and 
decellularized (decell) human aortic valves are included for comparison [ref]. * indicates a 






Figure 6.1: Histology of TEHVs from various bioreactor conditioning groups 
Representative H&E stained sections of tissue engineered valve leaflets from the Hypoxic/HighP 
(A,E), Normoxic/HighP (B,F), Hypoxic/NegP (C,G) and Normoxic/NegP (D,H) groups. Positive 
and negative controls (E & J, respectively) are presented as cryopreserved (cryo) and 
decellularized (decell) ovine valve samples. All images are taken of the distal tip of the leaflet. 
Both the Hypoxic/HighP valves and the Hypoxic/NegP valves exhibited a high degree of 
recellularization with cells infiltrated into the leaflet matrix. Conversely, Normoxic/HighP valves 
and Normoxic/NegP valves exhibited minimal cellular infiltration and an increased amount of 






Figure 6.2: Cell density of TEHVs after bioreactor conditioning 
Box and whisker plot of the cellular density of the tissue engineered valve leaflets from the 
various bioreactor conditioning groups. Cellularity was measured at the tip, middle, and base 
regions of the leaflet. The box boundaries represent the first and third quartiles, the horizontal 
line indicates the median, and the whiskers indicate the maximum and minimum values. 
Significance was analyzed between hypoxic/normoxic conditioning, within individual pressure 





Figure 6.3: Protein expression of TEHVs from bioreactor conditioning groups 
Immunohistochemical sections of bioreactor conditioned valve leaflets dual stained for the 
expression of: cell nuclei (blue) (all), αSMA (red) & HSP47 (green) (A-D), VIM (red) & CD90 
(green) (E-H), and CD73 (red) & vWF (green) (I-L). All groups show positive expression for 
αSMA, HSP47, VIM, and CD90. The Hypoxic/HighP group shows positive expression for 






Figure 7.1: Cytokine production of MNC seeded TEHVs 
Temporal cytokine production of MNC seeded TEHVs. During culture, the entire media was 
changed at day 1 and half the media was changed at day 10. Values represent the mean of the 




Supplemental Figure 1: Secondary antibody only staining for immunohistochemistry 
Representative images of negative control slides for immunohistochemical staining using DAPI 
staining and secondary antibodies only (Alexa Fluor 488 or Alexa Fluor 594). The images 
represent different magnifications at 100x (A) 200x (B), and 400x (C). DAPI staining shows 
positive expression of cell nuclei. The lack of red or green staining indicates little to no 
background staining by the secondary antibodies.   
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Effectiveness General Effect on Valve ECM Ref 
Anionic Detergent SDS or Sodium deoxycholate 
Lack of visible cell nuclei; 
~95% DNA removal 
Increased areal strain & peak stretch 
ratio; Decreased flexural stiffness; 
Preservation of GAGs. Can disrupt 
ECM fiber structure. 
19, 29, 56, 
58, 87, 101, 
172, 194 
Non-Ionic 
Detergent Triton X-100; Lack of visible cell nuclei 
Increased areal strain and peak stretch 
ratio; Decreased flexural stiffness; 
Loose ECM network; Histological 
reduction of GAG, laminin, 
fibronectin, and collagen 
63, 87, 101, 
116, 157 
Multi-detergent 
Triton X-100 + 
Sodium cholate ~30% DNA removal 
Increased extensibility & decreased 
stiffness; GAG reduction; Preservation 
of elastin and collagen components 
118, 159 
Triton X-100 + 
Sodium 
deoxycholate 
Lack of visible cell nuclei; 
98% DNA removal 
Histologic preservation of structure 
and ECM components 
87, 190 
Osmotic Shock + 
Triton X-100 + 
NLS salt + Ethanol 
Lack of visible cell nuclei; 
>97% dsDNA removal 
Increased areal strain & peak stretch 
ratio; Decreased stress relaxation; 
Reduced GAG content 
32, 173 
Enzymatic Trypsin + EDTA Incomplete cell removal 
Decreased mechanical properties; 
Histologic tissue damage & loss of 
basement membrane; Histologic 
reduction of GAG, laminin, 







Trypsin + SDS Lack of visible cell nuclei; 96% DNA removal 
Reduction of GAG and αGal antigen; 
Preservation of mechanical properties 
108 
Trypsin + Sodium 
deoxycholate 
Visible cell remnants; 98% 
DNA removal 
Histologic disruption of ECM 
components 
190 
Trypsin + Osmotic 
shock + Triton X-
100 
Lack of visible cells Misalignment of collagen fibers 82, 194 
Trypsin + Osmotic 
shock Visible cell remnants 
Histologic loss of collagen; GAG 
reduction; Decreased mechanical 
strength 
157 
Glycol Radiation PEG + Gamma irradiation 
Lack of visible cell nuclei; 
>92% cusp DNA removal 
Preserved leaflet ultrastructure; 
Removal of αGal antigen 
122 
Osmotic shock Hypotonic/Hypertonic Tris buffer Many visible cell remnants 
Histologic reduction in MHC antigens; 








Lack of visibile cell 
remnants and reduced 
antigenicity 
Preservation of Young’s modulus and 
ultimate tensile strength. Preservation 




Supercritical Fluid CO2; Ethanol Lack of visible cell nuclei; 90% phospholipid removal 
Stiffening of tissue; Tissue 
dehydration 
143 
ECM: extracellular matrix; SDS: sodium dodecyl sulfate; NLS: N-Llauroylsarcosine sodium salt. 
PEG:  polyethylene glycol. MHC: major histocompatibility complex.  
The general effectiveness and general effect on ECM are overall observations and individual 
results may vary based on the protocol or tissue used. 
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Table 2.2: Summary of in situ results for the implantation of non-conditioned 
decellularized valve scaffolds in various animal models and clinical trials. 
Recell 
Method Tissue Conditioning 
Implant 














mPV79 None Mouse PV 
Decell valve 




Leaflets were thickened with many 
aSMA+ cells present early, though less 









Rabbit valve leaflets degenerated. Porcine 
valves re-endothelialized with minimal 
cell infiltration near leaflet surface 
oAV13 
pAV84, 125 












Re-endothelialization. Recell of valve 
wall. Minimal recell of leaflet. Xenograft 
comparable to allograft. 











Aorta implants led to loss of leaflets. PV 
implants led to good recell of surface and 
interior of leaflet. AV implants showed 
recell of conduit wall only. 
hPV27, 120 
hAV39 
pPV28, 56, 95, 
96, 127, 138, 142, 













Allogeneic performed better than 
xenogeneic. Recell of valve wall and 
endothelialization evident. No evidence of 
leaflet recell unless by inflammatory cells. 
 
 
αSMA: alpha-activated smooth muscle actin. 
The results are overall observations and the outcome of individual studies may vary. Lower case 




Table 2.3: Summary of methods for in situ recellularization of decellularized valve 
scaffolds with chemical conditioning. 
Recell 
Method Tissue Conditioning 
Implant 




















Valves treated with 
FN6, FN + SDF-
1a57  







FN alone led to luminal recell. FN + SDF-
1a led to moderate leaflet recell. FN + HGF 
led to great recell of the entire leaflet. 





Early endothelial layer and leaflet 
















Treated valves re-endothelialized but no 
distal leaflet recell. Treated valves 
decreased antibody production in baboons.  
 
FN: fibronectin; SDF-1α: stromal cell–derived factor 1α; HGF: hepatocyte growth factor; 
αSMA: alpha-activated smooth muscle actin; MMP: matrix metallopeptidase. 
The results are overall observations and the outcome of individual studies may vary. Lower case 




Table 2.4: Summary of in vitro recellularization methods of decellularized valve scaffolds 
with no conditioning steps applied. 
Recell 
Method Cell Source Conditioning 
Implant 














ECs 18, 63, 135, 136 None None Leaflets seeded statically  
EC coverage. No internal leaflet 
repopulation 
Fibroblast-like 
cells 40, 94, 191 None None 
Leaflets seeded 
statically 
Mild cell infiltration in leaflet 
interior. Cells aSMA+ and VIM+ 
MFs & ECs 90, 161 None cPV
90 
oPV161 
Valve seeded statically 
- no conditioning 
Complete surface coverage and 
partial interstitial repopulation 
MNC or MSC 175 None oPV Cells injected into valve and implanted 
Complete cell surface coverage 
for both groups. MNC leaflets 
were damaged.  MSC leaflets 
were healthy with aSMA+ cells 
 
EC: endothelial cell; αSMA: alpha-activated smooth muscle actin; VIM: vimentin; MF: 
myofibroblast; MNC: mononuclear cell; MSC: mesenchymal stem cell. 
The results are overall observations and the outcome of individual studies may vary. Lower case 




Table 2.5: Various methods for in vitro recellularization of decellularized valve scaffolds 



























and flow  
None 
Valves seeded with 
EC or MF then EC 
then cultured 
EC seeding led to surface coverage. 
MF & EC seeding led to great recell 
with appropriate phenotype. 
MSC 34 
Cultured at static, 







Negative & positive pressure led to 
EC coverage and moderate cell 




Cultured in pulsatile 








TE valves showed complete 
endothelium at explant. Partial 
recellularization of leaflets. 





implant in two 
patients 
In vitro seeding led to complete EC 
monolayer. Both patients showed 
somatic growth, valve growth, and no 
valve degradation at 3.5y.   
 
MF: myofibroblast; EC: endothelial cell; MSC: mesenchymal stem cell; HSP47: heat shock 
protein 47; VIM: vimentin; αSMA: alpha-activated smooth muscle actin; TE: tissue-engineered; 
MNC: mononuclear cell. 
The results are overall observations and the outcome of individual studies may vary. Lower case 




Table 2.6: Various methods for in vitro recellularization of decellularized valve scaffolds 



























Valves coated with 
P3/4HB before 
seeding 
None Hybrid valves seeded in vitro 
Hybrid valves had increased 
mechanics. In vitro seeding led to cell 





with PEG plus 





seeded with cells  
PEGylation increased mechanics and 
cell surface density, regardless of 








cells seeded on 
decell scaffold 
then implanted in 
goats 
PEG-cell seeding increased tensile 
strength, increased ratio of 















seeded with cells 
Treated valves led to reduced platelet 
activation. Chitosan and VEGF 
increased EC adherence, and 
proliferation in vitro. SDF-1a had 
increased endothelial layer after 
implant in vivo 
oECs 170 Valves coated in CCN1 oPV 
Valves coated in 
CCN1 and before 
implant 
Treated valves had good recell in 
vivo. Cell coverage higher on 
ventricularis with mild infiltration of 
VIM+ & aSMA+ cells 
rMSCs 189 Valves conjugated with CD90 antibody None 
Treated leaflets 
cultured in shear 
flow chamber 
with MSCs 
Treated leaflets had increased cell 
attachment distributed across surface 
pVIC16 
hMSC77 
Valves treated with 
fibronectin before 
seeding 
None Treated leaflets seeded statically 
Leaflet surface coverage and mild 
cell infiltration by appropriate 
phenotypes 
oECs47 







Treated valves had complete EC 
layer and good interstitial 
repopulation 
hECs 49-51 
Valve treated with 





implanted in 11 
patients  
100% survival at 10y. 3m biopsy of 
valve wall showed endothelialization 
and partial recell by fibroblast cells.  
 
MSC: mesenchymal stem cell; MF: myofibroblast; EC: endothelial cell; P3/4HB: poly(3-
hydroxybutyrate-co-4-hydroxybutyrate); PEG: polyethylene glycol; TGF-β1: transforming 
growth factor beta 1; VEGF: vascular endothelial growth factor; EPC: endothelial progenitor 
cell; SDF-1α: stromal cell–derived factor 1α; VIM: vimentin; αSMA: alpha-smooth muscle 
actin; VIC: valvular interstitial cell. 
The results are overall observations and the outcome of individual studies may vary. Lower case 















Decell 24.52 (7.72) 6.64 (1.52) 0.39 (0.47)** 133.42 (64.27) 
Cryo 25.78 (2.85)  6.78 (1.45) 1.62 (1.20)** 153.47 (46.65) 
Human 
Decell 22.28 (8.46) 4.77 (1.73)* 0.78 (0.21)* 167.20 (67.58) 
Cryo 19.35 (2.25) 6.52 (1.43)* 1.73 (0.41)* 160.17 (47.01) 
 
Biochemical makeup of human and ovine aortic valve ECM before (cryo) and after 
decellularization (decell). Mass measurements of samples were made using wet tissue. Values 
reported as mean (standard deviation). 
* statistically significant difference between groups of the same species (p < 0.05, t-Test) 
**statistically significant difference between groups of the same species (p < 0.05 Mann-





Table 4.1: Mechanical properties of TEHVs seeded with MNC, MSC, MSC2, or VIC 
populations. 
Cell Type Areal Strain (%) Circ. Stretch Ratio Radial Stretch Ratio 
MNC 124.01 ± 19.06 a,b,c 1.27 ± 0.11 1.77 ± 0.13 
MSC 153.83 ± 28.12 b,d 1.37 ± 0.11 b 1.85 ± 0.12 
MSC2 134.48 ± 8.43 1.30 ± 0.07 1.81 ± 0.06 
VIC 151.99 ± 18.24 c 1.39 ± 0.05 a 1.82 ± 0.13 
Cryo 124.53 ± 19.73 d,e 1.21 ± 0.06 a,b,c 1.84 ± 0.14 
Decell 158.09 ± 15.40 a,e 1.36 ± 0.07 c 1.90 ± 0.11 
 
Biaxial mechanical properties of MNC, MSC, MSC2, and VIC seeded ovine aortic valves. 
Previously reported data for cryopreserved (cryo) and decellularized (decell) ovine aortic valves 
are included for comparison [24]. Data is reported as mean ± standard deviation. Superscript 





Table 4.2 Biochemical concentrations of TEHVs seeded with MNC, MSC, MSC2, or VIC 
populations. 
Cell Type GAG Collagen Tot. Protein 
MNC 0.93 ± 0.31  73.50 ± 8.29 a,b 203.2 ± 28.5 
MSC 0.99 ± 0.32 68.00 ± 18.80 c,d 216.2 ± 88.4 
VIC 1.04 ± 0.25 64.49 ± 10.18 e,f 197.2 ± 50.5 
2x MSC 0.917 ± 0.26 70.40 ± 12.64 g,h 248.6 ± 45.1 a,b 
Cryo 1.62 ± 1.20 a 39.49 ± 7.11 a,c,e,g 153.5 ± 46.6 a 
Decell 0.39 ± 0.47 a 40.25 ± 3.79 b,d,f,h 133.4 ± 64.3 b 
 
Biochemical concentrations of MNC, MSC, MSC2, and VIC seeded ovine aortic valves. 
Previously reported data for cryopreserved (cryo) and decellularized (decell) ovine aortic valves 
are included for comparison [24]. Data is reported as mean ± standard deviation. Superscript 









(µg/mg wet tissue) 
GAG 
(µg/mg wet tissue) 
Cryo 48.24 ± 4.92 1.73 ± 0.41* 
Decell 44.33 ± 11.59 0.78 ± 0.21* 
3wk 47.89 ± 14.82 0.58 ± 0.25 
6wk 39.73 ± 11.22 0.64 ± 0.23 
 
Biochemical data for 3 week and 6 week conditioned heart valve leaflets. Previously reported 
data for cryopreserved (cryo) and decellularized (decell) human aortic valves are included for 
comparison [ref]. Data reported as the mean ± standard deviation. * indicates a significant 





Table 6. 1: Gene expression of TEHVs from bioreactor conditioned groups 







VIC VIM ! !	 !	 !	
ACTA2 " ""	 "	 ""	
MSC THY1 "	 "	 !	 !!	
CD44 !	 !	 !	 !	
ITGB1 "	 "	 !	 !	
ANPEP !	 !	 !!	 !!	
ECM Remodeling HSP47 "	 "	 !	 !	
COL1A1 "	 "	 !	 !	
COL3A1 "	 "	 !	 !	
MMP1 !!!	 !!!	 !!!	 -	
Cell Proliferation MKI67 "	 "	 !	 -	
Apoptosis BAX !	 !	 !	 !!	
Hypoxia EPAS1 "	 "	 "	 "	
HSC CD34 -	 -	 -	 -	
Endothelial vWF -	 !!	 -	 -	
ENG "	 "	 !	 !	
Leukocyte PTPRC ""	 "	 -	 -	
Macrophage CD14 "	 "	 !	 -	
Chondrocyte ACAN """	 """	 ""	 -	
Osteoblast ALPL "	 "	 "	 -	
Adipocyte ADIPOQ !	 "	 -	 -	
 
Gene expression of the tissue engineered heart valves from each bioreactor conditioning group. 
Data is qualitatively presented as the fold change in expression for each gene of the tissue 
engineered valves relative to their matched pre-seeded cell populations. 
Note: changes in gene expression in bioreactor conditioned tissues were evaluated relative to 
their matched pre-seeded cell populations. Fold change in expression is presented qualitatively 
based on the scale described below.  
“!” or “"” = Fold change (increased or decreased, respectively) in range 1 to 9.99. 
“!!” or “""” = Fold change (increased or decreased, respectively) in range 10 to 99.99.  
“!!!” or “"""” = Fold change (increased or decreased, respectively) in range 100 to 295.  




Table 6.2: Biochemical concentrations of TEHVs from bioreactor conditioned groups 
  
Concentration of GAG, collagen, and total protein measured within the extracellular matrix of 
the tissue engineered heart valve groups. Data is presented as the mean ± standard deviation. 




(µg/mg wet tissue) 
Collagen 
(µg/mg wet tissue) 
Total Protein 
(µg/mg wet tissue) 
Hypox/High P 0.649 ± 0.173 54.59 ± 15.64 a,b 131.93 ± 44.44  
Norm/High P 0.427 ± 0.204 63.61 ± 13.54 c,d 139.47 ± 38.28 
Hypox/Neg P 0.516 ± 0.172 50.17 ± 9.32 e,f 106.20 ± 35.13 
Norm/Neg P 0.474 ± 0.157 53.43 ± 4.90 g,h 128.47 ± 32.88 
Cryo 1.622 ± 1.199 a 25.78 ± 2.85 a,c,e,g 153.47 ± 46.65 
Decell 0.390 ± 0.473 a 24.52 ± 7.72 b,d,f,h 133.42 ± 64.27 
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Table 6.3: Recellularization comparison of donor matched hypoxic/normoxic conditioned 
TEHVs 
Donor Pressure Conditioning 
Hypoxic Valve Cell Density 
(cells/mm2) 




Donor 1 Positive 259.53 ± 22.96 30.96 ± 30.09 8.38 
Donor 2 Positive 44.92 ± 13.75 38.41 ± 17.63 1.17 
Donor 3 Positive 41.11 ± 19.00 22.80 ± 19.82 1.80 
Donor 4 Negative 38.25 ± 9.41 18.18 ± 13.83 2.10 
Donor 5 Negative 160.93 ± 106.26 70.38 ± 0.06 2.29 
Donor 6 Negative 142.35 ± 42.27 24.70 ± 19.81 5.76 
 
Measured cell densities at the distal tip region of each donor matched hypoxic and normoxic 
valve. Measurements were made on a per leaflet basis. Data is presented as the average per valve 
± standard deviation. The fold change displays the cell density of the hypoxic valve compared to 
the normoxic valve. Superscript letters of the same type indicate a significant difference between 
matched valves (p < 0.05). 
 
 
